[X] Close
You are about to erase all the values you have customized, search history, page format, etc.
Click here to RESET all values       Click here to GO BACK without resetting any value
Items 1 to 100 of about 138
1. Naini S, Etheridge KT, Adam SJ, Qualman SJ, Bentley RC, Counter CM, Linardic CM: Defining the cooperative genetic changes that temporally drive alveolar rhabdomyosarcoma. Cancer Res; 2008 Dec 1;68(23):9583-8
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Defining the cooperative genetic changes that temporally drive alveolar rhabdomyosarcoma.
  • Rhabdomyosarcoma (RMS) is the most common soft tissue sarcoma of childhood and adolescence.
  • Despite advances in therapy, patients with a histologic variant of RMS known as alveolar (aRMS) have a 5-year survival rate of <30%.

  • Genetic Alliance. consumer health - Rhabdomyosarcoma alveolar.
  • COS Scholar Universe. author profiles.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Proc Natl Acad Sci U S A. 1999 Nov 9;96(23):13264-9 [10557309.001]
  • [Cites] Mol Cancer Res. 2007 Nov;5(11):1181-9 [17982115.001]
  • [Cites] J Clin Oncol. 2002 Jun 1;20(11):2672-9 [12039929.001]
  • [Cites] Cancer Biol Ther. 2002 Mar-Apr;1(2):97-104 [12170781.001]
  • [Cites] Nat Cell Biol. 2004 Apr;6(4):308-18 [15048125.001]
  • [Cites] Cancer Treat Rev. 2004 May;30(3):269-80 [15059650.001]
  • [Cites] Oncogene. 2004 Sep 9;23(41):6864-71 [15286710.001]
  • [Cites] Cancer Res. 1993 Nov 1;53(21):5108-12 [8221646.001]
  • [Cites] Nat Genet. 1993 Nov;5(3):230-5 [8275086.001]
  • [Cites] Nature. 1999 Jul 29;400(6743):464-8 [10440377.001]
  • [Cites] Oncogene. 1999 Sep 20;18(38):5340-8 [10498887.001]
  • [Cites] Genes Dev. 2004 Nov 1;18(21):2614-26 [15489287.001]
  • [Cites] J Clin Oncol. 2005 Feb 1;23(4):880-8 [15681534.001]
  • [Cites] Cancer Res. 2005 Jun 1;65(11):4490-5 [15930263.001]
  • [Cites] Cancer Res. 2005 Nov 1;65(21):9824-8 [16267004.001]
  • [Cites] Cancer. 2006 Apr 15;106(8):1766-75 [16544315.001]
  • [Cites] Am J Surg Pathol. 2006 Aug;30(8):962-8 [16861966.001]
  • [Cites] Cell. 2006 Oct 20;127(2):265-75 [17055429.001]
  • [Cites] Cancer Res. 2007 Jul 15;67(14):6691-9 [17638879.001]
  • [Cites] J Clin Invest. 2007 Aug;117(8):2030-2 [17671635.001]
  • [Cites] Curr Opin Genet Dev. 2001 Aug;11(4):440-8 [11448631.001]
  • (PMID = 19047133.001).
  • [ISSN] 1538-7445
  • [Journal-full-title] Cancer research
  • [ISO-abbreviation] Cancer Res.
  • [Language] ENG
  • [Grant] United States / NICHD NIH HHS / HD / HD043494-06; United States / NICHD NIH HHS / HD / 5K12-HD043494; United States / NCI NIH HHS / CA / CA094184-07; United States / NICHD NIH HHS / HD / K12 HD043494-05; United States / NCI NIH HHS / CA / R01-CA94184; United States / NCI NIH HHS / CA / R01 CA094184; United States / NICHD NIH HHS / HD / K12 HD043494; United States / NICHD NIH HHS / HD / K12 HD043494-06; United States / NCI NIH HHS / CA / R01 CA094184-07; United States / NICHD NIH HHS / HD / HD043494-05
  • [Publication-type] Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Cyclin-Dependent Kinase Inhibitor p16; 0 / Oncogene Proteins, Fusion; 0 / PAX3-FKHR fusion protein, human
  • [Other-IDs] NLM/ NIHMS73714; NLM/ PMC2593800
  •  go-up   go-down


2. Cen L, Arnoczky KJ, Hsieh FC, Lin HJ, Qualman SJ, Yu S, Xiang H, Lin J: Phosphorylation profiles of protein kinases in alveolar and embryonal rhabdomyosarcoma. Mod Pathol; 2007 Sep;20(9):936-46
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Phosphorylation profiles of protein kinases in alveolar and embryonal rhabdomyosarcoma.
  • Rhabdomyosarcoma is the most common pediatric soft-tissue sarcoma, which includes two major subtypes, alveolar and embryonal rhabdomyosarcoma.
  • However, the oncogenic process of rhabdomyosarcoma involves multi-stages of signaling protein dysregulation characterized by prolonged activation of tyrosine and serine/threonine kinases.
  • To better understand this protein dysregulation, we evaluated the phosphorylation profiles of multiple tyrosine and serine/threonine kinases to identify whether these protein kinases are activated in rhabdomyosarcoma.
  • We applied immunohistochemistry with phospho-specific antibodies to examine phosphorylation levels of selected receptor and non-receptor tyrosine kinases, mammalian target of rapamycin (mTOR), p70S6K, and protein kinase C (PKC) isozymes on alveolar and embryonal rhabdomyosarcoma tissue microarray slides.
  • Our results showed that the phosphorylation levels of these kinases are elevated in some rhabdomyosarcoma tissues compared to normal tissues.
  • Phosphorylation levels of receptor and non-receptor tyrosine kinases are elevated between 26 and 68% in alveolar rhabdomyosarcoma and between 24 and 71% in embryonal rhabdomyosarcoma, respectively, compared to normal tissues.
  • In addition, phosphorylation levels of mTOR and its downstream targets, p70S6K, S6, and 4EBP1, are increased between 50 and 72% in both subtypes of rhabdomyosarcoma.
  • Further, phosphorylation levels of PKCalpha, PKCdelta, PKCtheta, and PKCzeta/lambda are upregulated between 57 and 69% in alveolar rhabdomyosarcoma and between 43 and 72% in embryonal rhabdomyosarcoma.
  • This is the first report to create a phosphorylation profile of tyrosine and serine/threonine kinases involved in the mTOR and PKC pathways of alveolar and embryonal rhabdomyosarcoma.
  • [MeSH-major] Protein-Serine-Threonine Kinases / analysis. Protein-Tyrosine Kinases / analysis. Rhabdomyosarcoma, Alveolar / enzymology. Rhabdomyosarcoma, Embryonal / enzymology
  • [MeSH-minor] Adaptor Proteins, Signal Transducing / analysis. Adolescent. Child. Child, Preschool. Female. Humans. Immunohistochemistry. Infant. Infant, Newborn. Isoenzymes / analysis. Male. Neoplasm Staging. Phosphoproteins / analysis. Phosphorylation. Pilot Projects. Protein Kinase C / analysis. Protein Kinases / analysis. Receptor Protein-Tyrosine Kinases / analysis. Ribosomal Protein S6 / analysis. Ribosomal Protein S6 Kinases, 70-kDa / analysis. TOR Serine-Threonine Kinases. Tissue Array Analysis

  • Genetic Alliance. consumer health - Rhabdomyosarcoma alveolar.
  • Genetic Alliance. consumer health - Rhabdomyosarcoma embryonal.
  • COS Scholar Universe. author profiles.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17585318.001).
  • [ISSN] 0893-3952
  • [Journal-full-title] Modern pathology : an official journal of the United States and Canadian Academy of Pathology, Inc
  • [ISO-abbreviation] Mod. Pathol.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Adaptor Proteins, Signal Transducing; 0 / EIF4EBP1 protein, human; 0 / Isoenzymes; 0 / Phosphoproteins; 0 / Ribosomal Protein S6; EC 2.7.- / Protein Kinases; EC 2.7.1.1 / MTOR protein, human; EC 2.7.1.1 / TOR Serine-Threonine Kinases; EC 2.7.10.1 / Protein-Tyrosine Kinases; EC 2.7.10.1 / Receptor Protein-Tyrosine Kinases; EC 2.7.11.1 / Protein-Serine-Threonine Kinases; EC 2.7.11.1 / Ribosomal Protein S6 Kinases, 70-kDa; EC 2.7.11.13 / Protein Kinase C
  •  go-up   go-down


3. Breitfeld PP, Meyer WH: Rhabdomyosarcoma: new windows of opportunity. Oncologist; 2005 Aug;10(7):518-27
The Lens. Cited by Patents in .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Rhabdomyosarcoma: new windows of opportunity.
  • Rhabdomyosarcoma is a highly malignant, small blue cell tumor characterized by muscle differentiation.
  • Adequate biopsy to obtain sufficient tissue for accurate diagnosis and molecular characterization is critical.
  • Patients must be assessed for tumor extent; the Intergroup Rhabdomyosarcoma Study (IRS) clinical group and Staging system is universally applied in North America.
  • Local control relies on complete surgical excision when possible; those whose tumors are not completely excised and those with alveolar histology tumors require local irradiation to maximize local control.
  • [MeSH-major] Rhabdomyosarcoma. Soft Tissue Neoplasms

  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16079319.001).
  • [ISSN] 1083-7159
  • [Journal-full-title] The oncologist
  • [ISO-abbreviation] Oncologist
  • [Language] eng
  • [Publication-type] Journal Article; Review
  • [Publication-country] United States
  • [Number-of-references] 99
  •  go-up   go-down


Advertisement
4. Püsküllüoglu M, Lukasiewicz E, Miekus K, Jarocha D, Majka M: Differential expression of Snail1 transcription factor and Snail1-related genes in alveolar and embryonal rhabdomyosarcoma subtypes. Folia Histochem Cytobiol; 2010 Dec;48(4):671-7
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Differential expression of Snail1 transcription factor and Snail1-related genes in alveolar and embryonal rhabdomyosarcoma subtypes.
  • Rhabdomyosarcoma (RMS) represents the most common sarcoma of soft tissue among children.
  • Two main RMS subtypes are alveolar (ARMS) and embryonal (ERMS).
  • The major goal of this study was to find differentially expressed genes between RMS subtypes that could explain higher metastatic potential in ARMS and would be useful for the differential diagnosis.
  • Using RQ-PCR analysis we compared expression of Snail1 and Snail-related genes among 7 ARMS and 8 ERMS patients' samples obtained from the primary tumors and among 2 alveolar and 2 embryonal cell lines.
  • Our results show that Snail1 is highly expressed both in ARMS patients' samples and the alveolar cell lines.

  • Genetic Alliance. consumer health - Rhabdomyosarcoma alveolar.
  • Genetic Alliance. consumer health - Rhabdomyosarcoma embryonal.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 21478114.001).
  • [ISSN] 1897-5631
  • [Journal-full-title] Folia histochemica et cytobiologica
  • [ISO-abbreviation] Folia Histochem. Cytobiol.
  • [Language] ENG
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] Poland
  • [Chemical-registry-number] 0 / Transcription Factors; 0 / beta Catenin; 0 / snail family transcription factors; EC 3.4.24.24 / Matrix Metalloproteinase 2; EC 3.4.24.35 / Matrix Metalloproteinase 9
  •  go-up   go-down


5. Ben Arush MW, Bar Shalom R, Postovsky S, Militianu D, Haimi M, Zaidman I, Israel O: Assessing the use of FDG-PET in the detection of regional and metastatic nodes in alveolar rhabdomyosarcoma of extremities. J Pediatr Hematol Oncol; 2006 Jul;28(7):440-5
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Assessing the use of FDG-PET in the detection of regional and metastatic nodes in alveolar rhabdomyosarcoma of extremities.
  • Alveolar rhabdomyosarcoma (ARS) accounts for 20% to 30% of childhood rhabdomyosarcoma and is known to have a worse prognosis than embryonal rhabdomyosarcoma.
  • Metastatic disease is more frequent in patients with alveolar tumors and these children with metastatic disease fare poorly, with a 5-year survival between 20% and 30%.
  • The value of FDG in patients with soft tissue sarcomas has been demonstrated in several series, but none specifically in ARS.
  • All the 3 patients we present had focally increased tracer uptake in nodal stations on a pretherapy PET performed at diagnosis.
  • Tissue confirmation available in 2 patients was negative in 1 patient and positive for metastatic nodal spread in the other.
  • [MeSH-major] Extremities / pathology. Fluorodeoxyglucose F18. Lymphoma, Non-Hodgkin / diagnosis. Positron-Emission Tomography / methods. Rhabdomyosarcoma, Alveolar / diagnosis. Soft Tissue Neoplasms / diagnosis

  • Genetic Alliance. consumer health - Rhabdomyosarcoma alveolar.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16825990.001).
  • [ISSN] 1077-4114
  • [Journal-full-title] Journal of pediatric hematology/oncology
  • [ISO-abbreviation] J. Pediatr. Hematol. Oncol.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0Z5B2CJX4D / Fluorodeoxyglucose F18
  •  go-up   go-down


6. Blizniukov OP, Petrovichev NN, Perevoshchikov AG, Poliakov VG: [Diagnosis of micrometastases of alveolar rhabdomyosarcoma]. Arkh Patol; 2008 Mar-Apr;70(2):36-40
NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Diagnosis of micrometastases of alveolar rhabdomyosarcoma].
  • Alveolar rhabgomyosarcoma is a highly malignant, small blue cell pediatric soft tissue tumor.
  • Identification of micrometastases in alveolar rhabdomyosarcoma is important because the poor prognosis associated with this subgroup necessitates a modified therapeutic regimen.
  • Since the obtained lymph node specimen can be very small; rhabdomyosarcoma cells are not easily detected using conventional histological methods.
  • To assess the value of myogenin staining in the diagnosis of micrometastases in alveolar rhabdomyosarcoma, the authors examined 36 lymph nodes from children bearing this tumor.
  • The PAX3/7-FKHR gene fusion that resulted from chromosomal translocation in alveolar rhabdomyosarcoma provided potential molecular diagnostic markers.
  • Thirty-six lymph nodes were examined and of them 17 lymph nodes had PAX3/7-FKHR fusion transcripts of alveolar rhadomyosarcoma cells.
  • The study demonstrates that molecular RT-PCR detection of micrometastases is the most sensitive method for diagnosing alveolar rhabdomyosarcoma.
  • [MeSH-major] Biomarkers, Tumor / biosynthesis. Eye Proteins / biosynthesis. Forkhead Transcription Factors / biosynthesis. Homeodomain Proteins / biosynthesis. Oncogene Proteins, Fusion / biosynthesis. Rhabdomyosarcoma, Alveolar / diagnosis. Rhabdomyosarcoma, Alveolar / metabolism. Soft Tissue Neoplasms / diagnosis. Soft Tissue Neoplasms / metabolism. Transcription Factors / biosynthesis

  • Genetic Alliance. consumer health - Rhabdomyosarcoma alveolar.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18540440.001).
  • [ISSN] 0004-1955
  • [Journal-full-title] Arkhiv patologii
  • [ISO-abbreviation] Arkh. Patol.
  • [Language] rus
  • [Publication-type] English Abstract; Journal Article
  • [Publication-country] Russia (Federation)
  • [Chemical-registry-number] 0 / Biomarkers, Tumor; 0 / Eye Proteins; 0 / FOXO1 protein, human; 0 / Forkhead Transcription Factors; 0 / Homeodomain Proteins; 0 / Oncogene Proteins, Fusion; 0 / RAX protein, human; 0 / RNA, Neoplasm; 0 / Transcription Factors
  •  go-up   go-down


7. Brown BJ, Oluwasola AO: Childhood rhabdomyosarcoma in Ibadan, Nigeria: 1984-2003. Ann Trop Paediatr; 2006 Dec;26(4):349-55
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Childhood rhabdomyosarcoma in Ibadan, Nigeria: 1984-2003.
  • BACKGROUND: Rhabdomyosarcoma is the most common soft tissue sarcoma in children under 15 years of age.
  • AIM: To describe the pattern of childhood rhabdomyosarcoma in Ibadan with respect to demography, morphology and tumour site.
  • All histologically confirmed cases of rhabdomyosarcoma in children under 15 years of age seen at the University College Hospital Ibadan between 1984 and 2003 were included.
  • Other subtypes were alveolar (13.2%), pleomorphic (4.4%) and rhabdomyosarcoma 'not otherwise specified' (20.9%).
  • The majority (50.6%) of tumours were in the head and neck region and the common primary sites were soft tissue of the head, face (24.2%) and orbit (14.3%).
  • Other sites included soft tissue of the pelvis (11.0%), genito-urinary tract (9.9%) and abdomen (9.9%).
  • CONCLUSION: The pattern of rhabdomyosarcoma in Nigeria is similar to that in the United States and Europe, except for the rarity of parameningeal sites and extremities.
  • There is a need for larger descriptive studies on childhood rhabdomyosarcoma in Africa.
  • [MeSH-major] Rhabdomyosarcoma / epidemiology. Soft Tissue Neoplasms / epidemiology
  • [MeSH-minor] Adolescent. Age Distribution. Child. Child, Preschool. Female. Head and Neck Neoplasms / epidemiology. Humans. Infant. Infant, Newborn. Male. Nigeria / epidemiology. Registries. Retrospective Studies. Rhabdomyosarcoma, Alveolar / epidemiology. Rhabdomyosarcoma, Alveolar / pathology. Rhabdomyosarcoma, Embryonal / epidemiology. Rhabdomyosarcoma, Embryonal / pathology

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17132301.001).
  • [ISSN] 0272-4936
  • [Journal-full-title] Annals of tropical paediatrics
  • [ISO-abbreviation] Ann Trop Paediatr
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] England
  •  go-up   go-down


8. Ganti R, Skapek SX, Zhang J, Fuller CE, Wu J, Billups CA, Breitfeld PP, Dalton JD, Meyer WH, Khoury JD: Expression and genomic status of EGFR and ErbB-2 in alveolar and embryonal rhabdomyosarcoma. Mod Pathol; 2006 Sep;19(9):1213-20
antibodies-online. View related products from antibodies-online.com (subscription/membership/fee required).

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Expression and genomic status of EGFR and ErbB-2 in alveolar and embryonal rhabdomyosarcoma.
  • EGFR and ErbB-2 expression has been observed in rhabdomyosarcoma cell lines but not analyzed systematically in rhabdomyosarcoma tumors.
  • Tissue microarray sections representing 66 rhabdomyosarcoma tumors (34 embryonal rhabdomyosarcoma, 32 alveolar rhabdomyosarcoma) were surveyed by immunohistochemistry using antibodies specific for EGFR and ErbB-2.
  • Expression of ErbB-2 was identified in 22/66 (33%) cases and tended to be more frequent in the alveolar subtype (13/32, 41%, vs 9/34, 26%, P=0.30).
  • Coexpression of EGFR and ErbB-2 was identified in eight tumors, of which six were embryonal rhabdomyosarcoma.
  • Furthermore, analysis of 11 additional rhabdomyosarcoma tumors (six alveolar; five embryonal) revealed no evidence of mutations in EGFR exons 18, 19, 20, and 21.
  • In summary, expression of EGFR and/or ErbB-2 is detected in a sizeable subset of rhabdomyosarcoma tumors without evidence of EGFR or ErbB-2 amplification or mutations in the EGFR tyrosine kinase domain.
  • [MeSH-major] Receptor, Epidermal Growth Factor / metabolism. Receptor, ErbB-2 / metabolism. Rhabdomyosarcoma, Alveolar / metabolism. Rhabdomyosarcoma, Embryonal / metabolism. Soft Tissue Neoplasms / metabolism
  • [MeSH-minor] Adolescent. Adult. Child. Child, Preschool. DNA Mutational Analysis. DNA, Neoplasm / analysis. Female. Gene Dosage. Humans. Immunoenzyme Techniques. In Situ Hybridization, Fluorescence. Infant. Male. Tissue Array Analysis

  • Genetic Alliance. consumer health - Rhabdomyosarcoma alveolar.
  • Genetic Alliance. consumer health - Rhabdomyosarcoma embryonal.
  • COS Scholar Universe. author profiles.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] Published online 26 May 2006.
  • (PMID = 16729016.001).
  • [ISSN] 0893-3952
  • [Journal-full-title] Modern pathology : an official journal of the United States and Canadian Academy of Pathology, Inc
  • [ISO-abbreviation] Mod. Pathol.
  • [Language] eng
  • [Grant] United States / NCI NIH HHS / CA / CA-023099
  • [Publication-type] Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / DNA, Neoplasm; EC 2.7.10.1 / Receptor, Epidermal Growth Factor; EC 2.7.10.1 / Receptor, ErbB-2
  •  go-up   go-down


9. Bolger JC, Walsh JC, Hughes RE, Eustace SJ, Harrington P: Alveolar rhabdomyosarcoma originating between the fourth and fifth metatarsal--case report and literature review. Foot Ankle Surg; 2010 Sep;16(3):e51-4
Genetic Alliance. consumer health - Rhabdomyosarcoma alveolar.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Alveolar rhabdomyosarcoma originating between the fourth and fifth metatarsal--case report and literature review.
  • We report a case of alveolar rhabdomyosarcoma arising between the fourth and fifth metatarsal.
  • Plain radiographs and MRI showed a soft tissue mass displacing the fourth metatarsal.
  • Percutaneous biopsy revealed an alveolar rhabdomyosarcoma.
  • [MeSH-major] Metatarsus. Rhabdomyosarcoma, Alveolar / diagnosis
  • [MeSH-minor] Adolescent. Biopsy. Diagnosis, Differential. Follow-Up Studies. Humans. Magnetic Resonance Imaging. Male. Positron-Emission Tomography

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] Copyright (c) 2010 European Foot and Ankle Society. Published by Elsevier Ltd. All rights reserved.
  • (PMID = 20654999.001).
  • [ISSN] 1460-9584
  • [Journal-full-title] Foot and ankle surgery : official journal of the European Society of Foot and Ankle Surgeons
  • [ISO-abbreviation] Foot Ankle Surg
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] France
  •  go-up   go-down


10. D'Angelo P, Carli M, Ferrari A, Manzitti C, Mura R, Miglionico L, Di Cataldo A, Grigoli A, Cecchetto G, Bisogno G, AIEOP Soft Tissue Sarcoma Committee: Breast metastases in children and adolescents with rhabdomyosarcoma: Experience of the Italian Soft Tissue Sarcoma Committee. Pediatr Blood Cancer; 2010 Dec 15;55(7):1306-9
MedlinePlus Health Information. consumer health - Breast Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Breast metastases in children and adolescents with rhabdomyosarcoma: Experience of the Italian Soft Tissue Sarcoma Committee.
  • BACKGROUND: Breast metastasis from rhabdomyosarcoma (RMS) is an uncommon event but may be problematic in treatment decision-making.
  • Aim of the study was to evaluate clinical characteristics, treatment, and subsequent outcome, of patients with RMS metastasis in the breast, enrolled in four consecutive Associazione Italiana di Ematologia ed Oncologia Pediatrica (AIEOP) Soft Tissue Sarcoma Committee protocols during the last 20 years, in order to obtain information to establish a more adequate diagnostic and therapeutic approach.
  • RESULTS: From 1988 to 2008, among 189 patients with metastatic RMS, we identified 7 (3.7%) patients with RMS with breast involvement at diagnosis.
  • All patients were females, aged 13-17 years with alveolar histology and multiple metastasis sites (2-5).
  • CONCLUSIONS: Our data suggest that investigations of the mammary region should be part of the usual diagnostic workup in adolescent girls with alveolar RMS, especially if the primary tumor arises in the extremities.
  • [MeSH-major] Breast Neoplasms / secondary. Muscle Neoplasms / pathology. Rhabdomyosarcoma / secondary

  • Genetic Alliance. consumer health - Soft tissue sarcoma.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] Copyright © 2010 Wiley-Liss, Inc.
  • (PMID = 20730885.001).
  • [ISSN] 1545-5017
  • [Journal-full-title] Pediatric blood & cancer
  • [ISO-abbreviation] Pediatr Blood Cancer
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  •  go-up   go-down


11. Croes R, Debiec-Rychter M, Cokelaere K, De Vos R, Hagemeijer A, Sciot R: Adult sclerosing rhabdomyosarcoma: cytogenetic link with embryonal rhabdomyosarcoma. Virchows Arch; 2005 Jan;446(1):64-7
NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Adult sclerosing rhabdomyosarcoma: cytogenetic link with embryonal rhabdomyosarcoma.
  • Rhabdomyosarcomas are classified into three well-defined categories: embryonal, alveolar and pleomorphic rhabdomyosarcoma.
  • Recently, seven cases of an unusual adult type of rhabdomyosarcoma with a prominent hyaline sclerosis have been described.
  • We report the hitherto unreported cytogenetic changes of an adult sclerosing rhabdomyosarcoma.
  • A 79-year-old woman underwent an amputation for a rapidly growing soft tissue mass in the anterior compartment of the right lower leg.
  • Using fluorescent in situ hybridization (FISH) analysis, the tumor cells were negative for FOXO1A-disrupting translocations specific for alveolar rhabdomyosarcoma.
  • The chromosomal composition of malignant cells resembled the pattern of numerical changes frequently observed in embryonal rhabdomyosarcoma, suggesting a close relationship of an adult sclerosing rhabdomyosarcoma with this entity.
  • [MeSH-major] Rhabdomyosarcoma / genetics. Rhabdomyosarcoma, Embryonal / genetics. Translocation, Genetic

  • Genetic Alliance. consumer health - Rhabdomyosarcoma embryonal.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Med Pediatr Oncol. 2001 Feb;36(2):259-67 [11452933.001]
  • [Cites] Hum Mol Genet. 1996 Jan;5(1):15-21 [8789435.001]
  • [Cites] Cancer Res. 1993 Nov 1;53(21):5108-12 [8221646.001]
  • [Cites] Mod Pathol. 2000 Sep;13(9):988-93 [11007039.001]
  • [Cites] Virchows Arch. 2000 Apr;436(4):305-11 [10834531.001]
  • [Cites] Cancer Genet Cytogenet. 1999 Mar;109(2):161-5 [10087953.001]
  • [Cites] Cancer Res. 1994 Jun 1;54(11):2869-72 [8187070.001]
  • [Cites] Am J Surg Pathol. 2002 Sep;26(9):1175-83 [12218574.001]
  • [Cites] Genes Chromosomes Cancer. 2000 Apr;27(4):337-44 [10719362.001]
  • (PMID = 15660283.001).
  • [ISSN] 0945-6317
  • [Journal-full-title] Virchows Archiv : an international journal of pathology
  • [ISO-abbreviation] Virchows Arch.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Germany
  •  go-up   go-down


12. Jones AE, Albano EA, Lovell MA, Hunger SP: Metastatic alveolar rhabdomyosarcoma in multiple endocrine neoplasia type 2A. Pediatr Blood Cancer; 2010 Dec 1;55(6):1213-6
Genetic Alliance. consumer health - Rhabdomyosarcoma alveolar.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Metastatic alveolar rhabdomyosarcoma in multiple endocrine neoplasia type 2A.
  • Rhabdomyosarcoma (RMS), the most common pediatric soft tissue sarcoma, accounts for 3% of childhood malignancies.
  • We describe a previously unreported association of MEN-2A with metastatic alveolar RMS and review the literature on associated hereditary cancer predisposition syndromes and current therapeutic options.
  • The diagnosis of RMS should prompt consideration of screening for familial genetic syndromes in certain patients.
  • [MeSH-major] Multiple Endocrine Neoplasia Type 2a / pathology. Rhabdomyosarcoma, Alveolar / secondary

  • Genetic Alliance. consumer health - Multiple Endocrine Neoplasia.
  • Genetic Alliance. consumer health - Multiple endocrine neoplasia type 2A.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20533522.001).
  • [ISSN] 1545-5017
  • [Journal-full-title] Pediatric blood & cancer
  • [ISO-abbreviation] Pediatr Blood Cancer
  • [Language] eng
  • [Grant] United States / NCI NIH HHS / CA / T32 CA082086
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] United States
  •  go-up   go-down


13. Hulse N, Raja S, Kumar A, Paul AS: Rhabdomyosarcoma of the extremities in adults. Acta Orthop Belg; 2006 Apr;72(2):199-203

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Rhabdomyosarcoma of the extremities in adults.
  • Eight patients with an average age of 32.6 years (range: 21 to 75) who were treated for rhabdomyosarcomas on the extremities between 1991 and 2002 in a regional centre for the treatment of soft tissue sarcomas were studied retrospectively.
  • Histologically there were four alveolar, two pleomorphic, one embryonal and one anaplastic subtype.
  • Extremity rhabdomyosarcoma is a highly malignant tumour and our results are poor compared to the reported results in children.
  • [MeSH-major] Extremities. Rhabdomyosarcoma / therapy. Soft Tissue Neoplasms / therapy

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16768266.001).
  • [ISSN] 0001-6462
  • [Journal-full-title] Acta orthopaedica Belgica
  • [ISO-abbreviation] Acta Orthop Belg
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Belgium
  •  go-up   go-down


14. Verkarre V, Galmiche-Rolland L, Sarnacki S, Jaubert F: Rhabdomyosarcoma an ubiquitous pediatric tumour. Arkh Patol; 2008 May-Jun;70(3):50-3

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Rhabdomyosarcoma an ubiquitous pediatric tumour.
  • Rhabdomyosarcoma is the most common soft tissue tumor in children.
  • It occurs everywhere and its prognosis depends on the location and its histological type--embryonic or alveolar.
  • The new immunohistochemical markers desmin and myogenin in combination with molecular biological detection of specific translocations in alveolar rhabdomyosarcoma improved diagnostic capacities.
  • [MeSH-major] Rhabdomyosarcoma

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18727437.001).
  • [ISSN] 0004-1955
  • [Journal-full-title] Arkhiv patologii
  • [ISO-abbreviation] Arkh. Patol.
  • [Language] eng
  • [Publication-type] Lectures
  • [Publication-country] Russia (Federation)
  •  go-up   go-down


15. Paulino AC, Pappo A: Alveolar rhabdomyosarcoma of the extremity and nodal metastasis: Is the in-transit lymphatic system at risk? Pediatr Blood Cancer; 2009 Dec 15;53(7):1332-3
Hazardous Substances Data Bank. NICOTINAMIDE .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Alveolar rhabdomyosarcoma of the extremity and nodal metastasis: Is the in-transit lymphatic system at risk?
  • Alveolar rhabdomyosarcoma (RMS) of the extremity is not infrequently associated with regional node metastasis.
  • In this report we describe two patients with alveolar RMS of the lower extremity with inguinal metastasis at presentation.
  • The in-transit lymphatics can be a site of failure in children with alveolar RMS of the extremity and nodal involvement.
  • [MeSH-major] Lymphatic Metastasis / physiopathology. Rhabdomyosarcoma, Alveolar / secondary. Soft Tissue Neoplasms / pathology

  • Genetic Alliance. consumer health - Rhabdomyosarcoma alveolar.
  • Hazardous Substances Data Bank. ETOPOSIDE .
  • Hazardous Substances Data Bank. IFOSFAMIDE .
  • Hazardous Substances Data Bank. DACARBAZINE .
  • Hazardous Substances Data Bank. CYCLOPHOSPHAMIDE .
  • Hazardous Substances Data Bank. DACTINOMYCIN .
  • Hazardous Substances Data Bank. VINCRISTINE .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] (c) 2009 Wiley-Liss, Inc.
  • (PMID = 19711439.001).
  • [ISSN] 1545-5017
  • [Journal-full-title] Pediatric blood & cancer
  • [ISO-abbreviation] Pediatr Blood Cancer
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Benzenesulfonates; 0 / Phenylurea Compounds; 0 / Pyridines; 1CC1JFE158 / Dactinomycin; 24R60NVC41 / cositecan; 25X51I8RD4 / Niacinamide; 5J49Q6B70F / Vincristine; 6PLQ3CP4P3 / Etoposide; 7673326042 / irinotecan; 7GR28W0FJI / Dacarbazine; 85622-93-1 / temozolomide; 8N3DW7272P / Cyclophosphamide; 9ZOQ3TZI87 / sorafenib; UM20QQM95Y / Ifosfamide; XT3Z54Z28A / Camptothecin
  •  go-up   go-down


16. Mercado GE, Barr FG: Fusions involving PAX and FOX genes in the molecular pathogenesis of alveolar rhabdomyosarcoma: recent advances. Curr Mol Med; 2007 Feb;7(1):47-61
NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Fusions involving PAX and FOX genes in the molecular pathogenesis of alveolar rhabdomyosarcoma: recent advances.
  • Rhabdomyosarcoma is the most frequent soft tissue sarcoma in the pediatric population.
  • Two main histopathologic variants have been described, embryonal (ERMS) and alveolar (ARMS), which demonstrate clinical and genetic differences.
  • This review highlights recent advances in numerous areas of biomedical investigation that are providing new insights into the biology, molecular pathology, and translational science of ARMS: the identification of downstream targets of PAX3-FKHR and collaborating events in the process of tumorigenesis and metastasis; generation of animal models based on the gene fusion and collaborating events; development of new assays for diagnosis, prognosis, and detection of minimal disseminated disease; and exploration of immune recognition of this tumor and the fusion protein.
  • [MeSH-major] Oncogene Proteins, Fusion / genetics. Paired Box Transcription Factors / genetics. Rhabdomyosarcoma, Alveolar / pathology

  • Genetic Alliance. consumer health - Rhabdomyosarcoma alveolar.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17311532.001).
  • [ISSN] 1566-5240
  • [Journal-full-title] Current molecular medicine
  • [ISO-abbreviation] Curr. Mol. Med.
  • [Language] eng
  • [Grant] United States / NCI NIH HHS / CA / CA64202; United States / NCI NIH HHS / CA / CA87812; United States / NCI NIH HHS / CA / CA89461
  • [Publication-type] Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't; Review
  • [Publication-country] Netherlands
  • [Chemical-registry-number] 0 / Oncogene Proteins, Fusion; 0 / PAX3-FOXO1A fusion protein, human; 0 / Paired Box Transcription Factors
  • [Number-of-references] 101
  •  go-up   go-down


17. Kohashi K, Oda Y, Yamamoto H, Tamiya S, Takahira T, Takahashi Y, Tajiri T, Taguchi T, Suita S, Tsuneyoshi M: Alterations of RB1 gene in embryonal and alveolar rhabdomyosarcoma: special reference to utility of pRB immunoreactivity in differential diagnosis of rhabdomyosarcoma subtype. J Cancer Res Clin Oncol; 2008 Oct;134(10):1097-103
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Alterations of RB1 gene in embryonal and alveolar rhabdomyosarcoma: special reference to utility of pRB immunoreactivity in differential diagnosis of rhabdomyosarcoma subtype.
  • PURPOSE: Rhabdomyosarcoma (RMS), which is the most common pediatric soft tissue sarcoma, is classified into two major histologic subtypes, embryonal RMS (ERMS) and alveolar RMS (ARMS).
  • In addition, immunohistochemical pRB LI may have the potential to be a useful ancillary tool in the differential diagnosis of RMS subtypes.
  • [MeSH-major] Retinoblastoma Protein / biosynthesis. Retinoblastoma Protein / genetics. Rhabdomyosarcoma, Alveolar / diagnosis. Rhabdomyosarcoma, Alveolar / genetics. Rhabdomyosarcoma, Embryonal / diagnosis. Rhabdomyosarcoma, Embryonal / genetics
  • [MeSH-minor] Base Sequence. Diagnosis, Differential. Gene Expression. Humans. Immunohistochemistry. Mutation. Reverse Transcriptase Polymerase Chain Reaction

  • Genetic Alliance. consumer health - Rhabdomyosarcoma alveolar.
  • Genetic Alliance. consumer health - Rhabdomyosarcoma embryonal.
  • COS Scholar Universe. author profiles.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Mod Pathol. 2005 Nov;18(11):1461-70 [15933756.001]
  • [Cites] Cancer Res. 1994 Jun 1;54(11):3042-8 [8187094.001]
  • [Cites] Nature. 1987 Oct 15-21;329(6140):645-7 [3657988.001]
  • [Cites] Proc Natl Acad Sci U S A. 1992 Mar 1;89(5):1755-9 [1347425.001]
  • [Cites] J Mol Diagn. 2004 Nov;6(4):356-65 [15507675.001]
  • [Cites] Med Pediatr Oncol. 2001 Feb;36(2):259-67 [11452933.001]
  • [Cites] AJR Am J Roentgenol. 2003 Sep;181(3):879-84 [12933497.001]
  • [Cites] Cancer. 2004 Dec 15;101(12 ):2817-24 [15536621.001]
  • [Cites] Am J Med Genet. 1998 Oct 2;79(4):253-9 [9781904.001]
  • [Cites] Cancer Genet Cytogenet. 2006 Jan 1;164(1):1-9 [16364756.001]
  • [Cites] Clin Cancer Res. 2003 Jan;9(1):235-42 [12538475.001]
  • [Cites] Genes Chromosomes Cancer. 2002 Mar;33(3):310-21 [11807989.001]
  • [Cites] Cancer Biol Ther. 2002 Mar-Apr;1(2):97-104 [12170781.001]
  • [Cites] Cancer Genet Cytogenet. 2006 May;167(1):57-65 [16682288.001]
  • [Cites] Cancer Genet Cytogenet. 1999 Mar;109(2):161-5 [10087953.001]
  • [Cites] Nat Rev Cancer. 2003 Sep;3(9):685-94 [12951587.001]
  • [Cites] Cancer Cell. 2003 Dec;4(6):421-2 [14706332.001]
  • [Cites] Eur J Cancer. 2004 Jul;40(10):1522-9 [15196536.001]
  • [Cites] Science. 1993 Apr 16;260(5106):361-4 [8469989.001]
  • [Cites] Oncogene. 2001 Mar 1;20(9):1103-9 [11314047.001]
  • [Cites] Diagn Mol Pathol. 2003 Dec;12(4):224-30 [14639108.001]
  • (PMID = 18386058.001).
  • [ISSN] 0171-5216
  • [Journal-full-title] Journal of cancer research and clinical oncology
  • [ISO-abbreviation] J. Cancer Res. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] Germany
  • [Chemical-registry-number] 0 / Retinoblastoma Protein
  •  go-up   go-down


18. Odoi AT, Dassah ET, Darkey DE, Owusu-Afriyie O, Valkov AY: Advanced alveolar rhabdomyosarcoma of the uterus: a case report. Afr J Reprod Health; 2009 Mar;13(1):167-73
MedlinePlus Health Information. consumer health - Uterine Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Advanced alveolar rhabdomyosarcoma of the uterus: a case report.
  • Alveolar rhabdomyosarcoma is an uncommon malignant soft tissue tumour rarely found in the female genital tract and carries a very poor prognosis especially in adults.
  • The cervical, uterine and omental biopsies were all diagnosed alveolar rhabdomyosarcoma.
  • While the optimal management of this rare tumour is unknown, early recognition and diagnosis, and a prompt multimodality treatment approach of surgery, chemotherapy and radiotherapy offers the best chance of cure.
  • [MeSH-major] Omentum / pathology. Peritoneal Neoplasms / pathology. Rhabdomyosarcoma, Alveolar / pathology. Uterine Neoplasms / pathology

  • Genetic Alliance. consumer health - Rhabdomyosarcoma alveolar.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20687274.001).
  • [ISSN] 1118-4841
  • [Journal-full-title] African journal of reproductive health
  • [ISO-abbreviation] Afr J Reprod Health
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Nigeria
  • [Chemical-registry-number] 0 / Oncogene Proteins, Fusion; 0 / PAX3-FKHR fusion protein, human
  •  go-up   go-down


19. Arush MW, Kollender Y, Issakov J, Shalom RB, Arieh YB, Malkin L, Postovsky S: Unusual leptomeningeal dissemination in a child with extracranial metastatic alveolar rhabdomyosarcoma. Pediatr Hematol Oncol; 2009 Sep;26(6):473-8
MedlinePlus Health Information. consumer health - Lung Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Unusual leptomeningeal dissemination in a child with extracranial metastatic alveolar rhabdomyosarcoma.
  • The authors describe a 6-year-old boy diagnosed with alveolar rhabdomyosarcoma located in the thigh, with distal metastases to lungs, bones, and bone marrow.
  • This case demonstrates the rapidity with which leptomeningeal spread of extracranial metastatic alveolar rhabdomyosarcoma can occur and underscores the importance of diagnostic lumbar puncture and brain radiological investigations at diagnosis, even when the tumors are not in the parameningeal location.
  • [MeSH-major] Bone Marrow Neoplasms / secondary. Brain Neoplasms / secondary. Lung Neoplasms / secondary. Meningeal Neoplasms / secondary. Rhabdomyosarcoma, Alveolar / secondary. Soft Tissue Neoplasms / pathology


20. Masola V, Maran C, Tassone E, Zin A, Rosolen A, Onisto M: Heparanase activity in alveolar and embryonal rhabdomyosarcoma: implications for tumor invasion. BMC Cancer; 2009;9:304
NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Heparanase activity in alveolar and embryonal rhabdomyosarcoma: implications for tumor invasion.
  • BACKGROUND: Rhabdomyosarcoma (RMS) is a malignant soft tissue sarcoma of childhood including two major histological subtypes, alveolar (ARMS) and embryonal (ERMS) RMS.
  • [MeSH-major] Glucuronidase / metabolism. Neoplasm Invasiveness. Rhabdomyosarcoma, Alveolar / embryology. Rhabdomyosarcoma, Alveolar / enzymology

  • Genetic Alliance. consumer health - Rhabdomyosarcoma alveolar.
  • Genetic Alliance. consumer health - Rhabdomyosarcoma embryonal.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Biochemistry. 2000 Dec 26;39(51):15659-67 [11123890.001]
  • [Cites] PLoS One. 2009;4(4):e5181 [19360105.001]
  • [Cites] Semin Cancer Biol. 2001 Apr;11(2):143-52 [11322833.001]
  • [Cites] Nature. 2001 May 17;411(6835):375-9 [11357145.001]
  • [Cites] Biochimie. 2001 Aug;83(8):831-9 [11530216.001]
  • [Cites] J Cell Sci. 2002 May 15;115(Pt 10):2179-87 [11973358.001]
  • [Cites] Clin Cancer Res. 2003 Dec 1;9(16 Pt 1):5968-79 [14676122.001]
  • [Cites] J Cell Sci. 2004 May 1;117(Pt 11):2249-58 [15126626.001]
  • [Cites] Cancer Sci. 2004 Jul;95(7):553-8 [15245589.001]
  • [Cites] Cancer Res. 1987 Jun 15;47(12):3239-45 [2438036.001]
  • [Cites] Hum Pathol. 1994 Sep;25(9):900-7 [8088765.001]
  • [Cites] Nat Med. 1999 Jul;5(7):793-802 [10395325.001]
  • [Cites] Oncogene. 1999 Sep 20;18(38):5340-8 [10498887.001]
  • [Cites] Int J Oncol. 2005 Sep;27(3):791-8 [16077930.001]
  • [Cites] Oncologist. 2005 Aug;10(7):518-27 [16079319.001]
  • [Cites] J Cell Biochem. 2005 Dec 1;96(5):897-905 [16149080.001]
  • [Cites] Cancer. 2006 Feb 1;106(3):532-40 [16388520.001]
  • [Cites] Mol Aspects Med. 2006 Apr-Jun;27(2-3):95-125 [16460794.001]
  • [Cites] Curr Med Chem. 2006;13(18):2101-11 [16918340.001]
  • [Cites] Int J Biochem Cell Biol. 2006;38(12):2018-39 [16901744.001]
  • [Cites] Br J Pharmacol. 2007 May;151(1):1-14 [17339837.001]
  • [Cites] Perit Dial Int. 2007 Jun;27 Suppl 2:S104-9 [17556287.001]
  • [Cites] Curr Pharm Des. 2007;13(20):2057-73 [17627539.001]
  • [Cites] Neoplasia. 2007 Nov;9(11):909-16 [18030359.001]
  • [Cites] J Pathol. 2008 Feb;214(3):283-93 [18095256.001]
  • [Cites] Biochim Biophys Acta. 2001 Mar 21;1471(3):M99-108 [11250066.001]
  • (PMID = 19715595.001).
  • [ISSN] 1471-2407
  • [Journal-full-title] BMC cancer
  • [ISO-abbreviation] BMC Cancer
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] England
  • [Chemical-registry-number] EC 3.2.1.- / heparanase; EC 3.2.1.31 / Glucuronidase
  • [Other-IDs] NLM/ PMC2743710
  •  go-up   go-down


21. Ragsdale BD, Lee JP, Mines J: Alveolar rhabdomyosarcoma on the external ear: a case report. J Cutan Pathol; 2009 Feb;36(2):267-9
MedlinePlus Health Information. consumer health - Skin Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Alveolar rhabdomyosarcoma on the external ear: a case report.
  • Alveolar rhabdomyosarcoma (RMS) is the most common soft tissue sarcoma of childhood.
  • [MeSH-major] Ear Neoplasms / pathology. Rhabdomyosarcoma, Alveolar / pathology. Skin Neoplasms / pathology

  • Genetic Alliance. consumer health - Rhabdomyosarcoma alveolar.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19208077.001).
  • [ISSN] 1600-0560
  • [Journal-full-title] Journal of cutaneous pathology
  • [ISO-abbreviation] J. Cutan. Pathol.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Denmark
  •  go-up   go-down


22. Kazanowska B, Reich A, Stegmaier S, Békássy AN, Leuschner I, Chybicka A, Koscielniak E: Pax3-fkhr and pax7-fkhr fusion genes impact outcome of alveolar rhabdomyosarcoma in children. Fetal Pediatr Pathol; 2007 Jan-Feb;26(1):17-31
NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Pax3-fkhr and pax7-fkhr fusion genes impact outcome of alveolar rhabdomyosarcoma in children.
  • Rhabdomyosarcoma is a highly malignant embryonic tumor of childhood.
  • In addition, fusion gene analysis is a helpful tool in differential diagnosis of poorly differentiated soft tissue tumors.
  • [MeSH-major] Forkhead Transcription Factors / genetics. PAX7 Transcription Factor / genetics. Paired Box Transcription Factors / genetics. Rhabdomyosarcoma, Alveolar / diagnosis. Rhabdomyosarcoma, Alveolar / genetics
  • [MeSH-minor] Adolescent. Adult. Child. Child, Preschool. Female. Gene Fusion. Head and Neck Neoplasms / diagnosis. Head and Neck Neoplasms / genetics. Head and Neck Neoplasms / pathology. Humans. Infant. Male. Neoplasm Staging. Prognosis. Retrospective Studies. Survival Analysis. Translocation, Genetic. Urinary Bladder Neoplasms / diagnosis. Urinary Bladder Neoplasms / genetics. Urinary Bladder Neoplasms / pathology. Urogenital Neoplasms / diagnosis. Urogenital Neoplasms / genetics. Urogenital Neoplasms / pathology

  • Genetic Alliance. consumer health - Rhabdomyosarcoma alveolar.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17613043.001).
  • [ISSN] 1551-3815
  • [Journal-full-title] Fetal and pediatric pathology
  • [ISO-abbreviation] Fetal Pediatr Pathol
  • [Language] eng
  • [Publication-type] Journal Article; Multicenter Study
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / FOXO1 protein, human; 0 / Forkhead Transcription Factors; 0 / PAX3 protein, human; 0 / PAX7 Transcription Factor; 0 / PAX7 protein, human; 0 / Paired Box Transcription Factors
  •  go-up   go-down


23. Nishijo K, Chen QR, Zhang L, McCleish AT, Rodriguez A, Cho MJ, Prajapati SI, Gelfond JA, Chisholm GB, Michalek JE, Aronow BJ, Barr FG, Randall RL, Ladanyi M, Qualman SJ, Rubin BP, LeGallo RD, Wang C, Khan J, Keller C: Credentialing a preclinical mouse model of alveolar rhabdomyosarcoma. Cancer Res; 2009 Apr 1;69(7):2902-11
SciCrunch. ArrayExpress: Data: Microarray .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Credentialing a preclinical mouse model of alveolar rhabdomyosarcoma.
  • The highly aggressive muscle cancer alveolar rhabdomyosarcoma (ARMS) is one of the most common soft tissue sarcoma of childhood, yet the outcome for the unresectable and metastatic disease is dismal and unchanged for nearly three decades.

  • Genetic Alliance. consumer health - Rhabdomyosarcoma alveolar.
  • COS Scholar Universe. author profiles.
  • KOMP Repository. gene/protein/disease-specific - KOMP Repository (subscription/membership/fee required).
  • Mouse Genome Informatics (MGI). Mouse Genome Informatics (MGI) .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Oncogene. 2007 Nov 8;26(51):7267-81 [17525748.001]
  • [Cites] Pediatr Blood Cancer. 2007 Dec;49(7):928-40 [17066459.001]
  • [Cites] Pediatr Blood Cancer. 2008 Jul;51(1):34-41 [18260120.001]
  • [Cites] Nat Rev Cancer. 2008 Jun;8(6):438-49 [18500245.001]
  • [Cites] Genes Dev. 2008 Jun 15;22(12):1662-76 [18559481.001]
  • [Cites] Clin Cancer Res. 2008 Jul 15;14(14):4572-83 [18628472.001]
  • [Cites] Cancer Res. 2008 Aug 15;68(16):6587-97 [18701482.001]
  • [Cites] Oncogene. 2008 Nov 20;27(51):6550-60 [18679424.001]
  • [Cites] Proc Natl Acad Sci U S A. 1999 Nov 9;96(23):13264-9 [10557309.001]
  • [Cites] Br J Cancer. 2001 Sep 14;85(6):831-5 [11556833.001]
  • [Cites] Genomics. 2002 Mar;79(3):278-84 [11863357.001]
  • [Cites] Neuromuscul Disord. 2002 Oct;12 Suppl 1:S125-41 [12206807.001]
  • [Cites] J Biol Chem. 2002 Nov 22;277(47):45276-84 [12228231.001]
  • [Cites] Clin Cancer Res. 2002 Dec;8(12):3646-57 [12473573.001]
  • [Cites] J Biol Chem. 2003 Jan 3;278(1):27-36 [12401804.001]
  • [Cites] Nat Genet. 2004 Jul;36(7):687-93 [15220918.001]
  • [Cites] Lab Invest. 2004 Aug;84(8):1060-70 [15184910.001]
  • [Cites] Cancer Res. 2004 Aug 15;64(16):5539-45 [15313887.001]
  • [Cites] Cancer Res. 1994 Jun 1;54(11):2869-72 [8187070.001]
  • [Cites] Oncogene. 1995 Jul 6;11(1):119-30 [7624119.001]
  • [Cites] Mol Cell Biol. 1998 Jul;18(7):4118-30 [9632796.001]
  • [Cites] N Engl J Med. 1999 Jul 29;341(5):342-52 [10423470.001]
  • [Cites] Genes Dev. 2004 Nov 1;18(21):2614-26 [15489287.001]
  • [Cites] Genes Dev. 2004 Nov 1;18(21):2608-13 [15520281.001]
  • [Cites] Lancet Oncol. 2005 Feb;6(2):77-84 [15683816.001]
  • [Cites] Proc Natl Acad Sci U S A. 2005 Feb 1;102(5):1649-54 [15668399.001]
  • [Cites] Oncogene. 2005 Mar 10;24(11):1860-72 [15688035.001]
  • [Cites] Cancer Res. 2005 Sep 1;65(17):7530-2 [16140913.001]
  • [Cites] Genome Biol. 2005;6(9):R76 [16168083.001]
  • [Cites] Muscle Nerve. 2005 Oct;32(4):483-91 [15962335.001]
  • [Cites] Proc Natl Acad Sci U S A. 2005 Oct 25;102(43):15545-50 [16199517.001]
  • [Cites] Mol Imaging. 2005 Oct-Dec;4(4):417-24 [16285903.001]
  • [Cites] J Cell Biol. 2006 Jan 2;172(1):91-102 [16380438.001]
  • [Cites] Mol Cell Biol. 2006 Apr;26(7):2531-9 [16537899.001]
  • [Cites] Int J Cancer. 2006 Jun 1;118(11):2772-81 [16381018.001]
  • [Cites] Oncogene. 2006 Apr 27;25(18):2615-27 [16331253.001]
  • [Cites] Mol Cell Biol. 2006 Jul;26(13):4782-93 [16782868.001]
  • [Cites] Cancer Res. 2006 Jul 15;66(14):6936-46 [16849537.001]
  • [Cites] Proc Natl Acad Sci U S A. 2006 Sep 5;103(36):13439-44 [16938866.001]
  • [Cites] Cancer Res. 2006 Oct 15;66(20):10171-8 [17047082.001]
  • [Cites] Development. 2007 Mar;134(6):1171-80 [17301086.001]
  • [Cites] Proc Natl Acad Sci U S A. 2007 Apr 3;104(14):5959-64 [17389406.001]
  • [Cites] J Pathol. 2007 Jun;212(2):143-51 [17471488.001]
  • [Cites] Genes Dev. 2007 Jun 1;21(11):1382-95 [17510286.001]
  • [Cites] Biochemistry. 2007 Aug 21;46(33):9551-63 [17655330.001]
  • [Cites] Cell Cycle. 2007 Nov 15;6(22):2846-54 [18032922.001]
  • (PMID = 19339268.001).
  • [ISSN] 1538-7445
  • [Journal-full-title] Cancer research
  • [ISO-abbreviation] Cancer Res.
  • [Language] ENG
  • [Grant] United States / NCI NIH HHS / CA / R01 CA074907-06; United States / NCI NIH HHS / CA / CA090438-06; United States / NCI NIH HHS / CA / CA064202-07; United States / NCI NIH HHS / CA / CA064202-13; United States / NCI NIH HHS / CA / R01 CA064202-08S1; United States / NCI NIH HHS / CA / P30CA54174; United States / NCI NIH HHS / CA / R01 CA064202-11; United States / NCI NIH HHS / CA / CA064202-08S1; United States / NCI NIH HHS / CA / R01 CA074907-09; United States / NCI NIH HHS / CA / K08 CA090438; United States / NCI NIH HHS / CA / CA074907-11; United States / NCI NIH HHS / CA / CA64202; United States / NCI NIH HHS / CA / R01 CA064202-06; United States / NCI NIH HHS / CA / R01 CA074907; United States / NCI NIH HHS / CA / CA064202-08; United States / NCI NIH HHS / CA / CA074907-07; United States / NCI NIH HHS / CA / R01 CA064202-14; United States / NCI NIH HHS / CA / R01 CA064202-13; United States / NCI NIH HHS / CA / R01 CA064202-07; United States / NCI NIH HHS / CA / R29 CA074907; United States / NCI NIH HHS / CA / CA074907-08; United States / NCI NIH HHS / CA / R01 CA064202-09; United States / NCI NIH HHS / CA / R01 CA064202; United States / NCI NIH HHS / CA / CA074907; United States / NCI NIH HHS / CA / CA074907-10A1; United States / NCI NIH HHS / CA / CA064202-11; United States / NCI NIH HHS / CA / CA074907-09; United States / NCI NIH HHS / CA / CA074907-06; United States / NCI NIH HHS / CA / R01 CA064202-08; United States / NCI NIH HHS / CA / R01 CA074907-11; United States / NCI NIH HHS / CA / CA064202-14; United States / NCI NIH HHS / CA / CA064202-10A1; United States / NCI NIH HHS / CA / R01 CA074907-07; United States / NCI NIH HHS / CA / P30 CA054174; United States / NCI NIH HHS / CA / CA064202-12; United States / NCI NIH HHS / CA / R01 CA074907-08; United States / NCI NIH HHS / CA / CA064202-06; United States / NCI NIH HHS / CA / R01 CA064202-12; United States / NCI NIH HHS / CA / K08 CA090438-06; United States / NCI NIH HHS / CA / R01 CA064202-10A1; United States / NCI NIH HHS / CA / CA064202-09; United States / NCI NIH HHS / CA / R01 CA074907-10A1
  • [Publication-type] Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Cdkn2a protein, mouse; 0 / Cyclin-Dependent Kinase Inhibitor p16; 0 / Forkhead Transcription Factors; 0 / Foxo1 protein, mouse; 0 / Oncogene Proteins, Fusion; 0 / PAX3-FKHR fusion protein, human; 0 / Paired Box Transcription Factors; 0 / Tumor Suppressor Protein p53; 138016-91-8 / Pax3 protein, mouse
  • [Other-IDs] NLM/ NIHMS96027; NLM/ PMC2789740
  •  go-up   go-down


24. Zibat A, Missiaglia E, Rosenberger A, Pritchard-Jones K, Shipley J, Hahn H, Fulda S: Activation of the hedgehog pathway confers a poor prognosis in embryonal and fusion gene-negative alveolar rhabdomyosarcoma. Oncogene; 2010 Dec 2;29(48):6323-30
NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Activation of the hedgehog pathway confers a poor prognosis in embryonal and fusion gene-negative alveolar rhabdomyosarcoma.
  • Rhabdomyosarcoma (RMS) is the most common soft tissue sarcoma in children and comprises two major histological subtypes: alveolar rhabdomyosarcoma (ARMS) and embryonal rhabdomyosarcoma (ERMS).
  • [MeSH-major] Hedgehog Proteins / physiology. Rhabdomyosarcoma, Alveolar / metabolism. Rhabdomyosarcoma, Embryonal / metabolism. Signal Transduction / physiology
  • [MeSH-minor] Adolescent. Adult. Child. Child, Preschool. Female. Gene Fusion. Humans. Infant. Kruppel-Like Transcription Factors / analysis. Male. Myogenic Regulatory Factor 5 / analysis. Nerve Tissue Proteins / analysis. Prognosis. Receptors, Cell Surface / analysis. Transcription Factors / analysis

  • Genetic Alliance. consumer health - Rhabdomyosarcoma alveolar.
  • Genetic Alliance. consumer health - Rhabdomyosarcoma embryonal.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20818440.001).
  • [ISSN] 1476-5594
  • [Journal-full-title] Oncogene
  • [ISO-abbreviation] Oncogene
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] England
  • [Chemical-registry-number] 0 / GLI1 protein, human; 0 / GLI3 protein, human; 0 / Hedgehog Proteins; 0 / Kruppel-Like Transcription Factors; 0 / MYF5 protein, human; 0 / Myogenic Regulatory Factor 5; 0 / Nerve Tissue Proteins; 0 / Receptors, Cell Surface; 0 / Transcription Factors; 0 / patched receptors
  •  go-up   go-down


25. Cil T, Altintas A, Isikdogan A: Rhabdomyosarcoma presenting with destructive large lesion of the face. South Med J; 2008 Jan;101(1):104-5
MedlinePlus Health Information. consumer health - Soft Tissue Sarcoma.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Rhabdomyosarcoma presenting with destructive large lesion of the face.
  • Rhabdomyosarcoma (RMS) is the most common soft tissue sarcoma in children and adolescents.
  • Prognostic factors of RMS include tumor status, primary tumor site, localization in the organ or tissue of origin, patient age and histopathological type.
  • Alveolar histologic type is more aggressive than the other types and is seen in most patients with locally advanced and metastatic disease.
  • She was diagnosed with alveolar rhabdomyosarcoma on histopathological examination.
  • [MeSH-major] Facial Neoplasms / diagnosis. Rhabdomyosarcoma, Alveolar / diagnosis. Sarcoma / diagnosis

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18176304.001).
  • [ISSN] 1541-8243
  • [Journal-full-title] Southern medical journal
  • [ISO-abbreviation] South. Med. J.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] United States
  •  go-up   go-down


26. Siegel HJ, Connor GS, Lee D, Lopez-Ben R, Kelly DR: Synchronous bifocal alveolar rhabdomyosarcoma: a case report. J Bone Joint Surg Br; 2006 Jul;88(7):955-8
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Synchronous bifocal alveolar rhabdomyosarcoma: a case report.
  • We report a case of bifocal rhabdomyosarcoma involving the hand and thigh in an 11-year-old female.
  • [MeSH-major] Rhabdomyosarcoma, Alveolar / pathology. Soft Tissue Neoplasms / pathology

  • Genetic Alliance. consumer health - Rhabdomyosarcoma alveolar.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16799004.001).
  • [ISSN] 0301-620X
  • [Journal-full-title] The Journal of bone and joint surgery. British volume
  • [ISO-abbreviation] J Bone Joint Surg Br
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] England
  •  go-up   go-down


27. Ventura-Holman T, Hahn H, Subauste JS, Maher JF: The Fem1a gene is downregulated in Rhabdomyosarcoma. Tumour Biol; 2005 Nov-Dec;26(6):294-9
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] The Fem1a gene is downregulated in Rhabdomyosarcoma.
  • Rhabdomyosarcoma (RMS) is the most common soft tissue neoplasm of children, and those metastatic at presentation have a poor prognosis.
  • We find that the human homolog, FEM1A, is downregulated in all of 8 different human RMS cell lines, including those derived from embryonal and alveolar RMS.
  • [MeSH-major] Cell Cycle Proteins / genetics. Down-Regulation / genetics. Gene Expression Regulation, Neoplastic / genetics. Rhabdomyosarcoma / genetics

  • COS Scholar Universe. author profiles.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] Copyright 2005 S. Karger AG, Basel.
  • (PMID = 16254458.001).
  • [ISSN] 1010-4283
  • [Journal-full-title] Tumour biology : the journal of the International Society for Oncodevelopmental Biology and Medicine
  • [ISO-abbreviation] Tumour Biol.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, U.S. Gov't, Non-P.H.S.
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Cell Cycle Proteins; 0 / FEM1A protein, human; 0 / Fem1a protein, mouse
  •  go-up   go-down


28. Kuhnen C, Herter P, Leuschner I, Mentzel T, Druecke D, Jaworska M, Johnen G: Sclerosing pseudovascular rhabdomyosarcoma-immunohistochemical, ultrastructural, and genetic findings indicating a distinct subtype of rhabdomyosarcoma. Virchows Arch; 2006 Nov;449(5):572-8

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Sclerosing pseudovascular rhabdomyosarcoma-immunohistochemical, ultrastructural, and genetic findings indicating a distinct subtype of rhabdomyosarcoma.
  • Sclerosing (pseudovascular) rhabdomyosarcoma in adults has been described as a rare variant of rhabdomyosarcoma characterized by extensive hyaline fibrosis and pseudovascular growth patterns.
  • We describe another case of this rhabdomyosarcoma subtype including ultrastructural and genetic findings-the lesion presented in a 62-year-old male patient in the left lower leg.
  • The tumor was located within the deep soft tissue with maximum diameter of 11.8 cm and skin ulceration.
  • Reciprocal translocations t(1;13) and t(2;13)(q35;q14) which are characteristic of alveolar rhabdomyosarcoma could be excluded.
  • These findings, while showing a relation to other rhabdomyosarcoma subtypes, represent a relatively circumscribed genetic defect pattern in sclerosing (pseudovascular) rhabdomyosarcoma that is somewhat different from patterns described in most other rhabdomyosarcoma subtypes.
  • Further studies should concentrate on the identification of genes especially on chromosomal region 10q22 to elucidate more aspects in the pathogenesis of this rhabdomyosarcoma subtype.
  • [MeSH-major] Chromosome Aberrations. Rhabdomyosarcoma / pathology. Soft Tissue Neoplasms / pathology

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Am J Pathol. 2001 Nov;159(5):1925-32 [11696453.001]
  • [Cites] Cancer. 1988 Nov 1;62(9):2060-5 [3167818.001]
  • [Cites] Cancer Genet Cytogenet. 2003 Jan 1;140(1):73-7 [12550764.001]
  • [Cites] Mod Pathol. 2000 Sep;13(9):1005-13 [11007041.001]
  • [Cites] Virchows Arch. 2000 Sep;437(3):248-55 [11037344.001]
  • [Cites] Pediatr Dev Pathol. 2004 Nov-Dec;7(6):583-94 [15630526.001]
  • [Cites] Genes Chromosomes Cancer. 2002 Mar;33(3):310-21 [11807989.001]
  • [Cites] J Clin Oncol. 2000 Jul;18(13):2582-92 [10893290.001]
  • [Cites] Virchows Arch. 2000 Apr;436(4):305-11 [10834531.001]
  • [Cites] Am J Surg Pathol. 2002 Sep;26(9):1175-83 [12218574.001]
  • [Cites] Am J Surg Pathol. 1993 Jun;17(6):601-9 [8333559.001]
  • [Cites] Mod Pathol. 2001 Jun;14(6):595-603 [11406662.001]
  • [Cites] J Pathol. 2002 Jul;197(3):363-71 [12115883.001]
  • [Cites] Semin Diagn Pathol. 1994 Feb;11(1):47-57 [8202646.001]
  • [Cites] Laryngoscope. 2005 Jan;115(1):48-50 [15630365.001]
  • [Cites] Cancer Res. 1996 Jul 15;56(14):3220-4 [8764111.001]
  • [Cites] Am J Surg Pathol. 2005 Aug;29(8):1106-13 [16006807.001]
  • [Cites] Pediatr Dev Pathol. 2004 Jul-Aug;7(4):391-6 [15383934.001]
  • [Cites] Virchows Arch. 2005 Jan;446(1):64-7 [15660283.001]
  • (PMID = 17016719.001).
  • [ISSN] 0945-6317
  • [Journal-full-title] Virchows Archiv : an international journal of pathology
  • [ISO-abbreviation] Virchows Arch.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Germany
  •  go-up   go-down


29. Mercado GE, Xia SJ, Zhang C, Ahn EH, Gustafson DM, Laé M, Ladanyi M, Barr FG: Identification of PAX3-FKHR-regulated genes differentially expressed between alveolar and embryonal rhabdomyosarcoma: focus on MYCN as a biologically relevant target. Genes Chromosomes Cancer; 2008 Jun;47(6):510-20
NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Identification of PAX3-FKHR-regulated genes differentially expressed between alveolar and embryonal rhabdomyosarcoma: focus on MYCN as a biologically relevant target.
  • Rhabdomyosarcoma is a family of myogenic soft tissue tumors subdivided into two main subtypes: alveolar (ARMS) and embryonal (ERMS).
  • [MeSH-major] Gene Expression Regulation, Neoplastic. Nuclear Proteins / physiology. Oncogene Proteins / physiology. Oncogene Proteins, Fusion / physiology. Rhabdomyosarcoma, Alveolar / genetics. Rhabdomyosarcoma, Embryonal / genetics. Soft Tissue Neoplasms / genetics

  • Genetic Alliance. consumer health - Rhabdomyosarcoma alveolar.
  • Genetic Alliance. consumer health - Rhabdomyosarcoma embryonal.
  • COS Scholar Universe. author profiles.
  • Hazardous Substances Data Bank. CYCLOHEXIMIDE .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18335505.001).
  • [ISSN] 1098-2264
  • [Journal-full-title] Genes, chromosomes & cancer
  • [ISO-abbreviation] Genes Chromosomes Cancer
  • [Language] eng
  • [Grant] United States / NCI NIH HHS / CA / CA104896; United States / NCI NIH HHS / CA / CA106450; United States / NCI NIH HHS / CA / CA64202; United States / NCI NIH HHS / CA / CA87812
  • [Publication-type] Comparative Study; Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / MYCN protein, human; 0 / Neoplasm Proteins; 0 / Nuclear Proteins; 0 / Oncogene Proteins; 0 / Oncogene Proteins, Fusion; 0 / PAX3-FKHR fusion protein, human; 0 / Protein Synthesis Inhibitors; 0 / RNA, Messenger; 0 / RNA, Neoplasm; 0 / Recombinant Fusion Proteins; 98600C0908 / Cycloheximide
  •  go-up   go-down


30. Qualman S, Lynch J, Bridge J, Parham D, Teot L, Meyer W, Pappo A: Prevalence and clinical impact of anaplasia in childhood rhabdomyosarcoma : a report from the Soft Tissue Sarcoma Committee of the Children's Oncology Group. Cancer; 2008 Dec 1;113(11):3242-7
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Prevalence and clinical impact of anaplasia in childhood rhabdomyosarcoma : a report from the Soft Tissue Sarcoma Committee of the Children's Oncology Group.
  • BACKGROUND: Anapalsia is rare in childhood rhabdomyosarcoma and has not been included in the International Classification of Rhabdomyosarcoma (ICR).
  • A recent review of cases from the Soft Tissue Sarcoma Committee of the Children's Oncology Group (COG) suggests that anaplasia might be more common than previously reported and may impact clinical outcome.
  • METHODS: The prevalence of anaplasia (focal or diffuse) was prospectively assessed in 546 eligible cases who were registered in an Intergroup Rhabdomyosarcoma Study Group (IRSG) or COG therapeutic trial from 1995 through 1998.
  • Regardless of its distribution (focal or diffuse), on univariate analysis the presence of anaplasia negatively influenced the failure-free survival rate (63% vs 77% at 5 years) and overall survival (68% vs 82% at 5 years) rates in patients with embryonal rhabdomyosarcoma.
  • Anaplasia did not affect outcome in patients with alveolar tumors.
  • CONCLUSIONS: The incidence of anaplasia in patients with rhabdomyosarcoma is higher than previously described and may be of prognostic significance in children with intermediate-risk embryonal rhabdomyosarcoma.

  • Genetic Alliance. consumer health - Soft tissue sarcoma.
  • MedlinePlus Health Information. consumer health - Soft Tissue Sarcoma.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] (c) 2008 American Cancer Society
  • [Cites] J Clin Oncol. 2001 Jun 15;19(12):3091-102 [11408506.001]
  • [Cites] Genes Chromosomes Cancer. 2002 Mar;33(3):310-21 [11807989.001]
  • [Cites] J Pediatr Hematol Oncol. 2001 May;23(4):215-20 [11846299.001]
  • [Cites] Cancer. 2002 Jan 15;94(2):552-60 [11900240.001]
  • [Cites] Arch Pathol Lab Med. 2003 Oct;127(10):1290-7 [14521467.001]
  • [Cites] Brain Res Mol Brain Res. 2004 Feb 5;121(1-2):137-40 [14969745.001]
  • [Cites] J Clin Oncol. 2004 Mar 15;22(6):984-93 [14970185.001]
  • [Cites] Mod Pathol. 2004 May;17(5):518-25 [15044915.001]
  • [Cites] Cancer. 1988 Jan 15;61(2):209-20 [3275486.001]
  • [Cites] Cancer. 1993 Mar 1;71(5):1904-22 [8448756.001]
  • [Cites] Am J Surg Pathol. 1993 May;17(5):443-53 [8470759.001]
  • [Cites] Nat Genet. 1994 May;7(1):91-7 [8075648.001]
  • [Cites] J Clin Oncol. 1995 Mar;13(3):610-30 [7884423.001]
  • [Cites] Am J Pathol. 1996 May;148(5):1577-89 [8623926.001]
  • [Cites] Cancer. 1995 Sep 15;76(6):1073-85 [8625211.001]
  • [Cites] Am J Surg Pathol. 1996 Aug;20(8):909-20 [8712292.001]
  • [Cites] Cancer. 1997 Sep 15;80(6):1165-70 [9305719.001]
  • [Cites] Pediatr Dev Pathol. 1998 Nov-Dec;1(6):550-61 [9724344.001]
  • [Cites] J Clin Oncol. 2006 May 20;24(15):2352-8 [16710034.001]
  • [Cites] J Clin Oncol. 2006 Aug 20;24(24):3844-51 [16921036.001]
  • [Cites] Lancet Oncol. 2006 Oct;7(10):813-20 [17012043.001]
  • [Cites] Cancer Cell. 2006 Oct;10(4):281-93 [17045206.001]
  • [Cites] J Clin Oncol. 2007 Feb 1;25(4):362-9 [17264331.001]
  • [Cites] Clin Cancer Res. 2007 Nov 15;13(22 Pt 1):6593-602 [18006759.001]
  • [ErratumIn] Cancer. 2009 Jun 15;115(12):2806
  • (PMID = 18985676.001).
  • [ISSN] 0008-543X
  • [Journal-full-title] Cancer
  • [ISO-abbreviation] Cancer
  • [Language] ENG
  • [Grant] United States / NCI NIH HHS / CA / U10 CA098543-06; United States / NCI NIH HHS / CA / U10 CA098413-06; United States / NCI NIH HHS / CA / U10 CA098413; None / None / / U10 CA024507-25; United States / NCI NIH HHS / CA / U10 CA024507-26; United States / NCI NIH HHS / CA / U10 CA098543; None / None / / U10 CA098413-06; None / None / / U10 CA024507-26; United States / NCI NIH HHS / CA / U10 CA024507-25; None / None / / U10 CA098543-06; United States / NCI NIH HHS / CA / U10 CA024507
  • [Publication-type] Journal Article; Research Support, N.I.H., Extramural
  • [Publication-country] United States
  • [Other-IDs] NLM/ NIHMS107192; NLM/ PMC2727712
  •  go-up   go-down


31. Barr FG, Smith LM, Lynch JC, Strzelecki D, Parham DM, Qualman SJ, Breitfeld PP: Examination of gene fusion status in archival samples of alveolar rhabdomyosarcoma entered on the Intergroup Rhabdomyosarcoma Study-III trial: a report from the Children's Oncology Group. J Mol Diagn; 2006 May;8(2):202-8
The Lens. Cited by Patents in .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Examination of gene fusion status in archival samples of alveolar rhabdomyosarcoma entered on the Intergroup Rhabdomyosarcoma Study-III trial: a report from the Children's Oncology Group.
  • Alveolar rhabdomyosarcoma (ARMS) is a soft tissue cancer in which chromosomal translocations generate PAX3-FKHR and PAX7-FKHR gene fusions.
  • We applied this approach to a convenience sample of 78 formalin-fixed, paraffin-embedded ARMS tumors from the Intergroup Rhabdomyosarcoma Study (IRS)-III clinical trial and obtained satisfactory results in 59 (76%) cases.

  • Genetic Alliance. consumer health - Rhabdomyosarcoma alveolar.
  • COS Scholar Universe. author profiles.
  • Faculty of 1000. commentaries/discussion - See the articles recommended by F1000Prime's Faculty of more than 8,000 leading experts in Biology and Medicine. (subscription/membership/fee required).
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] J Clin Oncol. 1995 Mar;13(3):610-30 [7884423.001]
  • [Cites] Cancer. 1995 Sep 15;76(6):1073-85 [8625211.001]
  • [Cites] Diagn Mol Pathol. 1997 Apr;6(2):91-7 [9098647.001]
  • [Cites] JAMA. 1995 Feb 15;273(7):553-7 [7530783.001]
  • [Cites] Oncogene. 2001 Sep 10;20(40):5736-46 [11607823.001]
  • [Cites] J Clin Oncol. 2002 Jun 1;20(11):2672-9 [12039929.001]
  • [Cites] EMBO J. 1993 Dec;12(12):4481-7 [8223458.001]
  • [Cites] Cancer. 1958 Jan-Feb;11(1):181-99 [13500314.001]
  • (PMID = 16645206.001).
  • [ISSN] 1525-1578
  • [Journal-full-title] The Journal of molecular diagnostics : JMD
  • [ISO-abbreviation] J Mol Diagn
  • [Language] ENG
  • [Grant] United States / NCI NIH HHS / CA / CA24507; United States / NCI NIH HHS / CA / CA89461; United States / NCI NIH HHS / CA / CA98543; United States / NCI NIH HHS / CA / U10 CA098413; United States / NCI NIH HHS / CA / U10 CA098543; United States / NCI NIH HHS / CA / CA98413; United States / NCI NIH HHS / CA / U10 CA024507; United States / NCI NIH HHS / CA / R01 CA089461
  • [Publication-type] Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / FOXO1 protein, human; 0 / Forkhead Transcription Factors; 0 / Neoplasm Proteins; 0 / PAX3 protein, human; 0 / PAX7 Transcription Factor; 0 / PAX7 protein, human; 0 / Paired Box Transcription Factors; 0 / RNA, Messenger
  • [Other-IDs] NLM/ PMC1867584
  •  go-up   go-down


32. Javangula KC, O'Regan DJ: Emergency surgery for left atrial metastatic alveolar rhabdomyosarcoma manifesting as a right atrial mass. Ann Thorac Surg; 2008 Sep;86(3):1008-11
Genetic Alliance. consumer health - Rhabdomyosarcoma alveolar.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Emergency surgery for left atrial metastatic alveolar rhabdomyosarcoma manifesting as a right atrial mass.
  • We report the case of a 43-year-old woman with a history of alveolar rhabdomyosarcoma of the forearm, scalp, and paraspinal region who developed acute shortness of breath owing to a tumor arising from the left atrium and extending through the coronary sinus.
  • Emergency resection of the atrial mass was performed, and histologic analysis confirmed the presence of metastatic rhabdomyosarcoma.
  • To our knowledge, this is the first reported case of emergency surgical resection of intracardiac metastatic alveolar rhabdomyosarcoma.
  • [MeSH-major] Heart Neoplasms / secondary. Heart Neoplasms / surgery. Rhabdomyosarcoma, Alveolar / pathology. Rhabdomyosarcoma, Alveolar / secondary. Rhabdomyosarcoma, Alveolar / surgery. Soft Tissue Neoplasms / pathology

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18721606.001).
  • [ISSN] 1552-6259
  • [Journal-full-title] The Annals of thoracic surgery
  • [ISO-abbreviation] Ann. Thorac. Surg.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Netherlands
  •  go-up   go-down


33. Paner GP, McKenney JK, Epstein JI, Amin MB: Rhabdomyosarcoma of the urinary bladder in adults: predilection for alveolar morphology with anaplasia and significant morphologic overlap with small cell carcinoma. Am J Surg Pathol; 2008 Jul;32(7):1022-8
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Rhabdomyosarcoma of the urinary bladder in adults: predilection for alveolar morphology with anaplasia and significant morphologic overlap with small cell carcinoma.
  • Rhabdomyosarcoma (RMS) represents the most common malignant soft tissue tumor in children and adolescents with the urinary bladder representing a frequent site.
  • We report the clinicopathologic features of 5 bladder neoplasms with rhabdomyosarcomatous differentiation in adults and emphasize the differential diagnosis in the adult setting.
  • Three cases were of the alveolar subtype (1 admixed with embryonal histology) and 2 were RMS, not further classified.
  • In conclusion, (1) RMS of the urinary bladder in adults more commonly presents as a primitive round blue cell neoplasm that has significant morphologic and immunohistochemical overlap with small cell carcinoma of the bladder. (2) Although RMS in children generally have a botryoid embryonal histology with favorable outcome, bladder RMS in adults frequently demonstrates alveolar or unclassified histology, commonly with anaplasia, and have a uniformly aggressive clinical course.
  • [MeSH-major] Carcinoma, Small Cell / pathology. Rhabdomyosarcoma, Alveolar / pathology. Urinary Bladder Neoplasms / pathology
  • [MeSH-minor] Adult. Aged. Aged, 80 and over. Anaplasia. Biomarkers, Tumor / analysis. Cell Nucleus / pathology. Combined Modality Therapy. Desmin / analysis. Diagnosis, Differential. Fatal Outcome. Female. Humans. Male. Middle Aged. MyoD Protein / analysis. Myogenin / analysis. Synaptophysin / analysis

  • Genetic Alliance. consumer health - Rhabdomyosarcoma alveolar.
  • MedlinePlus Health Information. consumer health - Bladder Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18469707.001).
  • [ISSN] 1532-0979
  • [Journal-full-title] The American journal of surgical pathology
  • [ISO-abbreviation] Am. J. Surg. Pathol.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Biomarkers, Tumor; 0 / Desmin; 0 / MyoD Protein; 0 / MyoD1 myogenic differentiation protein; 0 / Myogenin; 0 / Synaptophysin
  •  go-up   go-down


34. Moon HS, Kwon SW, Lee JH: A case of alveolar rhabdomyosarcoma of the ethmoid sinus invading the orbit in an adult. Korean J Ophthalmol; 2006 Mar;20(1):70-5
Genetic Alliance. consumer health - Rhabdomyosarcoma alveolar.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] A case of alveolar rhabdomyosarcoma of the ethmoid sinus invading the orbit in an adult.
  • PURPOSE: A case study and literature review of alveolar rhabdomyosarcoma (RMS) in an adult.
  • A computed tomography (CT) scan revealed a destructive soft-tissue mass in the left ethmoid sinus with invasion of the left orbit and compression of the medial rectus muscle.
  • Endoscopic intranasal biopsy revealed alveolar RMS.
  • RESULTS: Immunohistochemical testing was positive for desmin, S-100, and smooth muscle actin (SMA), supporting the diagnosis of RMS.
  • CONCLUSIONS: Although rarely found in adults, RMS should be considered in the differential diagnosis of orbital tumors.
  • Immunohistochemical analysis plays an important role in the definitive diagnosis of RMS.
  • [MeSH-major] Ethmoid Sinus. Orbital Neoplasms / pathology. Paranasal Sinus Neoplasms / pathology. Rhabdomyosarcoma, Alveolar / pathology
  • [MeSH-minor] Biopsy. Diagnosis, Differential. Humans. Magnetic Resonance Imaging. Male. Middle Aged. Neoplasm Invasiveness. Tomography, X-Ray Computed

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Cancer. 2001 Feb 15;91(4):794-803 [11241248.001]
  • [Cites] Virchows Arch Pathol Anat Physiol Klin Med. 1962;335:329-44 [14488094.001]
  • [Cites] Ann Surg. 2001 Aug;234(2):215-23 [11505068.001]
  • [Cites] Ophthalmology. 2001 Dec;108(12):2284-92 [11733272.001]
  • [Cites] Trans Am Ophthalmol Soc. 2001;99:133-42; discussion 142-3 [11797301.001]
  • [Cites] Cancer. 2002 Jul 15;95(2):377-88 [12124838.001]
  • [Cites] Surv Ophthalmol. 2003 Jan-Feb;48(1):39-57 [12559326.001]
  • [Cites] Cancer Control. 2004 Sep-Oct;11(5):328-33 [15377992.001]
  • [Cites] Laryngoscope. 1975 Feb;85(2):400-10 [46581.001]
  • [Cites] J Oral Maxillofac Surg. 1988 Dec;46(12):1090-6 [3057148.001]
  • [Cites] Ophthal Plast Reconstr Surg. 1994 Dec;10(4):283-6 [7865452.001]
  • [Cites] J Clin Oncol. 1995 Mar;13(3):610-30 [7884423.001]
  • [Cites] Clin Imaging. 1995 Oct-Dec;19(4):234-6 [8564864.001]
  • [Cites] Clin Radiol. 1998 May;53(5):357-62 [9630275.001]
  • [Cites] Cancer. 1958 Jan-Feb;11(1):181-99 [13500314.001]
  • [Cites] J Clin Oncol. 2001 Jun 15;19(12):3091-102 [11408506.001]
  • (PMID = 16768194.001).
  • [ISSN] 1011-8942
  • [Journal-full-title] Korean journal of ophthalmology : KJO
  • [ISO-abbreviation] Korean J Ophthalmol
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Korea (South)
  • [Other-IDs] NLM/ PMC2908821
  •  go-up   go-down


35. Taulli R, Scuoppo C, Bersani F, Accornero P, Forni PE, Miretti S, Grinza A, Allegra P, Schmitt-Ney M, Crepaldi T, Ponzetto C: Validation of met as a therapeutic target in alveolar and embryonal rhabdomyosarcoma. Cancer Res; 2006 May 1;66(9):4742-9
The Lens. Cited by Patents in .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Validation of met as a therapeutic target in alveolar and embryonal rhabdomyosarcoma.
  • Rhabdomyosarcoma (RMS) is a highly malignant soft-tissue tumor of childhood deriving from skeletal muscle cells.
  • RMS can be classified in two major histologic subtypes: embryonal (ERMS) and alveolar (ARMS), the latter being characterized by the PAX3/7-FKHR translocation.
  • This property was lost in low serum but addition of hepatocyte growth factor/scatter factor (HGF/SF) rescued soft-agar growth.
  • Only Met(+/+) MEFs acquired anchorage-independent growth whereas PAX3-FKHR-transduced Met(D/D) cells were unable to form colonies in soft agar.
  • [MeSH-major] Proto-Oncogene Proteins / antagonists & inhibitors. Proto-Oncogene Proteins / physiology. Receptors, Growth Factor / antagonists & inhibitors. Receptors, Growth Factor / physiology. Rhabdomyosarcoma, Alveolar / therapy. Rhabdomyosarcoma, Embryonal / therapy

  • Genetic Alliance. consumer health - Rhabdomyosarcoma alveolar.
  • Genetic Alliance. consumer health - Rhabdomyosarcoma embryonal.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16651427.001).
  • [ISSN] 0008-5472
  • [Journal-full-title] Cancer research
  • [ISO-abbreviation] Cancer Res.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / FOXO1 protein, human; 0 / Forkhead Transcription Factors; 0 / Oncogene Proteins, Fusion; 0 / PAX3 protein, human; 0 / Paired Box Transcription Factors; 0 / Proto-Oncogene Proteins; 0 / RNA, Small Interfering; 0 / Receptors, Growth Factor; 67256-21-7 / Hepatocyte Growth Factor; EC 2.7.10.1 / MET protein, human; EC 2.7.10.1 / Proto-Oncogene Proteins c-met
  •  go-up   go-down


36. Cheung MC, Zhuge Y, Yang R, Ogilvie MP, Koniaris LG, Rodríguez MM, Sola JE: Incidence and outcomes of extremity soft-tissue sarcomas in children. J Surg Res; 2010 Oct;163(2):282-9
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Incidence and outcomes of extremity soft-tissue sarcomas in children.
  • The median age at diagnosis was 12 y, but most patients were ≥10 y of age (72%, n = 842).
  • Most tumors were non-rhabdomyosarcoma soft tissue sarcomas (NRSTS) (79%, n = 879).
  • The most common tissue of origin was muscle (43%, n = 474).
  • Most rhabdomyosarcoma (RMS) (n = 220) were alveolar type (n = 140).
  • Multivariate analysis identified RMS (HR 2.20, P < 0.001), nerve and muscle (not synovial sarcoma) tissue of origin (HR 2.26, P = 0.002, and HR 1.59, P = 0.036), regional or distant disease (HR 1.65, P = 0.011, and HR 5.96, P < 0.001, respectively), and lack of surgical intervention (HR 2.20, P < 0.001) as independent predictors of poor outcome.
  • [MeSH-major] Extremities. Sarcoma / epidemiology. Soft Tissue Neoplasms / epidemiology
  • [MeSH-minor] Adolescent. Adult. Child. Child, Preschool. Female. Humans. Incidence. Infant. Infant, Newborn. Male. Multivariate Analysis. Rhabdomyosarcoma / epidemiology. Rhabdomyosarcoma / mortality. SEER Program

  • MedlinePlus Health Information. consumer health - Soft Tissue Sarcoma.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] Copyright © 2010 Elsevier Inc. All rights reserved.
  • (PMID = 20638678.001).
  • [ISSN] 1095-8673
  • [Journal-full-title] The Journal of surgical research
  • [ISO-abbreviation] J. Surg. Res.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


37. Cecchetto G, Carretto E, Bisogno G, Dall'Igna P, Ferrari A, Scarzello G, Donfrancesco A, Alaggio R, Indolfi P, Carli M: Complete second look operation and radiotherapy in locally advanced non-alveolar rhabdomyosarcoma in children: A report from the AIEOP soft tissue sarcoma committee. Pediatr Blood Cancer; 2008 Nov;51(5):593-7
Genetic Alliance. consumer health - Soft tissue sarcoma.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Complete second look operation and radiotherapy in locally advanced non-alveolar rhabdomyosarcoma in children: A report from the AIEOP soft tissue sarcoma committee.
  • BACKGROUND: To evaluate the effect of radiotherapy (RT) in association with complete second look operation, histologically confirmed, on outcome of patients with IRS Gr.III non-alveolar RMS.
  • Although the limited number of patients does not allow statistically significant conclusions, our experience suggests that RT may have a positive influence on local control for completely resected non-alveolar RMS.
  • [MeSH-major] Rhabdomyosarcoma / radiotherapy. Rhabdomyosarcoma / surgery. Second-Look Surgery

  • Genetic Alliance. consumer health - Rhabdomyosarcoma alveolar.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] (c) 2008 Wiley-Liss, Inc.
  • (PMID = 18668515.001).
  • [ISSN] 1545-5017
  • [Journal-full-title] Pediatric blood & cancer
  • [ISO-abbreviation] Pediatr Blood Cancer
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  •  go-up   go-down


38. Goldstein M, Meller I, Issakov J, Orr-Urtreger A: Novel genes implicated in embryonal, alveolar, and pleomorphic rhabdomyosarcoma: a cytogenetic and molecular analysis of primary tumors. Neoplasia; 2006 May;8(5):332-43
NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Novel genes implicated in embryonal, alveolar, and pleomorphic rhabdomyosarcoma: a cytogenetic and molecular analysis of primary tumors.
  • Rhabdomyosarcoma, the most common pediatric soft tissue sarcoma, likely results from deregulation of the skeletal myogenesis program.
  • Using a combined approach of spectral karyotyping, array-based comparative genomic hybridization (CGH), and expression analysis, we examined 10 primary RMS tumors, including embryonal, alveolar, and the rare adult pleomorphic variant, to explore the involvement of different genes and genetic pathways in RMS tumorigenesis.
  • [MeSH-major] Biomarkers, Tumor / metabolism. Genetic Predisposition to Disease. Neoplasms / genetics. Rhabdomyosarcoma, Alveolar / genetics. Rhabdomyosarcoma, Alveolar / metabolism. Rhabdomyosarcoma, Embryonal / embryology. Rhabdomyosarcoma, Embryonal / genetics

  • Genetic Alliance. consumer health - Rhabdomyosarcoma alveolar.
  • Genetic Alliance. consumer health - Rhabdomyosarcoma embryonal.
  • MedlinePlus Health Information. consumer health - Cancer in Children.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] J Biol Chem. 2001 Oct 5;276(40):37307-16 [11489882.001]
  • [Cites] Int J Cancer. 2006 Jun 1;118(11):2772-81 [16381018.001]
  • [Cites] Oncogene. 2001 Sep 10;20(40):5736-46 [11607823.001]
  • [Cites] Am J Physiol Cell Physiol. 2002 Feb;282(2):C383-94 [11788350.001]
  • [Cites] Genes Chromosomes Cancer. 2002 Mar;33(3):310-21 [11807989.001]
  • [Cites] EMBO J. 2002 Feb 15;21(4):483-92 [11847097.001]
  • [Cites] J Pathol. 2002 Apr;196(4):450-8 [11920742.001]
  • [Cites] Oncogene. 2002 Apr 25;21(18):2901-7 [11973651.001]
  • [Cites] Cytogenet Cell Genet. 2001;95(3-4):134-42 [12063389.001]
  • [Cites] Jpn J Cancer Res. 2002 Jun;93(6):652-9 [12079513.001]
  • [Cites] Oncogene. 2002 Sep 9;21(40):6175-83 [12214247.001]
  • [Cites] Mol Cell Biol. 2002 Oct;22(20):7204-16 [12242297.001]
  • [Cites] Cancer Res. 2002 Dec 1;62(23):6803-7 [12460888.001]
  • [Cites] Cancer Genet Cytogenet. 2003 Jan 1;140(1):73-7 [12550764.001]
  • [Cites] Biol Cell. 2002 Nov;94(7-8):535-43 [12566226.001]
  • [Cites] Cancer Genet Cytogenet. 2003 Mar;141(2):120-7 [12606129.001]
  • [Cites] Biochem J. 2003 Apr 1;371(Pt 1):211-21 [12519076.001]
  • [Cites] J Cell Biol. 2003 Apr 14;161(1):197-209 [12695504.001]
  • [Cites] Matrix Biol. 2003 Mar;22(1):49-54 [12714041.001]
  • [Cites] Br J Cancer. 2003 Jul 21;89(2):327-32 [12865925.001]
  • [Cites] Annu Rev Biochem. 2003;72:743-81 [12676796.001]
  • [Cites] Clin Cancer Res. 2003 Nov 1;9(14):5271-81 [14614009.001]
  • [Cites] Cancer Genet Cytogenet. 2004 Jan 1;148(1):35-43 [14697639.001]
  • [Cites] Physiol Rev. 2004 Jan;84(1):209-38 [14715915.001]
  • [Cites] Cancer Res. 1989 Oct 1;49(19):5407-13 [2766305.001]
  • [Cites] Cancer Res. 1991 Oct 1;51(19):5100-6 [1717137.001]
  • [Cites] Cancer. 1994 Apr 15;73(8):2231-7 [8156531.001]
  • [Cites] Am J Clin Pathol. 1995 Dec;104(6):627-33 [8526204.001]
  • [Cites] Cytogenet Cell Genet. 1996;73(4):325-30 [8751388.001]
  • [Cites] Hum Mol Genet. 1996 Jan;5(1):15-21 [8789435.001]
  • [Cites] Med Pediatr Oncol. 1998 Mar;30(3):156-9 [9434823.001]
  • [Cites] Genes Chromosomes Cancer. 1998 May;22(1):16-25 [9591630.001]
  • [Cites] EMBO J. 1998 Jun 1;17(11):3052-65 [9606188.001]
  • [Cites] Nat Genet. 1998 Oct;20(2):189-93 [9771714.001]
  • [Cites] Oncogene. 1999 Sep 20;18(38):5340-8 [10498887.001]
  • [Cites] Nat Rev Cancer. 2005 Jan;5(1):42-50 [15630414.001]
  • [Cites] Cancer Res. 2005 Apr 1;65(7):2899-905 [15805292.001]
  • [Cites] Gene. 2005 Mar 28;348:65-71 [15777710.001]
  • [Cites] Genes Chromosomes Cancer. 1999 Dec;26(4):275-85 [10534762.001]
  • [Cites] Neoplasia. 1999 Aug;1(3):262-75 [10935481.001]
  • [Cites] Cancer Genet Cytogenet. 2000 Sep;121(2):139-45 [11063797.001]
  • [Cites] J Biol Chem. 2000 Nov 17;275(46):36238-44 [10945974.001]
  • [Cites] Med Pediatr Oncol. 2001 Feb;36(2):259-67 [11452933.001]
  • [Cites] Br J Cancer. 2001 Sep 14;85(6):831-5 [11556833.001]
  • [Cites] Am J Clin Pathol. 2004 Mar;121(3):358-65 [15023040.001]
  • [Cites] Cancer Genet Cytogenet. 2004 May;151(1):73-7 [15120913.001]
  • [Cites] Cancer Res. 2004 Jul 1;64(13):4428-33 [15231651.001]
  • [Cites] Nat Genet. 2004 Nov;36(11):1159-61 [15475955.001]
  • [Cites] J Natl Cancer Inst. 1973 Nov;51(5):1417-23 [4357758.001]
  • [Cites] Hum Pathol. 1985 Aug;16(8):838-43 [4018780.001]
  • [Cites] Nature. 1985 Nov 7-13;318(6041):69-73 [2997622.001]
  • [Cites] Cancer Res. 1987 Aug 15;47(16):4501-7 [3607778.001]
  • [Cites] Cytogenet Cell Genet. 1987;45(3-4):148-55 [3691179.001]
  • [Cites] Cancer Res. 1988 Feb 15;48(4):983-7 [3338090.001]
  • [Cites] Cancer Genet Cytogenet. 2005 May;159(1):10-7 [15860351.001]
  • [Cites] Cancer Genet Cytogenet. 2005 Dec;163(2):138-43 [16337856.001]
  • [Cites] Clin Exp Metastasis. 2000;18(6):439-43 [11592300.001]
  • (PMID = 16790082.001).
  • [ISSN] 1476-5586
  • [Journal-full-title] Neoplasia (New York, N.Y.)
  • [ISO-abbreviation] Neoplasia
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] Canada
  • [Chemical-registry-number] 0 / Biomarkers, Tumor
  • [Other-IDs] NLM/ PMC1592451
  •  go-up   go-down


39. Cribbs RK, Shehata BM, Ricketts RR: Primary ovarian rhabdomyosarcoma in children. Pediatr Surg Int; 2008 May;24(5):593-5
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Primary ovarian rhabdomyosarcoma in children.
  • Although rhabdomyosarcoma (RMS) is the most common soft tissue sarcoma in children, primary rhabdomyosarcomas of the ovary are extremely rare, with only eight well-documented pediatric cases previously reported in the literature.
  • We present two additional cases: an alveolar RMS originating in the right ovary with metastatic spread to the splenic flexure of the colon and to both lungs in a 13-year-old African American girl, and an embryonal RMS arising in the right ovary of a 6-year-old Caucasian girl with pre-operative intra-abdominal rupture and a malignant right pleural effusion.
  • [MeSH-major] Ovarian Neoplasms / diagnosis. Rhabdomyosarcoma / diagnosis
  • [MeSH-minor] Adolescent. Biopsy, Needle. Chemotherapy, Adjuvant. Child. Diagnosis, Differential. Female. Follow-Up Studies. Humans. Laparoscopy. Ovariectomy / methods. Tomography, X-Ray Computed

  • MedlinePlus Health Information. consumer health - Ovarian Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Cancer. 1997 Sep 15;80(6):1165-70 [9305719.001]
  • [Cites] AMA Arch Pathol. 1959 Jul;68(1):74-82 [13660587.001]
  • [Cites] Int J Gynecol Pathol. 1998 Apr;17(2):113-9 [9553806.001]
  • [Cites] J Pathol Bacteriol. 1955 Oct;70(2):433-8 [13295919.001]
  • [Cites] Histopathology. 1989 Sep;15(3):309-11 [2807189.001]
  • [Cites] Cancer. 1983 Jul 15;52(2):297-300 [6574802.001]
  • [Cites] Cancer. 1989 Aug 15;64(4):899-904 [2545329.001]
  • [Cites] Gynecol Oncol. 1983 Jun;15(3):325-39 [6345285.001]
  • (PMID = 18004572.001).
  • [ISSN] 0179-0358
  • [Journal-full-title] Pediatric surgery international
  • [ISO-abbreviation] Pediatr. Surg. Int.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Germany
  •  go-up   go-down


40. Ferguson SE, Gerald W, Barakat RR, Chi DS, Soslow RA: Clinicopathologic features of rhabdomyosarcoma of gynecologic origin in adults. Am J Surg Pathol; 2007 Mar;31(3):382-9
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Clinicopathologic features of rhabdomyosarcoma of gynecologic origin in adults.
  • Rhabdomyosarcoma (RMS) is the most common soft tissue tumor found in children.
  • Of the remaining 4 tumors, 2 were of alveolar (vulva) and 2 of pleomorphic (uterus, 1; fallopian tube, 1) histologic subtype.
  • [MeSH-major] Genital Neoplasms, Female / pathology. Rhabdomyosarcoma / pathology

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [CommentIn] Am J Surg Pathol. 2008 Jan;32(1):174 [18162788.001]
  • (PMID = 17325479.001).
  • [ISSN] 0147-5185
  • [Journal-full-title] The American journal of surgical pathology
  • [ISO-abbreviation] Am. J. Surg. Pathol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


41. Bois PR, Izeradjene K, Houghton PJ, Cleveland JL, Houghton JA, Grosveld GC: FOXO1a acts as a selective tumor suppressor in alveolar rhabdomyosarcoma. J Cell Biol; 2005 Sep 12;170(6):903-12
NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] FOXO1a acts as a selective tumor suppressor in alveolar rhabdomyosarcoma.
  • Rhabdomyosarcoma (RMS), the most common pediatric soft-tissue sarcoma, has two major histological subtypes: embryonal RMS (ERMS), which has a favorable prognosis, and alveolar RMS (ARMS), which has a poor outcome.

  • Genetic Alliance. consumer health - Rhabdomyosarcoma alveolar.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Trends Biochem Sci. 2002 Jul;27(7):352-60 [12114024.001]
  • [Cites] Oncogene. 2001 Sep 10;20(40):5736-46 [11607823.001]
  • [Cites] Mol Cell Biol. 2002 Oct;22(20):7204-16 [12242297.001]
  • [Cites] Biochem Soc Trans. 2003 Feb;31(Pt 1):292-7 [12546704.001]
  • [Cites] EMBO J. 2003 Mar 3;22(5):1147-57 [12606579.001]
  • [Cites] Sci STKE. 2003 Mar 4;2003(172):RE5 [12621150.001]
  • [Cites] Proc Natl Acad Sci U S A. 2003 Sep 30;100(20):11285-90 [13679577.001]
  • [Cites] Oncogene. 2003 Nov 6;22(50):8205-11 [14603261.001]
  • [Cites] Cell. 2004 May 14;117(4):421-6 [15137936.001]
  • [Cites] Gene. 1988 Jun 15;66(1):1-10 [3417148.001]
  • [Cites] J Cell Biol. 1994 Jun;125(6):1275-87 [8207057.001]
  • [Cites] Mol Cell Biol. 1995 Mar;15(3):1522-35 [7862145.001]
  • [Cites] J Biol Chem. 1995 May 19;270(20):11719-22 [7744814.001]
  • [Cites] Proc Natl Acad Sci U S A. 1995 May 9;92(10):4206-10 [7753783.001]
  • [Cites] Cancer Chemother Pharmacol. 1995;36(5):393-403 [7634381.001]
  • [Cites] J Cell Biochem. 1997 Dec 15;67(4):514-27 [9383710.001]
  • [Cites] Cardiovasc Res. 1997 Nov;36(2):163-73 [9463628.001]
  • [Cites] Mol Cell Biol. 2002 Apr;22(7):2025-36 [11884591.001]
  • [Cites] Dev Biol. 2002 Apr 15;244(2):305-18 [11944939.001]
  • [Cites] Cell Death Differ. 2002 May;9(5):493-504 [11973608.001]
  • [Cites] Proc Natl Acad Sci U S A. 2002 Aug 20;99(17):11025-30 [12177420.001]
  • [Cites] Br J Cancer. 2001 Sep 14;85(6):831-5 [11556833.001]
  • [Cites] Mol Cell Biol. 1999 Jan;19(1):594-601 [9858583.001]
  • [Cites] Cell. 1999 Mar 19;96(6):857-68 [10102273.001]
  • [Cites] Mol Biol Cell. 1999 Oct;10(10):3137-50 [10512856.001]
  • [Cites] J Biol Chem. 2004 Nov 5;279(45):47311-9 [15322110.001]
  • [Cites] Genes Dev. 2004 Nov 1;18(21):2608-13 [15520281.001]
  • [Cites] Mol Cell Biol. 2005 Sep;25(17):7645-56 [16107711.001]
  • [Cites] Am J Pathol. 2000 Feb;156(2):399-408 [10666368.001]
  • [Cites] Clin Genet. 2000 Jan;57(1):16-25 [10733231.001]
  • [Cites] Nature. 2000 Apr 13;404(6779):782-7 [10783894.001]
  • [Cites] Med Pediatr Oncol. 2000 Aug;35(2):96-103 [10918230.001]
  • [Cites] Cell. 2000 Sep 15;102(6):777-86 [11030621.001]
  • [Cites] Mol Cell Biol. 2000 Dec;20(24):9138-48 [11094066.001]
  • [Cites] Philos Trans R Soc Lond B Biol Sci. 2000 Jul 29;355(1399):965-70 [11128990.001]
  • [Cites] Biochem J. 2000 Jul 15;349(Pt 2):629-34 [10880363.001]
  • [Cites] Proc Natl Acad Sci U S A. 2001 Feb 13;98(4):1589-94 [11171995.001]
  • [CommentIn] NIH Guide Grants Contracts. 2011 Jun 17;:NOT-OD-11-084 [21714172.001]
  • [RetractionIn] Bois PR, Izeradjene K, Houghton PJ, Cleveland JL, Houghton JA, Grosveldz GC. J Cell Biol. 2007 May 7;177(3):563 [17485494.001]
  • [CommentIn] Fed Regist. 2011 Jun 9;76(111):33763-33764 [27737203.001]
  • (PMID = 16157701.001).
  • [ISSN] 0021-9525
  • [Journal-full-title] The Journal of cell biology
  • [ISO-abbreviation] J. Cell Biol.
  • [Language] ENG
  • [Grant] United States / NCI NIH HHS / CA / P01 CA071907; United States / NCI NIH HHS / CA / R01 CA087952; United States / NCI NIH HHS / CA / CA 71907; United States / NCI NIH HHS / CA / P01 CA023099; United States / NCI NIH HHS / CA / P30 CA021765; United States / NCI NIH HHS / CA / CA 96696; United States / NCI NIH HHS / CA / CA 87952; United States / NCI NIH HHS / CA / CA 23099; United States / NCI NIH HHS / CA / R01 CA096696; United States / NCI NIH HHS / CA / CA 21765
  • [Publication-type] Comparative Study; Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't; Research Support, U.S. Gov't, P.H.S.; Retracted Publication
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / FOXO1 protein, human; 0 / Fluorescent Dyes; 0 / Forkhead Transcription Factors; 0 / Indoles; 0 / Recombinant Fusion Proteins; 47165-04-8 / DAPI; EC 1.13.12.- / Luciferases; EC 3.4.22.- / CASP3 protein, human; EC 3.4.22.- / Casp3 protein, mouse; EC 3.4.22.- / Caspase 3; EC 3.4.22.- / Caspases
  • [Other-IDs] NLM/ PMC2171446
  •  go-up   go-down


42. van den Broeke LT, Pendleton CD, Mackall C, Helman LJ, Berzofsky JA: Identification and epitope enhancement of a PAX-FKHR fusion protein breakpoint epitope in alveolar rhabdomyosarcoma cells created by a tumorigenic chromosomal translocation inducing CTL capable of lysing human tumors. Cancer Res; 2006 Feb 1;66(3):1818-23
The Lens. Cited by Patents in .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Identification and epitope enhancement of a PAX-FKHR fusion protein breakpoint epitope in alveolar rhabdomyosarcoma cells created by a tumorigenic chromosomal translocation inducing CTL capable of lysing human tumors.
  • Here, we identify such a fusion protein breakpoint epitope in the PAX-FKHR fusion protein created by the t(2;13) translocation present in 80% of cases of alveolar rhabdomyosarcoma, a highly aggressive pediatric soft-tissue sarcoma.
  • These human peptide-specific CTL lyse human HLA-B7+ rhabdomyosarcoma tumor cells.
  • This epitope-enhanced peptide may serve as a candidate cancer vaccine for HLA-B7+ patients with alveolar rhabdomyosarcoma.
  • [MeSH-major] Epitopes / immunology. Forkhead Transcription Factors / immunology. Immunotherapy, Adoptive / methods. Oncogene Proteins, Fusion / immunology. Paired Box Transcription Factors / immunology. Rhabdomyosarcoma, Alveolar / immunology. T-Lymphocytes, Cytotoxic / immunology

  • Genetic Alliance. consumer health - Rhabdomyosarcoma alveolar.
  • COS Scholar Universe. author profiles.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16452243.001).
  • [ISSN] 0008-5472
  • [Journal-full-title] Cancer research
  • [ISO-abbreviation] Cancer Res.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Epitopes; 0 / Forkhead Transcription Factors; 0 / HLA-B7 Antigen; 0 / Oncogene Proteins, Fusion; 0 / Paired Box Transcription Factors
  •  go-up   go-down


43. Wang ZH, Shi HY, Wang ZB: [Metastatic alveolar soft tissue sarcoma of the central nervous system: a clinicopathological analysis of four cases]. Ai Zheng; 2009 Nov;28(11):1214-8
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Metastatic alveolar soft tissue sarcoma of the central nervous system: a clinicopathological analysis of four cases].
  • BACKGROUND AND OBJECTIVE: Metastatic alveolar soft tissue sarcoma (ASTS) of the central nervous system is rare and is easy to be misdiagnosed as other primary tumors of central nervous system.
  • This study was to analyze the clinical and pathological features of four patients with ASTS of the central nervous system and to clarify their differential diagnosis as well as prognosis.
  • The tumor cells had clear or eosinophilic cytoplasm and prominent nucleoli, arranged in alveolar structures, which were surrounded by delicate blood sinuses.
  • CONCLUSION: ASTS of the central nervous system was mostly metastatic and should be differentiated from other CNS tumors such as meningioma, melonocytic tumor, rhabdomyosarcoma and paraganglioma.
  • [MeSH-major] Cranial Fossa, Posterior. Sarcoma, Alveolar Soft Part / pathology. Sarcoma, Alveolar Soft Part / secondary. Skull Base Neoplasms / pathology. Skull Base Neoplasms / secondary
  • [MeSH-minor] Actins / metabolism. Adult. Desmin / metabolism. Diagnosis, Differential. Female. Follow-Up Studies. Humans. Male. Meningeal Neoplasms / diagnosis. Meningioma / diagnosis. Neoplasm Recurrence, Local. Paraganglioma / diagnosis. Prognosis. Rhabdomyosarcoma / diagnosis. S100 Proteins / metabolism. Survival Rate

  • Genetic Alliance. consumer health - Soft tissue sarcoma.
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19895745.001).
  • [Journal-full-title] Ai zheng = Aizheng = Chinese journal of cancer
  • [ISO-abbreviation] Ai Zheng
  • [Language] chi
  • [Publication-type] English Abstract; Journal Article
  • [Publication-country] China
  • [Chemical-registry-number] 0 / Actins; 0 / Desmin; 0 / S100 Proteins
  •  go-up   go-down


44. Thomas DM, O'Sullivan B, Gronchi A: Current concepts and future perspectives in retroperitoneal soft-tissue sarcoma management. Expert Rev Anticancer Ther; 2009 Aug;9(8):1145-57
MedlinePlus Health Information. consumer health - Soft Tissue Sarcoma.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Current concepts and future perspectives in retroperitoneal soft-tissue sarcoma management.
  • Retroperitoneal soft-tissue sarcomas are complex, heterogeneous cancers requiring expert multidisciplinary care.
  • Pediatric subtypes mainly comprise extraskeletal Ewing sarcoma/pPNET and alveolar rhabdomyosarcoma.

  • Genetic Alliance. consumer health - Soft tissue sarcoma.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19671034.001).
  • [ISSN] 1744-8328
  • [Journal-full-title] Expert review of anticancer therapy
  • [ISO-abbreviation] Expert Rev Anticancer Ther
  • [Language] eng
  • [Publication-type] Journal Article; Review
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Antineoplastic Agents
  • [Number-of-references] 93
  •  go-up   go-down


45. Rivasi F, Botticelli L, Bettelli SR, Masellis G: Alveolar rhabdomyosarcoma of the uterine cervix. A case report confirmed by FKHR break-apart rearrangement using a fluorescence in situ hybridization probe on paraffin-embedded tissues. Int J Gynecol Pathol; 2008 Jul;27(3):442-6
NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Alveolar rhabdomyosarcoma of the uterine cervix. A case report confirmed by FKHR break-apart rearrangement using a fluorescence in situ hybridization probe on paraffin-embedded tissues.
  • Alveolar rhabdomyosarcoma (ARMS) is a very rare malignant soft tissue tumor found in the uterine cervix.
  • The literature has been reviewed; the histologic differential diagnosis of this rare lesion has been discussed and FISH has been suggested to be useful in differentiating ARMS from other poorly differentiated round cell tumors.
  • [MeSH-major] Rhabdomyosarcoma, Alveolar / pathology. Uterine Cervical Neoplasms / pathology


46. Parham DM, Qualman SJ, Teot L, Barr FG, Morotti R, Sorensen PH, Triche TJ, Meyer WH, Soft Tissue Sarcoma Committee of the Children's Oncology Group: Correlation between histology and PAX/FKHR fusion status in alveolar rhabdomyosarcoma: a report from the Children's Oncology Group. Am J Surg Pathol; 2007 Jun;31(6):895-901
NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Correlation between histology and PAX/FKHR fusion status in alveolar rhabdomyosarcoma: a report from the Children's Oncology Group.
  • At the molecular level, alveolar rhabdomyosarcomas (ARMS) are characterized by 3 mutually exclusive PAX/FKHR conditions: PAX3/FKHR fusion (present in 60% of cases), PAX7/FKHR fusion (present in 20%), and PAX/FKHR fusion-negativity (present in 20%).
  • We evaluated cytohistologic parameters such as microcyst formation, solid foci, differentiation, giant cell formation, anaplasia, nuclear grade, mitosis/karyorrhexis index, rosette formation, geographic necrosis, presence and amount of rhabdomyoblastic differentiation, and the presence of foci resembling embryonal rhabdomyosarcoma.
  • Of these features, only totally solid alveolar architecture reached significance (P=0.00014), with 7 of 16 PAX/FKHR-negative cases lacking this feature, compared with 0 of 36 PAX3/FKHR cases and 2/13 PAX7/FKHR cases.
  • These preliminary results indicate that in general, only totally solid alveolar architecture in ARMS may predict the absence of a PAX/FKHR fusion.
  • [MeSH-major] Oncogene Proteins, Fusion / genetics. Rhabdomyosarcoma, Alveolar / genetics. Rhabdomyosarcoma, Alveolar / pathology

  • Genetic Alliance. consumer health - Rhabdomyosarcoma alveolar.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17527077.001).
  • [ISSN] 0147-5185
  • [Journal-full-title] The American journal of surgical pathology
  • [ISO-abbreviation] Am. J. Surg. Pathol.
  • [Language] eng
  • [Grant] United States / NCI NIH HHS / CA / CA 98543; United States / NCI NIH HHS / CA / CA24507; United States / NCI NIH HHS / CA / CA72989; United States / NCI NIH HHS / CA / CA81659; United States / NCI NIH HHS / CA / CA89461; United States / NCI NIH HHS / CA / CA98413; United States / NCI NIH HHS / CA / CA98543
  • [Publication-type] Journal Article; Research Support, N.I.H., Extramural
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / FOXO1 protein, human; 0 / Forkhead Transcription Factors; 0 / Oncogene Proteins, Fusion; 0 / PAX3 protein, human; 0 / PAX7 Transcription Factor; 0 / PAX7 protein, human; 0 / Paired Box Transcription Factors
  •  go-up   go-down


47. Linardic CM: PAX3-FOXO1 fusion gene in rhabdomyosarcoma. Cancer Lett; 2008 Oct 18;270(1):10-8
NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] PAX3-FOXO1 fusion gene in rhabdomyosarcoma.
  • Rhabdomyosarcoma (RMS) is the most common soft tissue sarcoma of childhood and adolescence.
  • The predominant histologic variants of this disease are termed embryonal (eRMS) and alveolar (aRMS), based on their appearance under light microscopy.

  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Biochem Biophys Res Commun. 2008 Jan 18;365(3):568-74 [18022385.001]
  • [Cites] Proc Natl Acad Sci U S A. 2007 Nov 13;104(46):18085-90 [17986608.001]
  • [Cites] Proc Natl Acad Sci U S A. 1999 Nov 9;96(23):13264-9 [10557309.001]
  • [Cites] Oncogene. 1999 Dec 2;18(51):7328-33 [10602488.001]
  • [Cites] Cell. 2000 Jan 7;100(1):57-70 [10647931.001]
  • [Cites] Mol Cell Biol. 2000 Jul;20(14):5019-31 [10866659.001]
  • [Cites] Oncogene. 2000 Jun 8;19(25):2921-9 [10871843.001]
  • [Cites] Cancer Res. 2000 Oct 15;60(20):5803-14 [11059777.001]
  • [Cites] Proc Natl Acad Sci U S A. 2001 Feb 13;98(4):1589-94 [11171995.001]
  • [Cites] Nat Med. 2001 Jun;7(6):673-9 [11385503.001]
  • [Cites] Med Pediatr Oncol. 2001 Aug;37(2):83-9 [11496344.001]
  • [Cites] Am J Pathol. 2001 Sep;159(3):1089-96 [11549601.001]
  • [Cites] Br J Cancer. 2001 Sep 14;85(6):831-5 [11556833.001]
  • [Cites] Am J Hematol. 2001 Sep;68(1):51-7 [11559937.001]
  • [Cites] Genomics. 2002 Mar;79(3):278-84 [11863357.001]
  • [Cites] Exp Cell Res. 2002 Apr 1;274(2):288-98 [11900489.001]
  • [Cites] J Clin Oncol. 2002 Jun 1;20(11):2672-9 [12039929.001]
  • [Cites] Blood. 2002 Oct 1;100(7):2597-606 [12239174.001]
  • [Cites] Mol Cell Biol. 2002 Oct;22(20):7204-16 [12242297.001]
  • [Cites] J Biol Chem. 2003 Jan 3;278(1):27-36 [12401804.001]
  • [Cites] Nat Rev Mol Cell Biol. 2003 Dec;4(12):915-25 [14685170.001]
  • [Cites] Lab Invest. 2004 Aug;84(8):1060-70 [15184910.001]
  • [Cites] Cancer Cell. 2004 Aug;6(2):171-83 [15324700.001]
  • [Cites] Cancer Res. 1993 Nov 1;53(21):5108-12 [8221646.001]
  • [Cites] Nat Genet. 1993 Nov;5(3):230-5 [8275086.001]
  • [Cites] Mol Cell Biol. 1995 Mar;15(3):1522-35 [7862145.001]
  • [Cites] J Biol Chem. 1995 May 19;270(20):11719-22 [7744814.001]
  • [Cites] Oncogene. 1996 Apr 18;12(8):1697-705 [8622890.001]
  • [Cites] Proc Natl Acad Sci U S A. 1996 Apr 30;93(9):4213-8 [8633043.001]
  • [Cites] Proc Natl Acad Sci U S A. 1996 May 28;93(11):5455-9 [8643596.001]
  • [Cites] Proc Natl Acad Sci U S A. 1996 Sep 3;93(18):9805-9 [8790412.001]
  • [Cites] Proc Natl Acad Sci U S A. 1996 Nov 12;93(23):13164-9 [8917562.001]
  • [Cites] Med Pediatr Oncol. 1997 Mar;28(3):165-70 [9024509.001]
  • [Cites] Curr Top Microbiol Immunol. 1997;220:113-29 [9103678.001]
  • [Cites] Genes Dev. 1997 Apr 15;11(8):973-83 [9136926.001]
  • [Cites] J Clin Oncol. 1997 May;15(5):1831-6 [9164192.001]
  • [Cites] J Cell Biol. 1997 Jun 2;137(5):1057-68 [9166406.001]
  • [Cites] Proc Natl Acad Sci U S A. 1997 Jul 22;94(15):8047-51 [9223312.001]
  • [Cites] Cancer Res. 1998 Aug 15;58(16):3542-6 [9721857.001]
  • [Cites] Cancer Res. 1998 Nov 15;58(22):5009-13 [9823299.001]
  • [Cites] Mol Cell Biol. 1999 Jan;19(1):594-601 [9858583.001]
  • [Cites] Cancer Res. 1999 Apr 1;59(7 Suppl):1711s-1715s [10197585.001]
  • [Cites] Genes Dev. 2004 Nov 1;18(21):2614-26 [15489287.001]
  • [Cites] FASEB J. 2005 Mar;19(3):404-6 [15629888.001]
  • [Cites] Oncogene. 2005 Mar 10;24(11):1860-72 [15688035.001]
  • [Cites] Cancer Res. 2005 Jun 1;65(11):4490-5 [15930263.001]
  • [Cites] Int J Oncol. 2005 Sep;27(3):791-8 [16077930.001]
  • [Cites] Int J Oncol. 2005 Oct;27(4):1087-96 [16142327.001]
  • [Cites] Oncogene. 2005 Dec 1;24(54):8025-37 [16116481.001]
  • [Cites] Blood. 2006 Mar 1;107(5):1761-7 [16269611.001]
  • [Cites] Int J Cancer. 2006 Jun 1;118(11):2772-81 [16381018.001]
  • [Cites] J Mol Diagn. 2006 May;8(2):202-8 [16645206.001]
  • [Cites] Cancer Res. 2006 May 1;66(9):4742-9 [16651427.001]
  • [Cites] Cancer Res. 2006 Jul 15;66(14):6936-46 [16849537.001]
  • [Cites] Exp Cell Res. 2006 Nov 15;312(19):3701-10 [17046749.001]
  • [Cites] Nat Rev Cancer. 2007 Mar;7(3):165-8 [17332760.001]
  • [Cites] J Pathol. 2007 Jun;212(2):143-51 [17471488.001]
  • [Cites] Cancer Res. 2007 Jul 15;67(14):6691-9 [17638879.001]
  • [Cites] Nat Rev Cancer. 2008 Feb;8(2):121-32 [18202696.001]
  • (PMID = 18457914.001).
  • [ISSN] 1872-7980
  • [Journal-full-title] Cancer letters
  • [ISO-abbreviation] Cancer Lett.
  • [Language] ENG
  • [Grant] United States / NICHD NIH HHS / HD / HD043494-05; United States / NICHD NIH HHS / HD / K12 HD043494; United States / NICHD NIH HHS / HD / 5K12-HD043494; United States / NICHD NIH HHS / HD / K12 HD043494-05
  • [Publication-type] Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't; Review
  • [Publication-country] Ireland
  • [Chemical-registry-number] 0 / CXCL12 protein, human; 0 / Chemokine CXCL12; 0 / FOXO1 protein, human; 0 / Forkhead Transcription Factors; 0 / Oncogene Proteins, Fusion; 0 / PAX3-FOXO1A fusion protein, human; 0 / Paired Box Transcription Factors; EC 2.7.10.1 / FLT1 protein, human; EC 2.7.10.1 / Vascular Endothelial Growth Factor Receptor-1
  • [Number-of-references] 59
  • [Other-IDs] NLM/ NIHMS72264; NLM/ PMC2575376
  •  go-up   go-down


48. De Corti F, Dall'Igna P, Bisogno G, Casara D, Rossi CR, Foletto M, Alaggio R, Carli M, Cecchetto G: Sentinel node biopsy in pediatric soft tissue sarcomas of extremities. Pediatr Blood Cancer; 2009 Jan;52(1):51-4
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Sentinel node biopsy in pediatric soft tissue sarcomas of extremities.
  • Our experience with sentinel node biopsy in soft tissue sarcomas of extremities in children is reported.
  • The diagnosis was rhabdomyosarcoma in 5 and other soft tissue sarcomas in 12: Ewing/PNET sarcoma 6, epithelioid sarcoma 1, malignant peripheral-nerve-sheath tumor 1, undifferentiated sarcoma 1, myxoid liposarcoma 2, adult-type fibrosarcoma 1.
  • Nodes were positive for metastasis in two patients with alveolar rhabdomyosarcoma and undifferentiated sarcoma.
  • No further lymph node metastases were recognized either at diagnosis or during the follow-up (6-78 months).
  • It could be an alternative to aggressive or random biopsies for extremity rhabdomyosarcoma and it can contribute to define those non-rhabdomyosarcoma soft tissue sarcomas that spread to regional nodes.
  • [MeSH-major] Extremities. Rhabdomyosarcoma / pathology
  • [MeSH-minor] Adolescent. Child. Child, Preschool. Female. Humans. Male. Neoplasm Metastasis / pathology. Sentinel Lymph Node Biopsy. Soft Tissue Neoplasms / pathology. Young Adult

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18819127.001).
  • [ISSN] 1545-5017
  • [Journal-full-title] Pediatric blood & cancer
  • [ISO-abbreviation] Pediatr Blood Cancer
  • [Language] eng
  • [Publication-type] Evaluation Studies; Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  •  go-up   go-down


49. Huh WW, Skapek SX: Childhood rhabdomyosarcoma: new insight on biology and treatment. Curr Oncol Rep; 2010 Nov;12(6):402-10
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Childhood rhabdomyosarcoma: new insight on biology and treatment.
  • Rhabdomyosarcoma (RMS) is the most common soft tissue sarcoma of childhood.
  • The two most common histologic variants are the embryonal and alveolar subtypes.
  • Recent studies have pointed to a possible mesenchymal stem cell as the progenitor for alveolar RMS.
  • [MeSH-major] Rhabdomyosarcoma, Alveolar / diagnosis. Rhabdomyosarcoma, Alveolar / genetics. Rhabdomyosarcoma, Alveolar / therapy. Rhabdomyosarcoma, Embryonal / diagnosis. Rhabdomyosarcoma, Embryonal / genetics. Rhabdomyosarcoma, Embryonal / therapy. Soft Tissue Neoplasms / diagnosis. Soft Tissue Neoplasms / genetics. Soft Tissue Neoplasms / therapy

  • Hazardous Substances Data Bank. SIROLIMUS .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Cancer. 2009 Sep 15;115(18):4218-26 [19536876.001]
  • [Cites] J Clin Invest. 2009 Nov;119(11):3395-407 [19809159.001]
  • [Cites] J Clin Oncol. 2010 Mar 10;28(8):1322-8 [20124176.001]
  • [Cites] J Clin Oncol. 2008 May 10;26(14):2384-9 [18467730.001]
  • [Cites] Genes Chromosomes Cancer. 2007 Apr;46(4):348-58 [17243166.001]
  • [Cites] Nature. 2004 Sep 23;431(7007):466-71 [15386014.001]
  • [Cites] J Pediatr Hematol Oncol. 2001 May;23(4):215-20 [11846299.001]
  • [Cites] Pediatr Dev Pathol. 2009 Mar-Apr;12 (2):127-35 [18788888.001]
  • [Cites] Genes Chromosomes Cancer. 2009 Jun;48(6):455-67 [19235922.001]
  • [Cites] Cancer Epidemiol Biomarkers Prev. 2009 Apr;18(4):1271-6 [19293315.001]
  • [Cites] Cancer Res. 2005 Jun 1;65(11):4490-5 [15930263.001]
  • [Cites] J Clin Oncol. 2007 Nov 1;25(31):4909-13 [17971587.001]
  • [Cites] Eur J Cancer. 2009 Nov;45(17):3035-41 [19783136.001]
  • [Cites] Cancer. 2008 Dec 1;113(11):3242-7 [18985676.001]
  • [Cites] J Clin Oncol. 2007 Dec 1;25(34):5435-41 [18048826.001]
  • [Cites] Stem Cells. 2008 Jul;26(7):1818-30 [18467664.001]
  • [Cites] Genes Dev. 2007 Jun 1;21(11):1382-95 [17510286.001]
  • [Cites] Cancer Res. 2006 Jul 15;66(14 ):6936-46 [16849537.001]
  • [Cites] Genes Chromosomes Cancer. 2010 Mar;49(3):224-36 [19953635.001]
  • [Cites] Science. 1990 Nov 30;250(4985):1233-8 [1978757.001]
  • [Cites] J Clin Oncol. 2010 Mar 1;28(7):1240-6 [20124188.001]
  • [Cites] Cancer Res. 2008 Aug 15;68(16):6587-97 [18701482.001]
  • [Cites] Br J Cancer. 2003 Jul 21;89(2):327-32 [12865925.001]
  • [Cites] Genes Chromosomes Cancer. 2009 Nov;48(11):975-82 [19681119.001]
  • [Cites] J Clin Oncol. 2002 Jun 1;20(11):2672-9 [12039929.001]
  • [Cites] Cancer Res. 2009 Oct 1;69(19):7662-71 [19789339.001]
  • [Cites] Proc Natl Acad Sci U S A. 2006 Sep 5;103(36):13439-44 [16938866.001]
  • [Cites] Cell. 2000 Dec 22;103(7):1099-109 [11163185.001]
  • [Cites] Pediatr Blood Cancer. 2008 Apr;50(4):739-45 [18286501.001]
  • [Cites] J Clin Oncol. 2006 Aug 20;24(24):3844-51 [16921036.001]
  • [Cites] Cancer Res. 2007 Apr 1;67(7):3431-40 [17409454.001]
  • [Cites] Genes Dev. 2004 Nov 1;18(21):2614-26 [15489287.001]
  • [Cites] Pediatr Blood Cancer. 2008 Apr;50(4):799-805 [17635004.001]
  • [Cites] Cancer Lett. 2009 Jul 8;279(2):126-36 [19008039.001]
  • [Cites] J Clin Oncol. 2009 Mar 20;27(9):1446-55 [19224858.001]
  • [Cites] J Pediatr. 2004 May;144(5):666-8 [15127010.001]
  • [Cites] J Clin Oncol. 2009 Nov 1;27(31):5182-8 [19770373.001]
  • [Cites] Genes Chromosomes Cancer. 2009 Aug;48(8):661-72 [19422036.001]
  • [Cites] Cancer Res. 2009 Jan 1;69(1):161-70 [19117999.001]
  • [Cites] Br J Cancer. 2010 Jan 5;102(1):227-31 [19997102.001]
  • [Cites] J Clin Oncol. 2010 May 1;28(13):2151-8 [20351326.001]
  • [Cites] Cell. 2005 Sep 9;122(5):659-67 [16143100.001]
  • [Cites] Am J Pathol. 2009 Feb;174(2):550-64 [19147825.001]
  • [Cites] J Pediatr Hematol Oncol. 2007 Sep;29(9):608-12 [17805034.001]
  • [Cites] Eur J Cancer. 2010 Jun;46(9):1588-95 [20338746.001]
  • [Cites] J Clin Oncol. 2009 Aug 1;27(22):3705-11 [19470937.001]
  • [Cites] Nat Med. 2002 Nov;8(11):1276-80 [12368906.001]
  • [Cites] Bone Marrow Transplant. 2009 Jan;43(2):179-80 [18762761.001]
  • [Cites] Future Oncol. 2009 Nov;5(9):1449-75 [19903072.001]
  • (PMID = 20820958.001).
  • [ISSN] 1534-6269
  • [Journal-full-title] Current oncology reports
  • [ISO-abbreviation] Curr Oncol Rep
  • [Language] eng
  • [Publication-type] Journal Article; Review
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Protein Kinase Inhibitors; EC 2.7.1.1 / TOR Serine-Threonine Kinases; W36ZG6FT64 / Sirolimus
  •  go-up   go-down


50. Mentzel T, Kuhnen C: Spindle cell rhabdomyosarcoma in adults: clinicopathological and immunohistochemical analysis of seven new cases. Virchows Arch; 2006 Nov;449(5):554-60
MedlinePlus Health Information. consumer health - Soft Tissue Sarcoma.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Spindle cell rhabdomyosarcoma in adults: clinicopathological and immunohistochemical analysis of seven new cases.
  • Rhabdomyosarcoma (RMS) is currently classified into embryonal RMS, including its botryoid and spindle cell variants, alveolar RMS, including a solid variant, and pleomorphic RMS.
  • In children and adolescents embryonal RMS occurs in a younger age group than alveolar RMS, and pleomorphic RMS is almost always seen in older adults.
  • All neoplasms arose in subcutaneous and deep soft tissues with dermal involvement in one case, and the size of the neoplasms ranged from 4 to 19 cm in largest diameter.
  • In summary, spindle cell rhabdomyosarcoma represents a rare neoplasm in adulthood characterized clinically by a rather poor prognosis, and shows a broad morphological spectrum including most likely the sclerosing, pseudovascular variant.
  • Immunohistochemically, tumour cells in RMS stain positively for CD 99 and WT1 as well, which is of importance in the differential diagnosis to other mesenchymal neoplasms, whereas fast myosin does not represent a reliable marker for RMS in adults.
  • [MeSH-major] Rhabdomyosarcoma / pathology. Sarcoma / pathology. Soft Tissue Neoplasms / pathology

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Cancer. 2003 Aug 1;98(3):571-80 [12879475.001]
  • [Cites] Cancer. 1995 Sep 15;76(6):1073-85 [8625211.001]
  • [Cites] Virchows Arch. 2006 Nov;449(5):572-8 [17016719.001]
  • [Cites] Am J Pathol. 2000 Feb;156(2):399-408 [10666368.001]
  • [Cites] Pediatr Dev Pathol. 2004 Nov-Dec;7(6):583-94 [15630526.001]
  • [Cites] Virchows Arch. 2000 Apr;436(4):305-11 [10834531.001]
  • [Cites] Am J Surg Pathol. 1998 Oct;22(10):1228-38 [9777985.001]
  • [Cites] Am J Surg Pathol. 2002 Sep;26(9):1175-83 [12218574.001]
  • [Cites] Am J Surg Pathol. 1993 Mar;17(3):221-30 [8434703.001]
  • [Cites] Mod Pathol. 2001 Jun;14(6):595-603 [11406662.001]
  • [Cites] Ann Surg. 2001 Aug;234(2):215-23 [11505068.001]
  • [Cites] Cancer. 2001 Feb 15;91(4):794-803 [11241248.001]
  • [Cites] Am J Surg Pathol. 1992 Mar;16(3):229-35 [1599014.001]
  • [Cites] Am J Surg Pathol. 2005 Aug;29(8):1106-13 [16006807.001]
  • [Cites] Mod Pathol. 2002 Oct;15(10):1080-6 [12379755.001]
  • [Cites] Virchows Arch. 2005 Jan;446(1):64-7 [15660283.001]
  • (PMID = 17013628.001).
  • [ISSN] 0945-6317
  • [Journal-full-title] Virchows Archiv : an international journal of pathology
  • [ISO-abbreviation] Virchows Arch.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Germany
  • [Chemical-registry-number] 0 / Antigens, CD; 0 / Antigens, CD99; 0 / CD99 protein, human; 0 / Cell Adhesion Molecules
  •  go-up   go-down


51. Pazzaglia L, Chiechi A, Conti A, Gamberi G, Magagnoli G, Novello C, Morandi L, Picci P, Mercuri M, Benassi MS: Genetic and molecular alterations in rhabdomyosarcoma: mRNA overexpression of MCL1 and MAP2K4 genes. Histol Histopathol; 2009 01;24(1):61-7
NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Genetic and molecular alterations in rhabdomyosarcoma: mRNA overexpression of MCL1 and MAP2K4 genes.
  • Rhabdomyosarcoma, the most common soft tissue sarcoma in childhood, belongs to the small round cell tumor family and is classified according to its histopathological features as embryonal, alveolar and pleomorphic.
  • In this study we propose to explore genetic alterations involved in rhabdomyosarcoma tumorigenesis and assess the level of mRNA gene expression of controlling survival signalling pathways.
  • Our findings on rhabdomyosarcoma samples showed multiple copy number alterations in chromosome regions implicated in malignancy progression and indicated a strong expression of MAP2K4 and MCL1 genes, both involved in different biological functions of complicated signalling pathways.
  • [MeSH-major] MAP Kinase Kinase 4 / genetics. Proto-Oncogene Proteins c-bcl-2 / genetics. RNA, Messenger / analysis. Rhabdomyosarcoma / genetics. Soft Tissue Neoplasms / genetics

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19012245.001).
  • [ISSN] 1699-5848
  • [Journal-full-title] Histology and histopathology
  • [ISO-abbreviation] Histol. Histopathol.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] Spain
  • [Chemical-registry-number] 0 / Myeloid Cell Leukemia Sequence 1 Protein; 0 / Proto-Oncogene Proteins c-bcl-2; 0 / RNA, Messenger; EC 2.7.12.2 / MAP Kinase Kinase 4; EC 2.7.12.2 / MAP2K4 protein, human
  •  go-up   go-down


52. Yuan XJ, Chan GC, Chan SK, Shek TW, Kwong DL, Wei WI, Ha SY, Chiang AK: Treatment outcome of rhabdomyosarcoma in Hong Kong Chinese children. Hong Kong Med J; 2008 Apr;14(2):116-23
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Treatment outcome of rhabdomyosarcoma in Hong Kong Chinese children.
  • OBJECTIVES: To review the treatment outcome of rhabdomyosarcoma in Hong Kong Chinese children.
  • PATIENTS: Consecutive cases of rhabdomyosarcoma diagnosed and treated by the Department of Paediatrics and Adolescent Medicine of Queen Mary Hospital between 1989 and 2005.
  • Each patient was staged and treated according to the Intergroup Rhabdomyosarcoma Study guidelines.
  • The median age at diagnosis was 6 (range, 0.5-17) years.
  • Primary sites of rhabdomyosarcoma included: the head and neck (n=8; 6 classified as cranial parameningeal), genitourinary (3), extremity (3), pelvis (3), and trunk (2).
  • Thirteen (68%) had embryonal and six (32%) had alveolar histology.
  • Two, 2, 9, and 6 were classified as belonging to Intergroup Rhabdomyosarcoma Study groups 1, 2, 3, and 4, respectively.
  • In non-metastatic cases (Intergroup Rhabdomyosarcoma Study groups 1-3), the 5-year overall survival rate was 66% (95% confidence interval, 39-93%) and in metastatic cases (group 4) it was 17% (0-46%).
  • CONCLUSIONS: Treatment outcome of rhabdomyosarcoma in this cohort of Chinese children was less favourable than that reported in international studies.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18382018.001).
  • [ISSN] 1024-2708
  • [Journal-full-title] Hong Kong medical journal = Xianggang yi xue za zhi
  • [ISO-abbreviation] Hong Kong Med J
  • [Language] ENG
  • [Publication-type] Journal Article
  • [Publication-country] China
  •  go-up   go-down


53. Kayton ML, Meyers P, Wexler LH, Gerald WL, LaQuaglia MP: Clinical presentation, treatment, and outcome of alveolar soft part sarcoma in children, adolescents, and young adults. J Pediatr Surg; 2006 Jan;41(1):187-93
NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Clinical presentation, treatment, and outcome of alveolar soft part sarcoma in children, adolescents, and young adults.
  • PURPOSE: Alveolar soft part sarcoma is a rare soft tissue neoplasm that can affect children and adolescents.
  • METHODS: After institutional review board approval, we examined the records of all patients younger than 25 years old who received treatment at our institution for alveolar soft part sarcoma in the past 30 years.
  • Younger patients tended to have Intergroup Rhabdomyosarcoma Study group I disease.
  • CONCLUSIONS: Achievement of complete microscopic resection is critical in localized alveolar soft part sarcoma, but incomplete excision and misdiagnosis are often encountered.


54. Burke M, Anderson JR, Kao SC, Rodeberg D, Qualman SJ, Wolden SL, Meyer WH, Breitfeld PP, Soft Tissue Sarcoma Committee of the Children's Oncology Group: Assessment of response to induction therapy and its influence on 5-year failure-free survival in group III rhabdomyosarcoma: the Intergroup Rhabdomyosarcoma Study-IV experience--a report from the Soft Tissue Sarcoma Committee of the Children's Oncology Group. J Clin Oncol; 2007 Nov 1;25(31):4909-13
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Assessment of response to induction therapy and its influence on 5-year failure-free survival in group III rhabdomyosarcoma: the Intergroup Rhabdomyosarcoma Study-IV experience--a report from the Soft Tissue Sarcoma Committee of the Children's Oncology Group.
  • For Intergroup Rhabdomyosarcoma Study (IRS) IV patients with group III rhabdomyosarcoma, we assessed whether reported response assessed by anatomic imaging at week 8 predicted FFS.
  • In these patients, response did not influence FFS except for those with alveolar histology.
  • [MeSH-major] Antineoplastic Combined Chemotherapy Protocols / administration & dosage. Neoadjuvant Therapy. Rhabdomyosarcoma / drug therapy. Soft Tissue Neoplasms / drug therapy

  • Genetic Alliance. consumer health - Soft tissue sarcoma.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17971587.001).
  • [ISSN] 1527-7755
  • [Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • [ISO-abbreviation] J. Clin. Oncol.
  • [Language] eng
  • [Grant] United States / NCI NIH HHS / CA / CA 98543; United States / NCI NIH HHS / CA / U10 CA098413; United States / NCI NIH HHS / CA / U10 CA24507
  • [Publication-type] Journal Article; Randomized Controlled Trial; Research Support, N.I.H., Extramural
  • [Publication-country] United States
  •  go-up   go-down


55. Ayati M, Izadpanahi MM, Nowroozi MR, Soroush Z, Jamshidian H, Rakhshani N: First case report of bilateral metastatic intratesticular rhabdomyosarcoma. Urology; 2010 Jun;75(6):1485-7
MedlinePlus Health Information. consumer health - Testicular Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] First case report of bilateral metastatic intratesticular rhabdomyosarcoma.
  • Rhabdomyosarcoma (RMS) is the most common soft-tissue sarcoma in children.
  • We present a case of an 18-year-old boy with metastatic alveolar RMS to the testis and the first reported case of bilateral testicular involvement.
  • [MeSH-major] Lung Neoplasms / pathology. Lymph Nodes / pathology. Rhabdomyosarcoma / secondary. Rhabdomyosarcoma / therapy. Testicular Neoplasms / secondary. Testicular Neoplasms / therapy

  • MedlinePlus Health Information. consumer health - Lung Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] Copyright (c) 2010 Elsevier Inc. All rights reserved.
  • (PMID = 19819527.001).
  • [ISSN] 1527-9995
  • [Journal-full-title] Urology
  • [ISO-abbreviation] Urology
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] United States
  •  go-up   go-down


56. Raney RB, Anderson JR, Brown KL, Huh WW, Maurer HM, Meyer WH, Parham DM, Rodeberg DA, Wolden SL, Donaldson SS, Soft-Tissue Sarcoma Committee of the Children's Oncology Group Arcadia California USA: Treatment results for patients with localized, completely resected (Group I) alveolar rhabdomyosarcoma on Intergroup Rhabdomyosarcoma Study Group (IRSG) protocols III and IV, 1984-1997: a report from the Children's Oncology Group. Pediatr Blood Cancer; 2010 Oct;55(4):612-6
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Treatment results for patients with localized, completely resected (Group I) alveolar rhabdomyosarcoma on Intergroup Rhabdomyosarcoma Study Group (IRSG) protocols III and IV, 1984-1997: a report from the Children's Oncology Group.
  • PURPOSE: To assess local control, event-free survival (EFS), and overall survival (OS) rates in 71 patients with localized, completely resected (Group I) alveolar rhabdomyosarcoma (ALV RMS) and their relation to radiation therapy (RT) on IRSG Protocols III and IV, 1984-1997.
  • PATIENTS AND TUMORS: Patients were 1-18 years at diagnosis (median, 6 years).

  • Genetic Alliance. consumer health - Rhabdomyosarcoma alveolar.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] Copyright 2010 Wiley-Liss, Inc.
  • [Cites] Cancer. 1993 Mar 1;71(5):1904-22 [8448756.001]
  • [Cites] J Clin Oncol. 1999 Nov;17(11):3468-75 [10550144.001]
  • [Cites] J Clin Oncol. 1999 Dec;17(12):3706-19 [10577842.001]
  • [Cites] J Clin Oncol. 2001 Jun 15;19(12):3091-102 [11408506.001]
  • [Cites] Cancer. 1988 Jan 15;61(2):209-20 [3275486.001]
  • [Cites] J Clin Oncol. 2009 Nov 1;27(31):5182-8 [19770373.001]
  • [Cites] J Clin Oncol. 1995 Mar;13(3):610-30 [7884423.001]
  • [Cites] Cancer. 1995 Sep 15;76(6):1073-85 [8625211.001]
  • [Cites] Eur J Cancer. 1998 Jun;34(7):1050-62 [9849454.001]
  • [Cites] J Clin Oncol. 2005 Apr 20;23(12):2618-28 [15728225.001]
  • [Cites] J Clin Oncol. 2009 Mar 20;27(9):1446-55 [19224858.001]
  • [CommentIn] Pediatr Blood Cancer. 2010 Oct;55(4):597-8 [20589627.001]
  • (PMID = 20806360.001).
  • [ISSN] 1545-5017
  • [Journal-full-title] Pediatric blood & cancer
  • [ISO-abbreviation] Pediatr Blood Cancer
  • [Language] ENG
  • [Grant] United States / NCI NIH HHS / CA / CA-98543; United States / NCI NIH HHS / CA / U10 CA072989; United States / NCI NIH HHS / CA / U10 CA029511; United States / NCI NIH HHS / CA / CA-24507; United States / NCI NIH HHS / CA / CA-72989; United States / NCI NIH HHS / CA / U10 CA098543; United States / NCI NIH HHS / CA / CA-29511; United States / NCI NIH HHS / CA / U10 CA024507
  • [Publication-type] Journal Article; Research Support, N.I.H., Extramural
  • [Publication-country] United States
  • [Other-IDs] NLM/ NIHMS263511; NLM/ PMC3128801
  •  go-up   go-down


57. Canner JA, Sobo M, Ball S, Hutzen B, DeAngelis S, Willis W, Studebaker AW, Ding K, Wang S, Yang D, Lin J: MI-63: a novel small-molecule inhibitor targets MDM2 and induces apoptosis in embryonal and alveolar rhabdomyosarcoma cells with wild-type p53. Br J Cancer; 2009 Sep 1;101(5):774-81
The Lens. Cited by Patents in .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] MI-63: a novel small-molecule inhibitor targets MDM2 and induces apoptosis in embryonal and alveolar rhabdomyosarcoma cells with wild-type p53.
  • METHODS: Rhabdomyosarcoma (RMS), the most common childhood soft tissue sarcoma, expresses either wild-type or mutant p53 protein.
  • We examined the inhibitory effects of MI-63 in embryonal RMS (ERMS) and alveolar RMS (ARMS) cell lines expressing wild-type or mutated p53.
  • [MeSH-major] Antineoplastic Agents / pharmacology. Apoptosis / drug effects. Indoles / pharmacology. Proto-Oncogene Proteins c-mdm2 / antagonists & inhibitors. Rhabdomyosarcoma, Alveolar / pathology. Rhabdomyosarcoma, Embryonal / pathology. Spiro Compounds / pharmacology. Tumor Suppressor Protein p53 / metabolism

  • Genetic Alliance. consumer health - Rhabdomyosarcoma alveolar.
  • Genetic Alliance. consumer health - Rhabdomyosarcoma embryonal.
  • Hazardous Substances Data Bank. DOXORUBICIN .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Oncogene. 1998 Nov 12;17(19):2543-7 [9824166.001]
  • [Cites] Growth Factors. 2005 Sep;23(3):183-92 [16243710.001]
  • [Cites] Proc Natl Acad Sci U S A. 2006 Feb 7;103(6):1888-93 [16443686.001]
  • [Cites] J Med Chem. 2006 Jun 15;49(12):3432-5 [16759082.001]
  • [Cites] Cancer Res. 2006 Jul 15;66(14):6936-46 [16849537.001]
  • [Cites] Clin Cancer Res. 2008 Sep 1;14(17):5416-25 [18765533.001]
  • [Cites] Med Pediatr Oncol. 2000 Aug;35(2):96-103 [10918230.001]
  • [Cites] J Pediatr Hematol Oncol. 2001 May;23(4):215-20 [11846299.001]
  • [Cites] J Clin Oncol. 2003 Jan 1;21(1):78-84 [12506174.001]
  • [Cites] Mol Cancer Res. 2004 Jan;2(1):20-8 [14757842.001]
  • [Cites] Mod Pathol. 2004 Jun;17(6):660-9 [15098008.001]
  • [Cites] Semin Cancer Biol. 2004 Aug;14(4):244-52 [15219617.001]
  • [Cites] Br J Cancer. 2004 Oct 18;91(8):1415-9 [15452548.001]
  • [Cites] Adv Enzyme Regul. 1984;22:27-55 [6382953.001]
  • [Cites] Genes Dev. 1994 May 15;8(10):1235-46 [7926727.001]
  • [Cites] J Clin Oncol. 1995 Mar;13(3):610-30 [7884423.001]
  • [Cites] J Clin Oncol. 1995 Aug;13(8):2123-39 [7636557.001]
  • [Cites] Mol Med. 1995 Jan;1(2):142-52 [8529093.001]
  • [Cites] Mol Cell Biol. 1996 May;16(5):2445-52 [8628312.001]
  • [Cites] Am J Pathol. 1996 Jul;149(1):143-51 [8686737.001]
  • [Cites] Science. 1996 Nov 8;274(5289):948-53 [8875929.001]
  • [Cites] FEBS Lett. 1997 Dec 22;420(1):25-7 [9450543.001]
  • [Cites] Pharmacol Res. 1998 Feb;37(2):83-5 [9572060.001]
  • [Cites] Nucleic Acids Res. 1998 Aug 1;26(15):3453-9 [9671804.001]
  • (PMID = 19707204.001).
  • [ISSN] 1532-1827
  • [Journal-full-title] British journal of cancer
  • [ISO-abbreviation] Br. J. Cancer
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Antineoplastic Agents; 0 / Imidazoles; 0 / Indoles; 0 / MI-63 compound; 0 / Piperazines; 0 / Spiro Compounds; 0 / Tumor Suppressor Protein p53; 0 / nutlin 3; 80168379AG / Doxorubicin; EC 3.4.22.- / Caspase 3; EC 6.3.2.19 / MDM2 protein, human; EC 6.3.2.19 / Proto-Oncogene Proteins c-mdm2
  • [Other-IDs] NLM/ PMC2736841
  •  go-up   go-down


58. Mentzel T: [Spindle cell rhabdomyosarcoma in adults: a new entity in the spectrum of malignant mesenchymal tumors of soft tissues]. Pathologe; 2010 Mar;31(2):91-6

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Spindle cell rhabdomyosarcoma in adults: a new entity in the spectrum of malignant mesenchymal tumors of soft tissues].
  • Rhabdomyosarcomas (RMS) are rare soft tissue sarcomas showing a skeletal muscle differentiation.
  • Histologically, embryonal, alveolar and pleomorphic subtypes are distinguished.
  • RMS represent one of the most frequent sarcomas in children and adolescents, and in this age group embryonal and alveolar subtypes predominate.
  • [MeSH-major] Rhabdomyosarcoma / pathology. Soft Tissue Neoplasms / pathology
  • [MeSH-minor] Adolescent. Adult. Aged. Child. Connective Tissue / pathology. Humans. Middle Aged. Muscle, Skeletal / pathology

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Cancer. 2003 Aug 1;98(3):571-80 [12879475.001]
  • [Cites] Cancer. 1995 Sep 15;76(6):1073-85 [8625211.001]
  • [Cites] Am J Surg Pathol. 1998 Apr;22(4):459-64 [9537474.001]
  • [Cites] Virchows Arch. 2000 Apr;436(4):305-11 [10834531.001]
  • [Cites] Am J Surg Pathol. 2002 Sep;26(9):1175-83 [12218574.001]
  • [Cites] Am J Surg Pathol. 1993 Mar;17(3):221-30 [8434703.001]
  • [Cites] Mod Pathol. 2001 Jun;14(6):595-603 [11406662.001]
  • [Cites] Virchows Arch. 2006 Nov;449(5):554-60 [17013628.001]
  • [Cites] Hum Pathol. 2009 Mar;40(3):341-8 [18973919.001]
  • [Cites] Cancer. 2001 Feb 15;91(4):794-803 [11241248.001]
  • [Cites] Am J Surg Pathol. 2005 Aug;29(8):1106-13 [16006807.001]
  • (PMID = 19997735.001).
  • [ISSN] 1432-1963
  • [Journal-full-title] Der Pathologe
  • [ISO-abbreviation] Pathologe
  • [Language] ger
  • [Publication-type] English Abstract; Journal Article; Review
  • [Publication-country] Germany
  • [Number-of-references] 11
  •  go-up   go-down


59. Hosoi H, Kakazu N, Konishi E, Tsuchihashi Y, Hada S, Amaya E, Nakabayahi Y, Misawa-Furihata A, Tabata-Maruyama H, Iehara T, Sugimoto T, Yamane H, Yamasaki M, Shiwaku K, Yanagisawa A, Ono M, Tokiwa K, Iwai N, Hashiba M, Abe T, Sawada T: A novel PAX3 rearrangement in embryonal rhabdomyosarcoma. Cancer Genet Cytogenet; 2009 Mar;189(2):98-104
NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] A novel PAX3 rearrangement in embryonal rhabdomyosarcoma.
  • Rhabdomyosarcoma is the most common soft tissue tumor seen in children and young adults, and it can be classified into 2 major histological subtypes, alveolar and embryonal.
  • In the alveolar subtype, 2 recurrent chromosomal translocations, t(2;13)(q35;q14) and its variant t(1;13)(p36;q14), have been identified as the specific cytogenetic abnormalities.
  • In this study, we analyzed the complex chromosomal translocation in one case with embryonal rhabdomyosarcoma by means of spectral karyotyping (SKY) and identified a novel translocation involving chromosome band 2q35, which is the locus of PAX3 gene.
  • [MeSH-major] Mutation. Paired Box Transcription Factors / genetics. Rhabdomyosarcoma, Embryonal / genetics. Urogenital Neoplasms / genetics

  • Genetic Alliance. consumer health - Rhabdomyosarcoma embryonal.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19215790.001).
  • [ISSN] 1873-4456
  • [Journal-full-title] Cancer genetics and cytogenetics
  • [ISO-abbreviation] Cancer Genet. Cytogenet.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Oncogene Proteins, Fusion; 0 / PAX3 protein, human; 0 / PAX3-FOXO1A fusion protein, human; 0 / Paired Box Transcription Factors; 0 / Recombinant Fusion Proteins
  •  go-up   go-down


60. Meza JL, Anderson J, Pappo AS, Meyer WH, Children's Oncology Group: Analysis of prognostic factors in patients with nonmetastatic rhabdomyosarcoma treated on intergroup rhabdomyosarcoma studies III and IV: the Children's Oncology Group. J Clin Oncol; 2006 Aug 20;24(24):3844-51
Hazardous Substances Data Bank. VINCRISTINE .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Analysis of prognostic factors in patients with nonmetastatic rhabdomyosarcoma treated on intergroup rhabdomyosarcoma studies III and IV: the Children's Oncology Group.
  • PURPOSE: The outcome for localized rhabdomyosarcoma (RMS) or undifferentiated sarcoma (UDS) is affected by age, histology, primary anatomic site, extent of disease, and therapy.
  • PATIENTS AND METHODS: We evaluated patient and disease characteristics for their ability to predict outcome for patients with nonmetastatic RMS or UDS treated on Intergroup Rhabdomyosarcoma Study (IRS) -III (1984 to 1991) or IRS-IV (1991 to 1997).
  • Overall, outcomes for patients with alveolar RMS (ARMS) or UDS were worse than for patients with ERMS.
  • CONCLUSION: Patient and disease characteristics identify distinct subsets with different outcomes, allowing the Soft Tissue Sarcoma Committee of the Children's Oncology Group to refine risk-adapted therapy assignment.
  • [MeSH-major] Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Rhabdomyosarcoma / therapy

  • COS Scholar Universe. author profiles.
  • Hazardous Substances Data Bank. CIS-DIAMINEDICHLOROPLATINUM .
  • Hazardous Substances Data Bank. DOXORUBICIN .
  • Hazardous Substances Data Bank. ETOPOSIDE .
  • Hazardous Substances Data Bank. IFOSFAMIDE .
  • Hazardous Substances Data Bank. CYCLOPHOSPHAMIDE .
  • Hazardous Substances Data Bank. DACTINOMYCIN .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16921036.001).
  • [ISSN] 1527-7755
  • [Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • [ISO-abbreviation] J. Clin. Oncol.
  • [Language] eng
  • [Grant] United States / NCI NIH HHS / CA / CA-24507; United States / NCI NIH HHS / CA / CA-72989
  • [Publication-type] Clinical Trial; Journal Article; Multicenter Study; Research Support, N.I.H., Extramural
  • [Publication-country] United States
  • [Chemical-registry-number] 1CC1JFE158 / Dactinomycin; 5J49Q6B70F / Vincristine; 6PLQ3CP4P3 / Etoposide; 80168379AG / Doxorubicin; 8N3DW7272P / Cyclophosphamide; Q20Q21Q62J / Cisplatin; UM20QQM95Y / Ifosfamide
  •  go-up   go-down


61. Ognjanovic S, Carozza SE, Chow EJ, Fox EE, Horel S, McLaughlin CC, Mueller BA, Puumala S, Reynolds P, Von Behren J, Spector L: Birth characteristics and the risk of childhood rhabdomyosarcoma based on histological subtype. Br J Cancer; 2010 Jan 5;102(1):227-31
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Birth characteristics and the risk of childhood rhabdomyosarcoma based on histological subtype.
  • BACKGROUND: Little is known about risk factors for childhood rhabdomyosarcoma (RMS) and the histology-specific details are rare.
  • METHODS: Case-control studies formed by linking cancer and birth registries of California, Minnesota, New York, Texas and Washington, which included 583 RMS cases (363 embryonal and 85 alveolar RMS) and 57 966 randomly selected control subjects, were analysed using logistic regression.
  • The associations of RMS (overall, and based on embryonal or alveolar histology) with birth weight across five 500 g categories (from 2000 to 4500 g) were examined using normal birth weight (2500-3999 g) as a reference.
  • CONCLUSIONS: These data suggest a positive association between accelerated in utero growth and embryonal RMS, but not alveolar RMS.
  • These results warrant cautious interpretation owing to the small number of alveolar RMS cases.
  • [MeSH-major] Rhabdomyosarcoma / epidemiology. Soft Tissue Neoplasms / epidemiology
  • [MeSH-minor] Adolescent. Adult. Age of Onset. Birth Order. Birth Weight. Child. Child, Preschool. Diseases in Twins / epidemiology. Embryonic Development. Female. Gestational Age. Humans. Infant. Infant, Newborn. Male. Maternal Age. Paternal Age. Rhabdomyosarcoma, Alveolar / embryology. Rhabdomyosarcoma, Alveolar / epidemiology. Rhabdomyosarcoma, Embryonal / embryology. Rhabdomyosarcoma, Embryonal / epidemiology. Risk Factors. Young Adult

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Eur J Pediatr. 2001 Jun;160(6):333-8 [11421411.001]
  • [Cites] Br J Cancer. 2008 Jul 8;99(1):179-81 [18560404.001]
  • [Cites] Clin Genet. 2002 Jul;62(1):84-8 [12123493.001]
  • [Cites] J Pediatr. 2002 Oct;141(4):538-42 [12378194.001]
  • [Cites] J Clin Endocrinol Metab. 2004 Jan;89(1):384-91 [14715876.001]
  • [Cites] Pediatr Clin North Am. 2004 Jun;51(3):639-54, viii [15157589.001]
  • [Cites] Eur J Obstet Gynecol Reprod Biol. 2004 Sep 10;116(1):3-15 [15294360.001]
  • [Cites] Cancer Genet Cytogenet. 2004 Oct 15;154(2):169-74 [15474156.001]
  • [Cites] Ann Intern Med. 1969 Oct;71(4):747-52 [5360287.001]
  • [Cites] J Natl Cancer Inst. 1969 Dec;43(6):1365-73 [5396222.001]
  • [Cites] J Natl Cancer Inst. 1982 Jan;68(1):107-13 [6948120.001]
  • [Cites] Med Pediatr Oncol. 1988;16(1):33-9 [3277029.001]
  • [Cites] Br J Cancer. 1988 Dec;58(6):838-42 [3224086.001]
  • [Cites] Genes Chromosomes Cancer. 1989 Sep;1(1):23-35 [2487144.001]
  • [Cites] Int J Cancer. 1992 Feb 1;50(3):365-8 [1735603.001]
  • [Cites] Nature. 1993 Apr 22;362(6422):747-9 [8385745.001]
  • [Cites] Cancer Causes Control. 1993 May;4(3):217-24 [8318638.001]
  • [Cites] J Clin Invest. 1995 Apr;95(4):1606-11 [7706467.001]
  • [Cites] J Pediatr. 1998 Mar;132(3 Pt 1):398-400 [9544889.001]
  • [Cites] Med Pediatr Oncol. 1999 Jan;32(1):38-43 [9917751.001]
  • [Cites] Oncologist. 1999;4(1):34-44 [10337369.001]
  • [Cites] Am J Clin Nutr. 2005 Mar;81(3):678-85 [15755839.001]
  • [Cites] Cancer. 2005 Apr 1;103(7):1457-67 [15712273.001]
  • [Cites] Am J Med Genet C Semin Med Genet. 2005 Aug 15;137C(1):72-7 [16010679.001]
  • [Cites] Nat Genet. 2005 Oct;37(10):1038-40 [16170316.001]
  • [Cites] J Obstet Gynecol Neonatal Nurs. 2006 Jan-Feb;35(1):3-12 [16466348.001]
  • [Cites] J Clin Oncol. 2006 Feb 10;24(5):816-22 [16391296.001]
  • [Cites] Cancer Res. 2006 Jul 15;66(14):6936-46 [16849537.001]
  • [Cites] Pediatr Blood Cancer. 2007 Mar;48(3):345-8 [16534790.001]
  • [Cites] Cancer. 2007 Apr 1;109(7):1406-12 [17330850.001]
  • [Cites] J Pediatr Hematol Oncol. 2007 May;29(5):341-4 [17483716.001]
  • [Cites] J Pathol. 2007 Jun;212(2):143-51 [17471488.001]
  • [Cites] Am J Epidemiol. 2008 Aug 15;168(4):366-73 [18579539.001]
  • [Cites] Cancer Epidemiol Biomarkers Prev. 2009 Jan;18(1):162-8 [19124494.001]
  • [Cites] Int J Cancer. 2009 Jun 1;124(11):2658-70 [19173295.001]
  • [Cites] Cancer Epidemiol Biomarkers Prev. 2009 Apr;18(4):1271-6 [19293315.001]
  • [Cites] Pediatrics. 2009 Jul;124(1):96-104 [19564288.001]
  • [Cites] Cancer. 2009 Sep 15;115(18):4218-26 [19536876.001]
  • [Cites] BMJ. 2002 Feb 2;324(7332):283-7 [11823363.001]
  • (PMID = 19997102.001).
  • [ISSN] 1532-1827
  • [Journal-full-title] British journal of cancer
  • [ISO-abbreviation] Br. J. Cancer
  • [Language] eng
  • [Publication-type] Comparative Study; Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] England
  • [Other-IDs] NLM/ PMC2813761
  •  go-up   go-down


62. Barlow JW, Wiley JC, Mous M, Narendran A, Gee MF, Goldberg M, Sexsmith E, Malkin D: Differentiation of rhabdomyosarcoma cell lines using retinoic acid. Pediatr Blood Cancer; 2006 Nov;47(6):773-84
NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Differentiation of rhabdomyosarcoma cell lines using retinoic acid.
  • BACKGROUND: Rhabdomyosarcoma (RMS) is the most frequent sporadic soft tissue sarcoma of childhood and adolescence.
  • Novel therapeutic approaches are necessary to improve on these outcomes particularly among the more aggressive alveolar RMS (ARMS) and late stages of disease, where 5-year survival is less than 20%.
  • [MeSH-major] Cell Differentiation / drug effects. Rhabdomyosarcoma / drug therapy. Tretinoin / pharmacology. Tumor Suppressor Protein p53 / genetics

  • Hazardous Substances Data Bank. ALL-TRANS-RETINOIC ACID .
  • Hazardous Substances Data Bank. ALITRETINOIN .
  • Hazardous Substances Data Bank. ETHANOL .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] (c) 2005 Wiley-Liss, Inc.
  • (PMID = 16283617.001).
  • [ISSN] 1545-5009
  • [Journal-full-title] Pediatric blood & cancer
  • [ISO-abbreviation] Pediatr Blood Cancer
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antineoplastic Agents; 0 / TP53 protein, human; 0 / Troponin T; 0 / Tumor Suppressor Protein p53; 3K9958V90M / Ethanol; 5300-03-8 / alitretinoin; 5688UTC01R / Tretinoin
  •  go-up   go-down


63. Seitz G, Warmann SW, Vokuhl CO, Heitmann H, Treuner C, Leuschner I, Fuchs J: Effects of standard chemotherapy on tumor growth and regulation of multidrug resistance genes and proteins in childhood rhabdomyosarcoma. Pediatr Surg Int; 2007 May;23(5):431-9
NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Effects of standard chemotherapy on tumor growth and regulation of multidrug resistance genes and proteins in childhood rhabdomyosarcoma.
  • The prognosis of rhabdomyosarcoma (RMS) in advanced stages is still sobering.
  • The aim of this study was to investigate the development of multidrug resistance in cell lines and in xenografts of alveolar and embryonal RMS treated according to the German Soft Tissue Sarcoma Study (CWS).
  • Alveolar and embryonal RMS cell lines were treated with Vincristine, Topotecan, Carboplatin, Actinomycin D, or Ifosfamide.
  • Nude mice (NMRI nu/nu, n = 10 per group) underwent xenotransplantation of human embryonal or alveolar RMS.
  • In the cell lines, an up-regulation of MDR-1 gene was found in alveolar rhabdomyosarcoma.
  • In embryonal rhabdomyosarcoma, an up-regulation of LRP and MRP was found.
  • Standard chemotherapy of alveolar rhabdomyosarcoma resulted in a significant reduction of tumor growth (P < 0.05) in all groups.
  • In embryonal rhabdomyosarcoma strongest effects were found after treatment with Ifosfamide, Vincristine and Carboplatin (P < 0.05).
  • RT-PCR revealed a MDR1-dependent mechanism in alveolar rhabdomyosarcoma.
  • In embryonal rhabdomyosarcoma, MDR1 occurred to a lower degree.
  • [MeSH-major] Drug Resistance, Neoplasm / drug effects. Gene Expression Regulation, Neoplastic / drug effects. Genes, MDR / genetics. Multidrug Resistance-Associated Proteins / drug effects. Rhabdomyosarcoma, Alveolar / drug therapy. Rhabdomyosarcoma, Embryonal / drug therapy. Soft Tissue Neoplasms / drug therapy

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Med Pediatr Oncol. 2000 Aug;35(2):96-103 [10918230.001]
  • [Cites] Cancer. 2002 Oct 15;95(8):1795-801 [12365029.001]
  • [Cites] Hum Pathol. 2003 Feb;34(2):150-5 [12612883.001]
  • [Cites] Pediatr Dev Pathol. 2002 May-Jun;5(3):276-82 [12007020.001]
  • [Cites] J Pediatr Hematol Oncol. 2001 May;23(4):215-20 [11846299.001]
  • [Cites] Cancer. 1997 Sep 15;80(6):1165-70 [9305719.001]
  • [Cites] Cell Mol Biol (Noisy-le-grand). 1994 Mar;40(2):137-45 [7911694.001]
  • [Cites] Pediatr Blood Cancer. 2007 Mar;48(3):311-7 [16609945.001]
  • [Cites] Methods. 2001 Dec;25(4):402-8 [11846609.001]
  • [Cites] Paediatr Drugs. 2002;4(1):21-8 [11817983.001]
  • [Cites] Cancer. 1995 Sep 15;76(6):1073-85 [8625211.001]
  • [Cites] Clin Cancer Res. 1999 Nov;5(11):3617-31 [10589779.001]
  • [Cites] Cancer. 1998 Dec 1;83(11):2400-7 [9840541.001]
  • [Cites] Clin Cancer Res. 1999 Aug;5(8):2198-204 [10473106.001]
  • [Cites] Cancer Chemother Pharmacol. 2003 Aug;52(2):131-8 [12783202.001]
  • [Cites] Int J Oncol. 1998 May;12(5):1143-9 [9538141.001]
  • [Cites] Pediatr Hematol Oncol. 2005 Jul-Aug;22(5):373-86 [16020127.001]
  • [Cites] Anticancer Res. 2000 Sep-Oct;20(5C):3759-65 [11268451.001]
  • [Cites] Int J Oncol. 2005 Sep;27(3):791-8 [16077930.001]
  • [Cites] Cancer Res. 2003 Apr 1;63(7):1515-9 [12670898.001]
  • [Cites] J Clin Oncol. 1990 Apr;8(4):689-704 [1968964.001]
  • [Cites] J Natl Cancer Inst. 1973 Nov;51(5):1417-23 [4357758.001]
  • [Cites] J Pathol. 1996 Sep;180(1):85-9 [8943821.001]
  • [Cites] Cancer. 2003 May 15;97(10):2597-604 [12733159.001]
  • [Cites] Cancer Gene Ther. 2005 Apr;12 (4):397-406 [15618970.001]
  • [Cites] Br J Cancer. 2000 Aug;83(3):338-45 [10917549.001]
  • [Cites] Br J Cancer. 2001 Nov 30;85(11):1746-52 [11742497.001]
  • [Cites] Curr Drug Targets. 2006 Jul;7(7):813-21 [16842213.001]
  • [Cites] Cancer Res. 1993 Apr 1;53(7):1475-9 [7680954.001]
  • [Cites] J Clin Oncol. 1990 Mar;8(3):443-52 [2407808.001]
  • [Cites] J Biol Chem. 2001 Mar 2;276(9):6874-8 [11152666.001]
  • [Cites] Clin Cancer Res. 2001 Oct;7(10 ):3193-8 [11595714.001]
  • [Cites] J Clin Oncol. 2006 Aug 20;24(24):3844-51 [16921036.001]
  • [Cites] Lancet Oncol. 2000 Oct;1:75-85 [11905672.001]
  • [Cites] J Clin Oncol. 2001 Jun 15;19(12):3091-102 [11408506.001]
  • [Cites] Anticancer Drugs. 1997 Feb;8(2):125-40 [9073309.001]
  • [Cites] Cancer Chemother Rep. 1966 May;50(4):219-44 [4957125.001]
  • [Cites] Cancer. 2003 Apr 15;97(8):1999-2005 [12673730.001]
  • [Cites] Cancer Invest. 2000;18(3):223-41 [10754991.001]
  • [Cites] J Clin Oncol. 2005 Apr 20;23(12):2618-28 [15728225.001]
  • [Cites] Cancer Res. 2006 May 1;66(9):4742-9 [16651427.001]
  • [Cites] Anticancer Res. 2003 Nov-Dec;23 (6C):4607-11 [14981903.001]
  • (PMID = 17211591.001).
  • [ISSN] 0179-0358
  • [Journal-full-title] Pediatric surgery international
  • [ISO-abbreviation] Pediatr. Surg. Int.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] Germany
  • [Chemical-registry-number] 0 / Antineoplastic Agents; 0 / Multidrug Resistance-Associated Proteins; 0 / Neoplasm Proteins
  •  go-up   go-down


64. Chen Y, Takita J, Mizuguchi M, Tanaka K, Ida K, Koh K, Igarashi T, Hanada R, Tanaka Y, Park MJ, Hayashi Y: Mutation and expression analyses of the MET and CDKN2A genes in rhabdomyosarcoma with emphasis on MET overexpression. Genes Chromosomes Cancer; 2007 Apr;46(4):348-58
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Mutation and expression analyses of the MET and CDKN2A genes in rhabdomyosarcoma with emphasis on MET overexpression.
  • Rhabdomyosarcoma (RMS) is the most common soft-tissue sarcoma of childhood.
  • No mutations were detected in exons 14-21 of MET whereas a nonsense mutation at codon 80 of p16(INK4A) was identified in an alveolar RMS cell line.
  • On the other hand, reduced or absent expression of p16INK4A and/or p14(ARF) showed no significant correlation with the clinicopathological parameters, except for the age at diagnosis.
  • [MeSH-major] Cyclin-Dependent Kinase Inhibitor p16 / genetics. DNA Mutational Analysis. Gene Expression Profiling. Proto-Oncogene Proteins / genetics. Receptors, Growth Factor / genetics. Rhabdomyosarcoma / genetics

  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] (c) 2007 Wiley-Liss, Inc.
  • (PMID = 17243166.001).
  • [ISSN] 1045-2257
  • [Journal-full-title] Genes, chromosomes & cancer
  • [ISO-abbreviation] Genes Chromosomes Cancer
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Codon, Nonsense; 0 / Cyclin-Dependent Kinase Inhibitor p16; 0 / Proto-Oncogene Proteins; 0 / Receptors, Growth Factor; EC 2.7.10.1 / MET protein, human; EC 2.7.10.1 / Proto-Oncogene Proteins c-met
  •  go-up   go-down


65. Fatusi OA, Ajike SO, Olateju SO, Adebayo AT, Gbolahan OO, Ogunmuyiwa SA: Clinico-epidemiological analysis of orofacial rhabdomyosarcoma in a Nigerian population. Int J Oral Maxillofac Surg; 2009 Mar;38(3):256-60
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Clinico-epidemiological analysis of orofacial rhabdomyosarcoma in a Nigerian population.
  • Rhabdomyosarcoma (RMS) is a malignant soft tissue neoplasm, with varying degrees of striated muscle cell differentiation and a relative predilection for the head and neck region.
  • Embryonal and alveolar subtypes were mainly found in the maxilla.
  • [MeSH-major] Facial Neoplasms / epidemiology. Head and Neck Neoplasms / epidemiology. Mouth Neoplasms / epidemiology. Neoplasms, Multiple Primary / epidemiology. Rhabdomyosarcoma / epidemiology

  • MedlinePlus Health Information. consumer health - Head and Neck Cancer.
  • MedlinePlus Health Information. consumer health - Oral Cancer.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19153030.001).
  • [ISSN] 1399-0020
  • [Journal-full-title] International journal of oral and maxillofacial surgery
  • [ISO-abbreviation] Int J Oral Maxillofac Surg
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Denmark
  •  go-up   go-down


66. Bui Nguyen Binh M, Collin F, Coindre JM: [Soft tissue sarcomas: update on molecular data]. Cancer Radiother; 2006 Feb-Mar;10(1-2):15-21
NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Soft tissue sarcomas: update on molecular data].
  • Soft tissue sarcomas are rare and may be a source of problems for diagnosis and treatment.
  • Detection of these disorders may help in diagnosis and in determining prognosis.
  • Detection of specific translocation is recommended in synovial sarcoma, alveolar rhabdomyosarcoma or PNET diagnosis because of therapeutic consequences; in case of rarer histologic type (low grade fibromyxoid sarcoma, clear cell sarcoma, infantile fibrosarcoma...), it may confirm the diagnosis.
  • In some cases, some translocations have a prognostic value (alveolar rhabdomyosarcoma) whereas it is discussed in others (synovial sarcoma).
  • The techniques used to detect these translocations are very sensitive so it may be used to detect microscopical metastasis (bone marrow metastasis of alveolar rhabdomyosarcoma for example).
  • Detection of MDM2 and CDK4 genes amplifications (FISH or quantitative PCR) may be sometimes useful in well differentiated and dedifferentiated liposarcomas diagnosis.
  • Mutation detection of KIT or PDGFRA may help in GIST diagnosis and type of mutation is predictive of response to treatment.
  • [MeSH-major] Sarcoma / genetics. Soft Tissue Neoplasms / genetics

  • MedlinePlus Health Information. consumer health - Soft Tissue Sarcoma.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16442827.001).
  • [ISSN] 1278-3218
  • [Journal-full-title] Cancer radiothérapie : journal de la Société française de radiothérapie oncologique
  • [ISO-abbreviation] Cancer Radiother
  • [Language] fre
  • [Publication-type] English Abstract; Journal Article; Review
  • [Publication-country] France
  • [Number-of-references] 35
  •  go-up   go-down


67. Sinha R, Bandyopadhyay SN, Pathak K, Hati G: Rhabdomyosarcoma of nose and paranasal sinuses--a therapeutic challenge. J Indian Med Assoc; 2006 Sep;104(9):519-21
MedlinePlus Health Information. consumer health - Nasal Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Rhabdomyosarcoma of nose and paranasal sinuses--a therapeutic challenge.
  • Rhabdomyosarcoma is a highly malignant tumour of striated muscle and it is the most common soft tissue sarcoma in the paediatric age group.
  • Histologically embryonal rhabdomyosarcoma is the most common variant.
  • The present series deals with seven such cases of different histopathological types including the embryonal, botryoid, and alveolar varieties in the paediatric age group.
  • [MeSH-major] Nose Neoplasms / therapy. Paranasal Sinus Neoplasms / therapy. Rhabdomyosarcoma / therapy
  • [MeSH-minor] Biopsy. Child. Child, Preschool. Combined Modality Therapy. Diagnosis, Differential. Female. Follow-Up Studies. Humans. India / epidemiology. Male. Retrospective Studies. Survival Rate. Tomography, X-Ray Computed. Treatment Outcome

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17388011.001).
  • [ISSN] 0019-5847
  • [Journal-full-title] Journal of the Indian Medical Association
  • [ISO-abbreviation] J Indian Med Assoc
  • [Language] eng
  • [Publication-type] Journal Article; Multicenter Study
  • [Publication-country] India
  •  go-up   go-down


68. Ognjanovic S, Linabery AM, Charbonneau B, Ross JA: Trends in childhood rhabdomyosarcoma incidence and survival in the United States, 1975-2005. Cancer; 2009 Sep 15;115(18):4218-26
The Lens. Cited by Patents in .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Trends in childhood rhabdomyosarcoma incidence and survival in the United States, 1975-2005.
  • BACKGROUND: Rhabdomyosarcoma (RMS) is the most common soft tissue sarcoma in children and adolescents aged<20 years; its etiology remains largely unknown.
  • It is believed that embryonal (ERMS) and alveolar rhabdomyosarcoma (ARMS), the most common subtypes, arise through distinct biologic mechanisms.
  • This trend may have been attributable in part to shifts in diagnosis, because a significant negative trend in RMS, not otherwise specified was observed concurrently.

  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] Copyright (c) 2009 American Cancer Society.
  • [Cites] Pediatr Dev Pathol. 2001 Nov-Dec;4(6):550-8 [11826361.001]
  • [Cites] Oncogene. 2001 Sep 10;20(40):5736-46 [11607823.001]
  • [Cites] Biometrics. 1983 Dec;39(4):941-8 [6671129.001]
  • [Cites] Med Pediatr Oncol. 1988;16(1):33-9 [3277029.001]
  • [Cites] Br J Cancer. 1988 Dec;58(6):838-42 [3224086.001]
  • [Cites] Science. 1990 Nov 30;250(4985):1233-8 [1978757.001]
  • [Cites] Int J Cancer. 1992 Feb 1;50(3):365-8 [1735603.001]
  • [Cites] Cancer Causes Control. 1993 May;4(3):217-24 [8318638.001]
  • [Cites] Genet Epidemiol. 1995;12(5):467-74 [8557179.001]
  • [Cites] Cancer. 1995 Sep 15;76(6):1073-85 [8625211.001]
  • [Cites] Cancer. 1995 Dec 1;76(11):2343-50 [8635041.001]
  • [Cites] Cancer. 1996 Oct 1;78(7):1483-91 [8839555.001]
  • [Cites] Diagn Mol Pathol. 1997 Apr;6(2):91-7 [9098647.001]
  • [Cites] Cancer Res. 1999 Apr 1;59(7 Suppl):1743s-1746s [10197590.001]
  • [Cites] Oncologist. 1999;4(1):34-44 [10337369.001]
  • [Cites] Pediatr Dev Pathol. 1998 Nov-Dec;1(6):550-61 [9724344.001]
  • [Cites] Cancer. 2005 Apr 1;103(7):1457-67 [15712273.001]
  • [Cites] Cancer Res. 2006 Jul 15;66(14):6936-46 [16849537.001]
  • [Cites] J Pathol. 2007 Jun;212(2):143-51 [17471488.001]
  • [Cites] Med Sci Monit. 2008 Jan;14(1):RA8-15 [18160950.001]
  • [Cites] Cancer. 2008 Jan 15;112(2):416-32 [18074355.001]
  • [Cites] Bone. 2008 May;42(5):982-9 [18337201.001]
  • [Cites] Am J Med Genet C Semin Med Genet. 2003 Feb 15;117C(1):42-8 [12561057.001]
  • [Cites] Cancer Res. 2003 Oct 15;63(20):6643-50 [14583457.001]
  • [Cites] J Pediatr. 2004 May;144(5):666-8 [15127010.001]
  • [Cites] Curr Probl Cancer. 1978 Mar;2(9):1-36 [109248.001]
  • [Cites] Eur J Cancer. 2008 Oct;44(15):2226-32 [18691878.001]
  • [Cites] Med Pediatr Oncol. 2002 Dec;39(6):554-7; discussion 552-3 [12376977.001]
  • [Cites] J Natl Cancer Inst. 1982 Jan;68(1):107-13 [6948120.001]
  • (PMID = 19536876.001).
  • [ISSN] 0008-543X
  • [Journal-full-title] Cancer
  • [ISO-abbreviation] Cancer
  • [Language] ENG
  • [Grant] United States / NCI NIH HHS / CA / T32 CA099936-07; United States / NCI NIH HHS / CA / T32 CA099936-06S1; United States / NCI NIH HHS / CA / CA099936-07; United States / NCI NIH HHS / CA / T32 CA099936; United States / NCI NIH HHS / CA / CA099936-06S1
  • [Publication-type] Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Other-IDs] NLM/ NIHMS218300; NLM/ PMC2953716
  •  go-up   go-down


69. Mazzoleni S, Bisogno G, Garaventa A, Cecchetto G, Ferrari A, Sotti G, Donfrancesco A, Madon E, Casula L, Carli M, Associazione Italiana di Ematologia e Oncologia Pediatrica Soft Tissue Sarcoma Committee: Outcomes and prognostic factors after recurrence in children and adolescents with nonmetastatic rhabdomyosarcoma. Cancer; 2005 Jul 1;104(1):183-90

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Outcomes and prognostic factors after recurrence in children and adolescents with nonmetastatic rhabdomyosarcoma.
  • BACKGROUND: Although > 90% of children with nonmetastatic rhabdomyosarcoma (RMS) achieve complete remission with current treatment, up to one-third of them experience a recurrence.
  • RESULTS: The median time from diagnosis to recurrence was 17.8 months.
  • 1) alveolar subtype (relative risk [RR], 2.0), 2) parameningeal or "other" sites (RR, 2.6), 3) systemic recurrence (RR, 3.1), and 4) recurrence on therapy (RR, 2.3).
  • [MeSH-major] Rhabdomyosarcoma / mortality

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15895378.001).
  • [ISSN] 0008-543X
  • [Journal-full-title] Cancer
  • [ISO-abbreviation] Cancer
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  •  go-up   go-down


70. Linardic CM, Naini S, Herndon JE 2nd, Kesserwan C, Qualman SJ, Counter CM: The PAX3-FKHR fusion gene of rhabdomyosarcoma cooperates with loss of p16INK4A to promote bypass of cellular senescence. Cancer Res; 2007 Jul 15;67(14):6691-9
eagle-i research resources. PMID 17638879 (Special Collections) .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] The PAX3-FKHR fusion gene of rhabdomyosarcoma cooperates with loss of p16INK4A to promote bypass of cellular senescence.
  • Rhabdomyosarcoma is the most common soft tissue sarcoma of childhood and adolescence.
  • Despite advances in therapy, patients with a histologic variant of rhabdomyosarcoma known as alveolar rhabdomyosarcoma (ARMS) have a 5-year survival of <30%.
  • This prompted us to explore the effect of expressing PAX3-FKHR in more relevant cells, specifically primary human skeletal muscle cells because these cells can be converted to a tumorigenic state that mimics rhabdomyosarcoma.
  • This association between PAX3-FKHR expression and p16(INK4A) loss was seen in human ARMS tumor tissue, as both human rhabdomyosarcoma cell lines and tissue microarrays showed a trend toward down-regulation of p16(INK4A) protein in alveolar subsets.
  • [MeSH-major] Cyclin-Dependent Kinase Inhibitor p16 / metabolism. Forkhead Transcription Factors / physiology. Gene Expression Regulation, Neoplastic. Lung Neoplasms / metabolism. Paired Box Transcription Factors / physiology. Rhabdomyosarcoma / metabolism

  • MedlinePlus Health Information. consumer health - Lung Cancer.
  • COS Scholar Universe. author profiles.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • SciCrunch. The Antibody Registry: Reagent: Antibodies .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17638879.001).
  • [ISSN] 0008-5472
  • [Journal-full-title] Cancer research
  • [ISO-abbreviation] Cancer Res.
  • [Language] eng
  • [Grant] United States / NICHD NIH HHS / HD / K12 HD043494; United States / NICHD NIH HHS / HD / 5K12 HD 043494; United States / NCI NIH HHS / CA / R01 CA 94184
  • [Publication-type] Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Cyclin-Dependent Kinase Inhibitor p16; 0 / FOXO1 protein, human; 0 / Forkhead Box Protein O1; 0 / Forkhead Transcription Factors; 0 / PAX3 Transcription Factor; 0 / PAX3 protein, human; 0 / Paired Box Transcription Factors; 0 / Recombinant Fusion Proteins
  •  go-up   go-down


71. Jelić-Puskarić B, Rajković-Molek K, Raić L, Batinić D, Konja J, Kardum-Skelin I: Rhabdomyosarcoma with bone marrow infiltration mimicking hematologic neoplasia. Coll Antropol; 2010 Jun;34(2):635-9

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Rhabdomyosarcoma with bone marrow infiltration mimicking hematologic neoplasia.
  • Rhabdomyosarcoma (RMS) is the most common soft tissue sarcoma in children younger than 15 years.
  • According to the World Health Organization, there are embryonal, alveolar and pleomorphic types of RMS.
  • Considering the morphological, cytochemical and phenotypic characteristics, the cytologic diagnosis was: bone marrow infiltration with RMS cells.
  • Tumor biopsy confirmed alveolar subtype of RMS.
  • Adjuvant technologies (cytochemistry, immunocytochemistry, cytogenetic analysis, flow cytometry, and molecular analysis) can be very helpful in diagnostic work-up, and may lead to definitive diagnosis in some cases.
  • [MeSH-major] Bone Marrow / pathology. Hematologic Neoplasms / pathology. Rhabdomyosarcoma / pathology
  • [MeSH-minor] Adolescent. Biopsy, Needle. Child. Diagnosis, Differential. Female. Gene Rearrangement. Genes, T-Cell Receptor gamma / genetics. Humans. Immunoglobulin Heavy Chains / genetics. Lymph Nodes / pathology. Purpura / pathology

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20698143.001).
  • [ISSN] 0350-6134
  • [Journal-full-title] Collegium antropologicum
  • [ISO-abbreviation] Coll Antropol
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Croatia
  • [Chemical-registry-number] 0 / Immunoglobulin Heavy Chains
  •  go-up   go-down


72. Casanova M, Meazza C, Gronchi A, Fiore M, Zaffignani E, Podda M, Collini P, Gandola L, Ferrari A: Soft-tissue sarcomas of the extremities in patients of pediatric age. J Child Orthop; 2007 Sep;1(3):195-203

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Soft-tissue sarcomas of the extremities in patients of pediatric age.
  • PURPOSE: The extremity site is a peculiar location for soft-tissue sarcomas (STS) of children and adolescents.
  • METHODS: The study series included 52 patients with rhabdomyosarcoma (RMS)(65% of which were of the alveolar subtype), nine with extraosseous Ewing sarcoma and 143 with non-rhabdomyosarcoma soft-tissue sarcomas (NRSTS), 38% of which were synovial sarcoma.
  • DISCUSSION: While the limbs are the most common sites of NRSTS and are often characterized by a more favorable prognosis than for axial tumors, the clinical features of extremity RMS often differ from those of RMS of other sites, with a higher incidence of unfavorable prognostic factors (e.g., alveolar subtype) and consequently unsatisfactory treatment results.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] J Pediatr Surg. 2000 Jun;35(6):961-4 [10873044.001]
  • [Cites] J Pediatr Surg. 2000 Feb;35(2):317-21 [10693687.001]
  • [Cites] Cancer. 2006 Feb 1;106(3):708-17 [16353216.001]
  • [Cites] J Clin Oncol. 2005 Nov 20;23(33):8422-30 [16293873.001]
  • [Cites] Cancer. 2005 Nov 1;104(9):2006-12 [16161038.001]
  • [Cites] J Clin Oncol. 2005 Jun 20;23(18):4021-30 [15767645.001]
  • [Cites] Expert Rev Anticancer Ther. 2005 Apr;5(2):307-18 [15877527.001]
  • [Cites] J Pediatr Surg. 1997 Aug;32(8):1181-4 [9269966.001]
  • [Cites] J Pediatr Surg. 1997 May;32(5):698-702 [9165454.001]
  • [Cites] J Pediatr Surg. 1996 Jan;31(1):191-6 [8632278.001]
  • [Cites] Semin Surg Oncol. 1993 Nov-Dec;9(6):510-9 [8284570.001]
  • [Cites] Cancer. 1990 Dec 15;66(12):2482-91 [2249188.001]
  • [Cites] Med Pediatr Oncol. 1990;18(6):466-71 [2233517.001]
  • [Cites] World J Surg. 1988 Oct;12(5):676-84 [3072777.001]
  • [Cites] J Pediatr Surg. 1989 Jan;24(1):5-10 [2723995.001]
  • [Cites] Cancer. 1988 Jan 15;61(2):209-20 [3275486.001]
  • [Cites] J Pediatr Surg. 1990 Feb;25(2):238-43; discussion 243-4 [2303993.001]
  • [Cites] Int J Cancer. 1984 Jan 15;33(1):37-42 [6693192.001]
  • [Cites] Pediatr Dev Pathol. 2004 Jul-Aug;7(4):361-9 [15383931.001]
  • [Cites] Clin Orthop Relat Res. 2004 Sep;(426):129-34 [15346063.001]
  • [Cites] Pediatr Blood Cancer. 2004 Apr;42(4):295-310 [14966825.001]
  • [Cites] J Pediatr Hematol Oncol. 2003 Nov;25(11):905-9 [14608203.001]
  • [Cites] Med Pediatr Oncol. 2003 Dec;41(6):584-7 [14595726.001]
  • [Cites] Pediatr Surg Int. 2003 Aug;19(6):453-6 [12740706.001]
  • [Cites] J Pediatr Surg. 2002 Oct;37(10):1424-9 [12378447.001]
  • [Cites] Eur J Surg Oncol. 2000 Nov;26(7):669-78 [11078614.001]
  • (PMID = 19308495.001).
  • [ISSN] 1863-2521
  • [Journal-full-title] Journal of children's orthopaedics
  • [ISO-abbreviation] J Child Orthop
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] England
  • [Other-IDs] NLM/ PMC2656726
  •  go-up   go-down


73. Fisher C: Soft tissue sarcomas with non-EWS translocations: molecular genetic features and pathologic and clinical correlations. Virchows Arch; 2010 Feb;456(2):153-66
MedlinePlus Health Information. consumer health - Soft Tissue Sarcoma.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Soft tissue sarcomas with non-EWS translocations: molecular genetic features and pathologic and clinical correlations.
  • Many soft tissue sarcoma subtypes have consistent chromosomal translocations with novel fusion genes, which result in disordered cellular function.
  • These include synovial sarcoma, alveolar rhabdomyosarcoma, alveolar soft part sarcoma, dermatofibrosarcoma protuberans, low-grade fibromyxoid sarcoma, infantile fibrosarcoma and inflammatory myofibroblastic tumour.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Am J Surg Pathol. 2001 May;25(5):610-7 [11342772.001]
  • [Cites] J Biol Chem. 2004 Feb 20;279(8):6225-34 [14668342.001]
  • [Cites] Am J Clin Pathol. 1999 Jul;112(1):43-9 [10396284.001]
  • [Cites] Hum Mol Genet. 1997 Sep;6(9):1559-64 [9285794.001]
  • [Cites] Am J Surg Pathol. 2003 Jan;27(1):27-39 [12502925.001]
  • [Cites] Diagn Mol Pathol. 2007 Sep;16(3):179-83 [17721327.001]
  • [Cites] Anticancer Drugs. 2006 Nov;17(10):1223-5 [17075323.001]
  • [Cites] Am J Surg Pathol. 2004 Aug;28(8):1063-9 [15252314.001]
  • [Cites] Am J Pathol. 2002 Apr;160(4):1215-21 [11943706.001]
  • [Cites] Am J Surg Pathol. 1992 Nov;16(11):1127-9 [1471731.001]
  • [Cites] Lab Invest. 2003 Sep;83(9):1255-65 [13679433.001]
  • [Cites] Pathol Res Pract. 1999;195(9):619-32 [10507082.001]
  • [Cites] Arch Dermatol. 2007 Feb;143(2):203-10 [17310000.001]
  • [Cites] Skeletal Radiol. 1996 Nov;25(8):766-9 [8958625.001]
  • [Cites] Hum Pathol. 1982 Jun;13(6):569-79 [7076238.001]
  • [Cites] Am J Surg Pathol. 1992 Oct;16(10):921-5 [1415902.001]
  • [Cites] Cancer Genet Cytogenet. 2001 Sep;129(2):102-6 [11566338.001]
  • [Cites] Am J Surg Pathol. 1997 Dec;21(12):1481-8 [9414192.001]
  • [Cites] Am J Surg Pathol. 1991 Aug;15(8):798-801 [2069214.001]
  • [Cites] Oncogene. 2000 Feb 17;19(7):906-15 [10702799.001]
  • [Cites] EMBO J. 1995 May 15;14(10):2333-40 [7539744.001]
  • [Cites] Proc Natl Acad Sci U S A. 2005 Nov 8;102(45):16239-44 [16258068.001]
  • [Cites] Histopathology. 2007 Oct;51(4):559-61 [17880539.001]
  • [Cites] N Engl J Med. 1998 Jan 15;338(3):153-60 [9428816.001]
  • [Cites] J Clin Oncol. 1997 May;15(5):1831-6 [9164192.001]
  • [Cites] Lancet. 2002 Apr 13;359(9314):1301-7 [11965276.001]
  • [Cites] Science. 1994 Mar 4;263(5151):1281-4 [8122112.001]
  • [Cites] Am J Surg Pathol. 2005 Dec;29(12):1558-75 [16327428.001]
  • [Cites] Nat Genet. 1997 Jan;15(1):95-8 [8988177.001]
  • [Cites] Genes Chromosomes Cancer. 2003 Oct;38(2):187-90 [12939746.001]
  • [Cites] Am J Surg Pathol. 1998 Jun;22(6):673-82 [9630174.001]
  • [Cites] J Clin Oncol. 2004 Oct 15;22(20):4040-50 [15364967.001]
  • [Cites] Am J Surg Pathol. 1992 Oct;16(10):1017-20 [1384367.001]
  • [Cites] Histopathology. 2004 Nov;45(5):526-37 [15500657.001]
  • [Cites] Cancer. 1977 Oct;40(4):1711-21 [561651.001]
  • [Cites] Am J Surg Pathol. 2006 Sep;30(9):1077-84 [16931951.001]
  • [Cites] Am J Surg Pathol. 1999 Jan;23(1):106-12 [9888710.001]
  • [Cites] Hum Pathol. 1997 Nov;28(11):1325-8 [9385945.001]
  • [Cites] Nat Rev Cancer. 2007 Apr;7(4):233-45 [17361217.001]
  • [Cites] Cancer. 1989 Aug 1;64(3):721-9 [2545326.001]
  • [Cites] Oncol Rep. 2008 Feb;19(2):467-76 [18202796.001]
  • [Cites] J Surg Oncol. 2001 Dec;78(4):225-31 [11745814.001]
  • [Cites] Int J Cancer. 2006 Jun 1;118(11):2772-81 [16381018.001]
  • [Cites] Oncogene. 2001 Sep 10;20(40):5736-46 [11607823.001]
  • [Cites] J Pathol. 2000 Nov;192(3):342-50 [11054718.001]
  • [Cites] J Am Acad Dermatol. 2007 Jun;56(6):968-73 [17141362.001]
  • [Cites] Cancer. 1989 Nov 15;64(10):2154-61 [2804904.001]
  • [Cites] Lab Invest. 2000 Jun;80(6):805-13 [10879732.001]
  • [Cites] Am J Pathol. 1998 Nov;153(5):1451-8 [9811336.001]
  • [Cites] Am J Surg Pathol. 2005 Feb;29(2):204-10 [15644777.001]
  • [Cites] Ann Oncol. 2000 Nov;11(11):1445-9 [11142485.001]
  • [Cites] Br J Cancer. 1999 Aug;80(11):1809-14 [10468301.001]
  • [Cites] Am J Surg Pathol. 2002 Nov;26(11):1434-40 [12409719.001]
  • [Cites] Cancer. 1995 Sep 15;76(6):1073-85 [8625211.001]
  • [Cites] Am J Dermatopathol. 1997 Dec;19(6):562-7 [9415611.001]
  • [Cites] Am J Surg Pathol. 1994 May;18(5):474-8 [8172322.001]
  • [Cites] Cancer Res. 2007 Feb 1;67(3):919-29 [17283122.001]
  • [Cites] Am J Clin Pathol. 2001 Mar;115(3):348-55 [11242790.001]
  • [Cites] Am J Surg Pathol. 2006 Oct;30(10):1322-5 [17001165.001]
  • [Cites] J Pathol. 2001 May;194(1):88-94 [11329146.001]
  • [Cites] Int J Gynecol Pathol. 2007 Apr;26(2):173-6 [17413985.001]
  • [Cites] Am J Surg Pathol. 2007 Feb;31(2):240-6 [17255769.001]
  • [Cites] Cancer Res. 2002 Jan 1;62(1):135-40 [11782370.001]
  • [Cites] Cancer Res. 2006 Jul 15;66(14 ):6936-46 [16849537.001]
  • [Cites] Cancer Res. 1999 Jul 1;59(13):3180-4 [10397263.001]
  • [Cites] Cancer Cell. 2002 Nov;2(5):367-76 [12450792.001]
  • [Cites] Fetal Pediatr Pathol. 2007 Jan-Feb;26(1):17-31 [17613043.001]
  • [Cites] Am J Pathol. 2001 Sep;159(3):1089-96 [11549601.001]
  • [Cites] J Natl Cancer Inst. 2001 Sep 5;93(17):1347-9 [11535711.001]
  • [Cites] Am J Pathol. 2001 Jul;159(1):179-92 [11438465.001]
  • [Cites] Am J Surg Pathol. 2003 Sep;27(9):1229-36 [12960807.001]
  • [Cites] Cancer. 1999 Jun 15;85(12):2596-607 [10375108.001]
  • [Cites] J Pathol. 2007 Jun;212(2):143-51 [17471488.001]
  • [Cites] Cancer Res. 2002 Aug 15;62(16):4704-10 [12183429.001]
  • [Cites] Semin Diagn Pathol. 1998 May;15(2):85-101 [9606801.001]
  • [Cites] Genes Chromosomes Cancer. 2003 May;37(1):1-19 [12661001.001]
  • [Cites] Oncogene. 1998 Sep 10;17(10):1313-9 [9771975.001]
  • [Cites] Am J Pathol. 2000 Aug;157(2):377-84 [10934142.001]
  • [Cites] Pathol Int. 2007 Mar;57(3):153-7 [17295648.001]
  • [Cites] Mol Cell Biol. 2006 Mar;26(5):1754-69 [16478996.001]
  • [Cites] Am J Surg Pathol. 2004 Sep;28(9):1117-32 [15316311.001]
  • [Cites] Curr Opin Cell Biol. 1997 Apr;9(2):213-21 [9069267.001]
  • [Cites] Blood. 1999 Feb 15;93(4):1355-63 [9949179.001]
  • [Cites] Arch Pathol Lab Med. 1992 Aug;116(8):847-55 [1497467.001]
  • [Cites] Am J Surg Pathol. 2007 Jun;31(6):895-901 [17527077.001]
  • [Cites] Int J Gynecol Pathol. 1995 Oct;14(4):283-92 [8598329.001]
  • [Cites] J Clin Pathol. 2006 Nov;59(11):1127-32 [17071801.001]
  • [Cites] J Clin Oncol. 2000 Nov 15;18(22):3794-803 [11078492.001]
  • [Cites] Mod Pathol. 2008 Jan;21(1):31-8 [17885669.001]
  • [Cites] J Clin Oncol. 2000 May;18(10):2087-94 [10811674.001]
  • [Cites] Cancer Res. 1998 Nov 15;58(22):5046-8 [9823307.001]
  • [Cites] Cancer. 1999 Oct 1;86(7):1246-50 [10506710.001]
  • [Cites] Mod Pathol. 2005 Jan;18(1):68-74 [15375433.001]
  • [Cites] Cancer Genet Cytogenet. 2006 May;167(1):82-8 [16682293.001]
  • [Cites] Genes Chromosomes Cancer. 2007 Feb;46(2):181-91 [17117415.001]
  • [Cites] Cancer. 2001 Feb 1;91(3):585-91 [11169942.001]
  • [Cites] Am J Surg Pathol. 2007 Apr;31(4):509-20 [17414097.001]
  • [Cites] Am J Pathol. 2003 Dec;163(6):2383-95 [14633610.001]
  • [Cites] Genes Chromosomes Cancer. 2001 Mar;30(3):305-9 [11170290.001]
  • [Cites] Am J Pathol. 2001 Aug;159(2):411-5 [11485898.001]
  • [Cites] Am J Surg Pathol. 2006 Dec;30(12):1502-12 [17122505.001]
  • [Cites] Lab Invest. 2005 Mar;85(3):408-15 [15640831.001]
  • [Cites] Nat Genet. 1998 Feb;18(2):184-7 [9462753.001]
  • [Cites] Cancer Genet Cytogenet. 1990 Sep;48(2):193-8 [2204476.001]
  • [Cites] Genes Chromosomes Cancer. 2003 Jun;37(2):195-200 [12696068.001]
  • [Cites] Am J Surg Pathol. 2001 Jun;25(6):761-8 [11395553.001]
  • [Cites] Cancer Genet Cytogenet. 2002 Apr 15;134(2):156-61 [12034531.001]
  • [Cites] Cancer. 2005 Feb 15;103(4):830-8 [15641030.001]
  • [Cites] J Clin Oncol. 2002 Jun 1;20(11):2672-9 [12039929.001]
  • [Cites] Cancer Genet Cytogenet. 1993 Nov;71(1):94-6 [8275459.001]
  • [Cites] J Pediatr Surg. 1987 Jul;22(7):665-70 [3612464.001]
  • [Cites] Ann Diagn Pathol. 1998 Dec;2(6):401-21 [9930576.001]
  • [Cites] Lab Invest. 2002 May;82(5):609-18 [12004001.001]
  • [Cites] Histopathology. 2006 Apr;48(5):569-78 [16623783.001]
  • [Cites] J Pathol. 1998 Mar;184(3):337-9 [9614388.001]
  • [Cites] Adv Cancer Res. 2007;97:247-74 [17419949.001]
  • [Cites] Int J Cancer. 2006 Mar 1;118(5):1165-72 [16152617.001]
  • [Cites] JAMA. 1990 Oct 10;264(14):1861 [2402048.001]
  • [Cites] Mod Pathol. 2007 May;20(5):522-8 [17334346.001]
  • [Cites] Mod Pathol. 2007 May;20(5):592-603 [17396140.001]
  • [Cites] Histopathology. 2001 Feb;38(2):141-5 [11207827.001]
  • [Cites] Cancer Genet Cytogenet. 1999 Apr;110(1):14-8 [10198616.001]
  • [Cites] Pediatr Pathol. 1994 Jan-Feb;14(1):133-50 [8159611.001]
  • [Cites] J Cancer Res Clin Oncol. 2008 Oct;134(10):1097-103 [18386058.001]
  • [Cites] Int J Cancer. 2006 Mar 1;118(5):1181-6 [16161041.001]
  • [Cites] Am J Surg Pathol. 2003 Jun;27(6):750-61 [12766578.001]
  • [Cites] Am J Surg Pathol. 1993 Jun;17(6):595-600 [8333558.001]
  • [Cites] Arch Pathol Lab Med. 1996 Nov;120(11):1052-5 [12049108.001]
  • [Cites] Hum Mol Genet. 1999 Apr;8(4):585-91 [10072425.001]
  • [Cites] J Pediatr Hematol Oncol. 2002 Dec;24(9):722-6 [12468912.001]
  • [Cites] Oncogene. 2001 Jan 4;20(1):48-57 [11244503.001]
  • [Cites] Cancer. 1976 Aug;38(2):729-39 [974993.001]
  • [Cites] Diagn Mol Pathol. 2008 Dec;17(4):237-40 [18382348.001]
  • [Cites] Cancer. 1992 Nov 15;70(10):2444-50 [1423174.001]
  • [Cites] Panminerva Med. 1976 Mar-Apr;18(3-4):95-8 [1256904.001]
  • [Cites] Mod Pathol. 2002 Sep;15(9):998-1004 [12218218.001]
  • [Cites] Mod Pathol. 2006 May;19(5):659-68 [16528378.001]
  • [Cites] Am J Clin Pathol. 1987 Nov;88(5):615-9 [3673943.001]
  • [Cites] Radiother Oncol. 1994 Oct;33(1):23-30 [7878206.001]
  • [Cites] Diagn Mol Pathol. 1999 Sep;8(3):113-9 [10565681.001]
  • [Cites] Am J Surg Pathol. 1994 Jan;18(1):14-24 [8279625.001]
  • [Cites] Hum Pathol. 2004 Jun;35(6):711-21 [15188137.001]
  • [Cites] Am J Surg Pathol. 2006 Apr;30(4):436-43 [16625088.001]
  • [Cites] Genes Dev. 2004 Nov 1;18(21):2614-26 [15489287.001]
  • [Cites] Hum Pathol. 2008 Apr;39(4):623-8 [18275982.001]
  • [Cites] Dig Liver Dis. 2007 Mar;39(3):274-7 [16522382.001]
  • [Cites] Cancer Genet Cytogenet. 2000 Oct 15;122(2):144-8 [11106828.001]
  • [Cites] Cancer Res. 1999 Aug 1;59(15):3719-23 [10446987.001]
  • [Cites] J Natl Compr Canc Netw. 2007 May;5(5):557-62 [17509258.001]
  • [Cites] Adv Anat Pathol. 2006 Jul;13(4):166-73 [16858150.001]
  • [Cites] J Clin Oncol. 2001 Jan 15;19(2):525-34 [11208847.001]
  • [Cites] Cancer. 1989 Jan 1;63(1):1-13 [2642727.001]
  • [Cites] J Clin Oncol. 2002 Sep 1;20(17 ):3586-91 [12202658.001]
  • [Cites] Int J Cancer. 2002 Aug 20;100(6):623-6 [12209598.001]
  • [Cites] Histopathology. 2006 Mar;48(4):473-5 [16487376.001]
  • [Cites] Am J Pathol. 2002 Nov;161(5):1587-95 [12414507.001]
  • [Cites] Cytogenet Cell Genet. 1996;72(2-3):171-4 [8978765.001]
  • [Cites] Cancer. 1989 May 1;63(9):1721-36 [2649226.001]
  • [Cites] Cancer Res. 2001 Dec 15;61(24):8909-16 [11751416.001]
  • [Cites] Am J Surg Pathol. 2006 Jul;30(7):787-94 [16819319.001]
  • [Cites] Histopathology. 1998 Dec;33(6):501-7 [9870143.001]
  • [Cites] Mod Pathol. 2001 Jun;14(6):569-76 [11406658.001]
  • [Cites] Am J Pathol. 1995 Dec;147(6):1584-91 [7495283.001]
  • [Cites] Am J Surg Pathol. 1994 Mar;18(3):302-8 [8116799.001]
  • [Cites] Cancer Genet Cytogenet. 2003 Jan 1;140(1):1-12 [12550751.001]
  • [Cites] J Clin Oncol. 2005 Feb 1;23(4):866-73 [15681532.001]
  • [Cites] Am J Pathol. 1995 Mar;146(3):626-34 [7887445.001]
  • [Cites] Pediatr Pathol Lab Med. 1996 Nov-Dec;16(6):951-9 [9025893.001]
  • [Cites] Mod Pathol. 2002 Sep;15(9):931-8 [12218210.001]
  • [Cites] Histopathology. 1989 Apr;14(4):391-9 [2737615.001]
  • [Cites] Cancer Treat Res. 2004;120:151-67 [15217223.001]
  • [Cites] Histopathology. 2003 Jun;42(6):588-93 [12786895.001]
  • [Cites] Am J Surg Pathol. 2000 Oct;24(10):1353-60 [11023096.001]
  • [Cites] Cancer Lett. 2000 Feb 28;149(1-2):31-6 [10737705.001]
  • [Cites] Crit Rev Oncol Hematol. 2007 Aug;63(2):111-24 [17555981.001]
  • [Cites] Cancer Res. 2001 Aug 1;61(15):5778-83 [11479215.001]
  • [Cites] J Mol Diagn. 2000 Feb;2(1):47-52 [11272901.001]
  • [Cites] Am J Surg Pathol. 2007 Sep;31(9):1387-402 [17721195.001]
  • [Cites] Hum Pathol. 2008 Feb;39(2):184-93 [17950782.001]
  • [Cites] Cancer Res. 2004 Aug 15;64(16):5539-45 [15313887.001]
  • [Cites] Genes Chromosomes Cancer. 2004 Jul;40(3):218-28 [15139001.001]
  • [Cites] J Neurosurg. 2008 Apr;108(4):798-802 [18377261.001]
  • [Cites] Cancer. 1964 Jul;17:821-30 [14179547.001]
  • [Cites] Curr Opin Oncol. 2006 Jul;18(4):341-6 [16721128.001]
  • [Cites] Cancer Res. 2007 Apr 1;67(7):3192-200 [17409427.001]
  • [Cites] Arch Pathol Lab Med. 2000 Aug;124(8):1179-84 [10923080.001]
  • [Cites] J Clin Oncol. 2005 May 20;23(15):3638-9; author reply 3639-40 [15908683.001]
  • [Cites] Med Pediatr Oncol. 2003 Apr;40(4):268-70 [12555264.001]
  • [Cites] Diagn Mol Pathol. 2000 Mar;9(1):1-8 [10718206.001]
  • [Cites] Am J Surg Pathol. 2001 Nov;25(11):1364-71 [11684952.001]
  • [Cites] Am J Surg Pathol. 1998 May;22(5):576-87 [9591728.001]
  • [Cites] Am J Surg Pathol. 1988 Apr;12(4):287-93 [3354755.001]
  • [Cites] Pediatr Dev Pathol. 2008 Mar-Apr;11(2):142-7 [17378669.001]
  • (PMID = 19396640.001).
  • [ISSN] 1432-2307
  • [Journal-full-title] Virchows Archiv : an international journal of pathology
  • [ISO-abbreviation] Virchows Arch.
  • [Language] eng
  • [Publication-type] Journal Article; Review
  • [Publication-country] Germany
  • [Number-of-references] 196
  •  go-up   go-down


74. Case AS, Kirby TO, Conner MG, Huh WK: A case report of rhabdomyosarcoma of the uterus associated with uterine inversion. Gynecol Oncol; 2005 Mar;96(3):850-3
Hazardous Substances Data Bank. VINCRISTINE .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] A case report of rhabdomyosarcoma of the uterus associated with uterine inversion.
  • BACKGROUND: Alveolar rhabdomyosarcoma is an uncommon malignant soft tissue tumor rarely found in the genital tract.
  • On exam, a large pedunculated mass protruding from the cervix was seen and biopsy of this mass revealed an alveolar rhabdomyosarcoma.
  • The patient was treated with adjuvant chemotherapy consisting of VAC (Vincristine, Actinomycin, and Cyclophosphamide) for a presumed cervical rhabdomyosarcoma.
  • Final pathology showed alveolar rhabdomyosarcoma of the uterus.
  • The patient then received additional postoperative VAC regimen for a total of 10 treatments and remains in good health with no evidence of disease 20 months from diagnosis.
  • CONCLUSION: This case report describes the only reported case of uterine inversion secondary to alveolar rhabdomyosarcoma of the uterus and discusses current therapeutic options for adults.
  • [MeSH-major] Rhabdomyosarcoma, Alveolar / complications. Uterine Inversion / etiology. Uterine Neoplasms / complications

  • MedlinePlus Health Information. consumer health - Uterine Cancer.
  • COS Scholar Universe. author profiles.
  • Hazardous Substances Data Bank. CYCLOPHOSPHAMIDE .
  • Hazardous Substances Data Bank. DACTINOMYCIN .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15721436.001).
  • [ISSN] 0090-8258
  • [Journal-full-title] Gynecologic oncology
  • [ISO-abbreviation] Gynecol. Oncol.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 1CC1JFE158 / Dactinomycin; 5J49Q6B70F / Vincristine; 8N3DW7272P / Cyclophosphamide; VAC protocol
  •  go-up   go-down


75. Zhu L, Wang J: [Sclerosing rhabdomyosarcoma: a clinicopathologic study of four cases with review of literature]. Zhonghua Bing Li Xue Za Zhi; 2007 Sep;36(9):587-91

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Sclerosing rhabdomyosarcoma: a clinicopathologic study of four cases with review of literature].
  • OBJECTIVE: To study the clinicopathologic characteristics of sclerosing rhabdomyosarcoma (SRMS) and its distinction from embryonal rhabdomyosarcoma (ERMS) and alveolar rhabdomyosarcoma (ARMS).
  • Histologically, SRMS was characterized by the presence of large amounts of heavily hyalinized matrix, mimicking osteoid or chondroid tissue.
  • A second spindle cell component was focally found in 2 cases, resembling spindle cell rhabdomyosarcoma or peripheral nerve sheath tumor.
  • Familiarity with its morphologic features and immunophenotype may help to distinguish this peculiar variant of rhabdomyosarcoma from a variety of lesions with abundant sclerosing matrix.
  • [MeSH-major] Facial Neoplasms / pathology. Rhabdomyosarcoma / pathology. Soft Tissue Neoplasms / pathology
  • [MeSH-minor] Actins / metabolism. Adult. Chondrosarcoma / pathology. Combined Modality Therapy. Desmin / metabolism. Diagnosis, Differential. Female. Follow-Up Studies. Hemangiosarcoma / pathology. Humans. Male. Middle Aged. MyoD Protein / metabolism. Osteosarcoma / pathology. Rhabdomyosarcoma, Alveolar / classification. Rhabdomyosarcoma, Alveolar / pathology. Rhabdomyosarcoma, Embryonal / classification. Rhabdomyosarcoma, Embryonal / pathology. Sclerosis / pathology. Vimentin / metabolism. Young Adult

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18070445.001).
  • [ISSN] 0529-5807
  • [Journal-full-title] Zhonghua bing li xue za zhi = Chinese journal of pathology
  • [ISO-abbreviation] Zhonghua Bing Li Xue Za Zhi
  • [Language] chi
  • [Publication-type] English Abstract; Journal Article; Review
  • [Publication-country] China
  • [Chemical-registry-number] 0 / Actins; 0 / Desmin; 0 / MyoD Protein; 0 / MyoD1 myogenic differentiation protein; 0 / Vimentin
  • [Number-of-references] 13
  •  go-up   go-down


76. Eyden B: Pleomorphic rhabdomyosarcoma showing smooth-muscle and fibrohistiocytic differentiation: a single case report. Ultrastruct Pathol; 2010 Feb;34(1):42-7

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Pleomorphic rhabdomyosarcoma showing smooth-muscle and fibrohistiocytic differentiation: a single case report.
  • Rhabdomyosarcoma has traditionally been subclassified into alveolar, embryonal, and pleomorphic variants.
  • The author recently encountered a myogenic sarcoma, with all the common markers of rhabdomyosarcoma, but expressing the unusual features of alpha-smooth-muscle actin and abundant rough endoplasmic reticulum (rER).
  • The patient was a 65-year-old man with an inguinal soft tissue mass.
  • Given the four lines of differentiation--striated muscle, smooth muscle, fibroblastic, and histiocytic--a name reflecting its phenotype would be pleomorphic rhabdomyosarcoma showing smooth-muscle and fibrohistiocytic differentiation.
  • [MeSH-major] Fibroblasts / ultrastructure. Histiocytes / ultrastructure. Muscle, Smooth / ultrastructure. Rhabdomyosarcoma / pathology. Soft Tissue Neoplasms / pathology

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20070153.001).
  • [ISSN] 1521-0758
  • [Journal-full-title] Ultrastructural pathology
  • [ISO-abbreviation] Ultrastruct Pathol
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] England
  • [Chemical-registry-number] 0 / ACTA2 protein, human; 0 / Actins; 0 / Biomarkers, Tumor
  •  go-up   go-down


77. Morgenstern DA, Anderson J: MYCN deregulation as a potential target for novel therapies in rhabdomyosarcoma. Expert Rev Anticancer Ther; 2006 Feb;6(2):217-24

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] MYCN deregulation as a potential target for novel therapies in rhabdomyosarcoma.
  • Rhabdomyosarcoma is the most common soft-tissue sarcoma of childhood.
  • Although overall outcomes have improved considerably, the outlook for patients with high-risk disease, particularly the alveolar subtype, remains bleak and there is a clear need for new chemotherapeutic strategies.
  • The importance of aberrant expression of this oncogene is well established in neuroblastoma and recent data indicate that MYCN deregulation also occurs in up to a quarter of alveolar subtype cases.
  • [MeSH-major] Gene Expression Regulation, Neoplastic / drug effects. Nuclear Proteins / genetics. Oncogene Proteins / genetics. Rhabdomyosarcoma / drug therapy. Rhabdomyosarcoma / genetics

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16445374.001).
  • [ISSN] 1744-8328
  • [Journal-full-title] Expert review of anticancer therapy
  • [ISO-abbreviation] Expert Rev Anticancer Ther
  • [Language] eng
  • [Publication-type] Journal Article; Review
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Antineoplastic Agents; 0 / MYCN protein, human; 0 / Nuclear Proteins; 0 / Nucleic Acids; 0 / Oligonucleotides, Antisense; 0 / Oncogene Proteins
  • [Number-of-references] 74
  •  go-up   go-down


78. Stiff PJ, Agovi MA, Antman KH, Blaise D, Camitta BM, Cairo MS, Childs RW, Edwards JR, Gale RP, Hale GA, Lazarus HM, Arora M: High-dose chemotherapy with blood or bone marrow transplants for rhabdomyosarcoma. Biol Blood Marrow Transplant; 2010 Apr;16(4):525-32
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] High-dose chemotherapy with blood or bone marrow transplants for rhabdomyosarcoma.
  • Rhabdomyosarcoma (RMS), the most common soft-tissue sarcoma in children, is cured with conventional therapy in 70%.
  • However, the 5-year survival for those who relapse is about 30%, and drops to about 15% for those with unfavorable histologies (alveolar/undifferentiated subtypes).
  • Overall, 73% of subjects were <20 years; 39% had cancer bulk >5 cm, 63% had metastasis at diagnosis, 55% had unfavorable histologies, 92% had cancer responsive to chemotherapy pretransplant, and 67% were in first remission.
  • Even when performed after relapse for alveolar/undifferentiated histologies, long-term survivals were seen seemingly better than results with conventional therapies.

  • MedlinePlus Health Information. consumer health - Bone Marrow Transplantation.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] Copyright (c) 2010 American Society for Blood and Marrow Transplantation. Published by Elsevier Inc. All rights reserved.
  • [Cites] J Clin Oncol. 1993 Oct;11(10):1911-8 [8410118.001]
  • [Cites] Med Pediatr Oncol. 1991;19(2):89-95 [2011101.001]
  • [Cites] J Clin Oncol. 1990 Mar;8(3):443-52 [2407808.001]
  • [Cites] Curr Opin Oncol. 2004 Mar;16(2):120-5 [15075902.001]
  • [Cites] J Clin Oncol. 2003 Jan 1;21(1):78-84 [12506174.001]
  • [Cites] J Pediatr Hematol Oncol. 2001 Jun-Jul;23(5):272-6 [11464981.001]
  • [Cites] J Clin Oncol. 1999 Sep;17(9):2796-803 [10561355.001]
  • [Cites] J Clin Oncol. 1999 Nov;17(11):3487-93 [10550146.001]
  • [Cites] J Clin Oncol. 2008 Jan 20;26(3):406-13 [18202417.001]
  • [Cites] J Clin Oncol. 2006 Jul 20;24(21):3415-22 [16849756.001]
  • [Cites] N Engl J Med. 2005 Aug 18;353(7):701-11 [16107623.001]
  • [Cites] Oncologist. 2005 Aug;10(7):518-27 [16079319.001]
  • [Cites] J Clin Oncol. 2004 Dec 1;22(23):4787-94 [15570080.001]
  • [Cites] Stat Med. 1999 Mar 30;18(6):695-706 [10204198.001]
  • [Cites] J Clin Oncol. 1995 Aug;13(8):2123-39 [7636557.001]
  • [Cites] Bone Marrow Transplant. 1997 Feb;19(3):227-31 [9028550.001]
  • [Cites] J Clin Oncol. 1998 May;16(5):1697-706 [9586881.001]
  • (PMID = 19961947.001).
  • [ISSN] 1523-6536
  • [Journal-full-title] Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation
  • [ISO-abbreviation] Biol. Blood Marrow Transplant.
  • [Language] ENG
  • [Grant] United States / NHLBI NIH HHS / HL / 5U01 HL 069294; United States / NCI NIH HHS / CA / U24-CA 76518; United States / NCI NIH HHS / CA / U24 CA076518; United States / NCI NIH HHS / CA / U24 CA076518-12; United States / NHLBI NIH HHS / HL / U01 HL069294; United States / NCI NIH HHS / CA / CA076518-12
  • [Publication-type] Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't; Research Support, U.S. Gov't, Non-P.H.S.; Research Support, U.S. Gov't, P.H.S.
  • [Publication-country] United States
  • [Other-IDs] NLM/ NIHMS162698; NLM/ PMC2838953
  •  go-up   go-down


79. Seitz G, Pfeiffer M, Fuchs J, Warmann SW, Leuschner I, Vokuhl C, Lang P, Handgretinger R, Armeanu-Ebinger S: Establishment of a rhabdomyosarcoma xenograft model in human-adapted mice. Oncol Rep; 2010 Oct;24(4):1067-72

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Establishment of a rhabdomyosarcoma xenograft model in human-adapted mice.
  • The outcome of patients with advanced stage rhabdomyosarcoma (RMS) is still sobering.
  • Eight weeks after transplantation, the subcutaneous xenotransplantation of human alveolar and embryonal RMS cell lines was carried out.
  • The xenotransplantation of alveolar RMS resulting in subcutaneous tumor growth was feasible in 7 animals.
  • A histological work up showed either alveolar or embryonal RMS cells with central necrosis.
  • The establishment of subcutaneous tumor xenografts was more effective in the alveolar subtype.
  • [MeSH-major] Disease Models, Animal. Rhabdomyosarcoma. Soft Tissue Neoplasms. Transplantation, Heterologous / methods

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20811690.001).
  • [ISSN] 1791-2431
  • [Journal-full-title] Oncology reports
  • [ISO-abbreviation] Oncol. Rep.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Greece
  •  go-up   go-down


80. Hosoi H, Teramukai S, Matsumoto Y, Tsuchiya K, Iehara T, Hara J, Mitsui T, Kaneko M, Hatae Y, Hayashi Y, Mabuchi O, Adachi N, Morikawa Y, Nishimura S, Kumagai M, Takamatsu H, Sawada T, Sugimoto T: A review of 331 rhabdomyosarcoma cases in patients treated between 1991 and 2002 in Japan. Int J Clin Oncol; 2007 Apr;12(2):137-45
MedlinePlus Health Information. consumer health - Cancer Chemotherapy.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] A review of 331 rhabdomyosarcoma cases in patients treated between 1991 and 2002 in Japan.
  • BACKGROUND: To prepare for a Japanese nationwide group study of patients with rhabdomyosarcoma (RMS), we examined the characteristics and outcomes of RMS patients treated recently in Japan.
  • METHODS: We classified 331 RMS patients treated between 1991 and 2002 at 63 institutions according to the Intergroup Rhabdomyosarcoma Study V (IRS-V) risk-group classification.
  • The frequency of the alveolar histological subtype was 21.8%.
  • Chimera genes, which are useful markers for the alveolar subtype, had been examined in only 10% of the patients treated in the period of this investigation.
  • The survival rates of our patients with embryonal and alveolar histological subtypes (65.9% and 63.4%, respectively) were not significantly different.
  • [MeSH-major] Antineoplastic Agents / therapeutic use. Rhabdomyosarcoma / drug therapy. Rhabdomyosarcoma / mortality
  • [MeSH-minor] Adolescent. Adult. Central Nervous System Neoplasms / drug therapy. Central Nervous System Neoplasms / mortality. Child. Child, Preschool. Female. Follow-Up Studies. Head and Neck Neoplasms / drug therapy. Head and Neck Neoplasms / mortality. Humans. Infant. Japan / epidemiology. Male. Neoplasm Staging. Orbital Neoplasms / drug therapy. Orbital Neoplasms / mortality. Retrospective Studies. Risk Factors. Soft Tissue Neoplasms / drug therapy. Soft Tissue Neoplasms / mortality. Surveys and Questionnaires. Survival Rate. Time Factors. Urogenital Neoplasms / drug therapy. Urogenital Neoplasms / mortality

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Prog Clin Biol Res. 1994;385:371-5 [7972233.001]
  • [Cites] Bone Marrow Transplant. 1998 Jul;22(1):7-12 [9678789.001]
  • [Cites] J Pediatr Hematol Oncol. 2001 May;23(4):215-20 [11846299.001]
  • [Cites] Cancer. 1997 Sep 15;80(6):1165-70 [9305719.001]
  • [Cites] J Clin Oncol. 2002 Jun 1;20(11):2672-9 [12039929.001]
  • [Cites] J Clin Oncol. 2001 Jun 15;19(12):3091-102 [11408506.001]
  • [Cites] Jpn J Surg. 1990 Sep;20(5):503-9 [2243442.001]
  • [Cites] J Clin Oncol. 1995 Mar;13(3):610-30 [7884423.001]
  • [Cites] J Clin Oncol. 1987 Jan;5(1):46-54 [3543238.001]
  • [Cites] Pediatr Hematol Oncol. 2003 Apr-May;20(3):201-10 [12637216.001]
  • (PMID = 17443282.001).
  • [ISSN] 1341-9625
  • [Journal-full-title] International journal of clinical oncology
  • [ISO-abbreviation] Int. J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article; Multicenter Study; Research Support, Non-U.S. Gov't
  • [Publication-country] Japan
  • [Chemical-registry-number] 0 / Antineoplastic Agents
  •  go-up   go-down


81. Meng MV, Grossfeld GD, Sudilovsky D, Baehner FL: Fine needle aspiration cytology of adult perineal rhabdomyosarcoma: a case report. Acta Cytol; 2006 Jan-Feb;50(1):88-92
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Fine needle aspiration cytology of adult perineal rhabdomyosarcoma: a case report.
  • BACKGROUND: Adult perineal soft tissue sarcomas are rare.
  • Below we report a case in which the diagnosis was established preoperatively by fine needle aspiration (FNA).
  • The diagnosis of rhabdomyosarcoma was favored on FNA and was corroborated by immunohistochemical stains for desmin, myogenin and CD56.
  • Upon surgical resection, the diagnosis of alveolar rhabdomyosarcoma was confirmed histologically and immunophenotypically.
  • CONCLUSION: FNA is a useful tool in diagnosing soft tissue lessions of the perineum, including rare primary tumors, such as adult rhabdomyosarcoma.
  • [MeSH-major] Perineum / pathology. Rhabdomyosarcoma / pathology. Soft Tissue Neoplasms / pathology

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16514847.001).
  • [ISSN] 0001-5547
  • [Journal-full-title] Acta cytologica
  • [ISO-abbreviation] Acta Cytol.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Biomarkers, Tumor; 0 / Desmin; 0 / Myogenin
  •  go-up   go-down


82. Cecchetto G, Alaggio R, Dall'Igna P, Bisogno G, Ferrari A, Gigante C, Casanova M, Sotti G, Zanetti I, Carli M: Localized unresectable non-rhabdo soft tissue sarcomas of the extremities in pediatric age: results from the Italian studies. Cancer; 2005 Nov 1;104(9):2006-12
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Localized unresectable non-rhabdo soft tissue sarcomas of the extremities in pediatric age: results from the Italian studies.
  • BACKGROUND: Treatment of initially unresectable nonrhabdo soft tissue sarcomas (NRSTS) in pediatric age is debated, due to their different chemosensitivity.
  • Clinical TNM and surgical Intergroup Rhabdomyosarcoma Staging systems were adopted.
  • Nonchemosensitive (CTns) sarcomas, 31: fibrosarcoma, 11; malignant peripheral nerve sheet tumors, 10; liposarcoma, 2; hemangiopericitoma adult type, 2; epithelioid sarcoma, 2; and alveolar soft part sarcoma, leiomyosarcoma, clear cell sarcoma, and sarcoma NOS, each 1.
  • [MeSH-major] Extremities. Sarcoma / diagnosis

  • MedlinePlus Health Information. consumer health - Soft Tissue Sarcoma.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] (c) 2005 American Cancer Society.
  • (PMID = 16161038.001).
  • [ISSN] 0008-543X
  • [Journal-full-title] Cancer
  • [ISO-abbreviation] Cancer
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  •  go-up   go-down


83. Tanas MR, Goldblum JR: Fluorescence in situ hybridization in the diagnosis of soft tissue neoplasms: a review. Adv Anat Pathol; 2009 Nov;16(6):383-91
NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Fluorescence in situ hybridization in the diagnosis of soft tissue neoplasms: a review.
  • This paper presents an overview of the role of fluorescence in situ hybridization (FISH) in the diagnosis of soft tissue neoplasms.
  • Many soft tissue neoplasms harbor characteristic translocations or amplification of gene regions, which can be assessed by FISH, and can be used to assist in their diagnosis.
  • We discuss the major morphologic categories in which FISH has come to be used including high-grade round cell sarcomas, spindle cell sarcomas, low-grade myxoid neoplasms, adipocytic neoplasms, and malignant melanocytic neoplasms on the basis of a recent review of soft tissue neoplasms which were analyzed by FISH.
  • Finally, we discuss the advantages and disadvantages of FISH as a technique when appraising soft tissue neoplasms.
  • [MeSH-major] In Situ Hybridization, Fluorescence / methods. Soft Tissue Neoplasms / diagnosis
  • [MeSH-minor] Calmodulin-Binding Proteins / genetics. Chondrosarcoma / genetics. Forkhead Transcription Factors / genetics. Humans. Lipoma / diagnosis. Lipoma / genetics. Liposarcoma / diagnosis. Liposarcoma / genetics. RNA-Binding Proteins / genetics. Rhabdomyosarcoma, Alveolar / genetics. Sarcoma / diagnosis. Sarcoma / genetics. Sarcoma, Clear Cell / diagnosis. Sarcoma, Clear Cell / genetics. Sarcoma, Ewing / diagnosis. Sarcoma, Ewing / genetics. Sarcoma, Small Cell / diagnosis. Sarcoma, Small Cell / genetics. Sarcoma, Synovial / diagnosis. Sarcoma, Synovial / genetics. Translocation, Genetic

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19851129.001).
  • [ISSN] 1533-4031
  • [Journal-full-title] Advances in anatomic pathology
  • [ISO-abbreviation] Adv Anat Pathol
  • [Language] eng
  • [Publication-type] Journal Article; Review
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Calmodulin-Binding Proteins; 0 / EWSR1 protein, human; 0 / FOXO1 protein, human; 0 / Forkhead Transcription Factors; 0 / RNA-Binding Proteins
  • [Number-of-references] 30
  •  go-up   go-down


84. Okamura K, Yamamoto H, Ishimaru Y, Takayasu H, Otani Y, Yamagishi J, Takahashi A, Kuwano H, Nagashima K, Ikeda H: Clinical characteristics and surgical treatment of perianal and perineal rhabdomyosarcoma: analysis of Japanese patients and comparison with IRSG reports. Pediatr Surg Int; 2006 Feb;22(2):129-34
MedlinePlus Health Information. consumer health - Anal Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Clinical characteristics and surgical treatment of perianal and perineal rhabdomyosarcoma: analysis of Japanese patients and comparison with IRSG reports.
  • Twenty-nine patients, 26 patients identified in the Japanese literature and three of our own, were analyzed and the results were compared with the data reported from the Intergroup Rhabdomyosarcoma Study Group (IRSG).
  • Alveolar histology was diagnosed in 18 patients.
  • In patients more than 10 years of age, the female predominance was more prominent and the incidences of advanced clinical groups/stages and alveolar histology were significantly higher than those in patients younger than 10 years of age.
  • [MeSH-major] Anus Neoplasms / surgery. Perineum. Rhabdomyosarcoma / surgery. Soft Tissue Neoplasms / surgery

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] J Pediatr Surg. 1989 Jan;24(1):5-10 [2723995.001]
  • [Cites] Med Pediatr Oncol. 2000 Aug;35(2):104-9 [10918231.001]
  • [Cites] Cancer. 1995 Sep 15;76(6):1073-85 [8625211.001]
  • [Cites] Cancer. 1990 Jun 15;65(12):2787-92 [2187589.001]
  • [Cites] J Pediatr Surg. 1995 Jul;30(7):942-4 [7472949.001]
  • [Cites] J Pediatr Surg. 2003 Mar;38(3):347-53 [12632347.001]
  • [Cites] J Clin Oncol. 2002 Jun 1;20(11):2672-9 [12039929.001]
  • [Cites] Cancer. 1994 Jan 1;73(1):109-17 [8275414.001]
  • [Cites] J Pediatr Surg. 2000 Feb;35(2):317-21 [10693687.001]
  • [Cites] J Clin Oncol. 2000 Jun;18(12):2427-34 [10856103.001]
  • [Cites] J Clin Oncol. 2001 Jun 15;19(12):3091-102 [11408506.001]
  • [Cites] J Clin Oncol. 1995 Mar;13(3):610-30 [7884423.001]
  • [Cites] J Pediatr Surg. 1999 May;34(5):731-4; discussion 734-5 [10359173.001]
  • (PMID = 16308704.001).
  • [ISSN] 0179-0358
  • [Journal-full-title] Pediatric surgery international
  • [ISO-abbreviation] Pediatr. Surg. Int.
  • [Language] eng
  • [Publication-type] Case Reports; Comparative Study; Journal Article; Review
  • [Publication-country] Germany
  • [Number-of-references] 36
  •  go-up   go-down


85. Taulli R, Bersani F, Foglizzo V, Linari A, Vigna E, Ladanyi M, Tuschl T, Ponzetto C: The muscle-specific microRNA miR-206 blocks human rhabdomyosarcoma growth in xenotransplanted mice by promoting myogenic differentiation. J Clin Invest; 2009 Aug;119(8):2366-78
eagle-i research resources. PMID 19620785 (Special Collections) .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] The muscle-specific microRNA miR-206 blocks human rhabdomyosarcoma growth in xenotransplanted mice by promoting myogenic differentiation.
  • In this work, we examined the role of the muscle-specific miRNAs miR-1 and miR-206 in human rhabdomyosarcoma (RMS), a soft tissue sarcoma thought to arise from skeletal muscle progenitors.
  • We have shown that miR-1 was barely detectable in primary RMS of both the embryonal and alveolar subtypes and that both miR-1 and miR-206 failed to be induced in RMS cell lines upon serum deprivation.
  • We propose that tissue-specific miRNAs such as miR-1 and miR-206, given their ability to modulate hundreds of transcripts and to act as nontoxic differentiating agents, may override the genomic heterogeneity of solid tumors and ultimately hold greater therapeutic potential than single gene-directed drugs.
  • [MeSH-major] MicroRNAs / physiology. Muscle Development / physiology. Rhabdomyosarcoma / prevention & control


86. Bersani F, Taulli R, Accornero P, Morotti A, Miretti S, Crepaldi T, Ponzetto C: Bortezomib-mediated proteasome inhibition as a potential strategy for the treatment of rhabdomyosarcoma. Eur J Cancer; 2008 Apr;44(6):876-84
The Lens. Cited by Patents in .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Bortezomib-mediated proteasome inhibition as a potential strategy for the treatment of rhabdomyosarcoma.
  • Rhabdomyosarcoma (RMS) is the most common soft-tissue sarcoma of childhood, divided into two major histological subtypes, embryonal (ERMS) and alveolar (ARMS).
  • To explore the possibility that the proteasome could be a target of therapeutic value in rhabdomyosarcoma, we treated several RMS cell lines with the proteasome inhibitor bortezomib (Velcade or PS-341) at a concentration of 13-26 nM.
  • [MeSH-major] Boronic Acids / therapeutic use. Protease Inhibitors / therapeutic use. Proteasome Inhibitors. Pyrazines / therapeutic use. Rhabdomyosarcoma / drug therapy

  • Hazardous Substances Data Bank. BORTEZOMIB .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18342500.001).
  • [ISSN] 0959-8049
  • [Journal-full-title] European journal of cancer (Oxford, England : 1990)
  • [ISO-abbreviation] Eur. J. Cancer
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Angiogenesis Inhibitors; 0 / Boronic Acids; 0 / Protease Inhibitors; 0 / Proteasome Inhibitors; 0 / Pyrazines; 69G8BD63PP / Bortezomib
  •  go-up   go-down


87. Kuçi S, Rettinger E, Voss B, Weber G, Stais M, Kreyenberg H, Willasch A, Kuçi Z, Koscielniak E, Klöss S, von Laer D, Klingebiel T, Bader P: Efficient lysis of rhabdomyosarcoma cells by cytokine-induced killer cells: implications for adoptive immunotherapy after allogeneic stem cell transplantation. Haematologica; 2010 Sep;95(9):1579-86
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Efficient lysis of rhabdomyosarcoma cells by cytokine-induced killer cells: implications for adoptive immunotherapy after allogeneic stem cell transplantation.
  • BACKGROUND: Rhabdomyosarcoma is the most common soft tissue sarcoma in childhood and has a poor prognosis.
  • Here we assessed the capability of ex vivo expanded cytokine-induced killer cells to lyse both alveolar and embryonic rhabdomyosarcoma cell lines and investigated the mechanisms involved.
  • The phenotype and composition of these cells were determined by multiparameter flow cytometry, while their cytotoxic effect against rhabdomyosarcoma cells was evaluated by a europium release assay.
  • RESULTS: Cytokine-induced killer cells efficiently lysed cells from both rhabdomyosarcoma cell lines.
  • Antibody-mediated masking of either NKG2D molecule on cytokine-induced killer cells or its ligands on rhabdomyosarcoma cells (major histocompatibility antigen related chain A and B and UL16 binding protein 2) diminished this effect by 50%, suggesting a major role for the NKG2D molecule in rhabdomyosarcoma cell killing.
  • Accordingly, blocking TRAIL receptors on embryonic rhabdomyosarcoma cell lines significantly reduced the anti-tumor effect of cytokine-induced killer cells.
  • CONCLUSIONS: Our data suggest that cytokine-induced killer cells may be used as a novel adoptive immunotherapy for the treatment of patients with rhabdomyosarcoma after allogeneic stem cell transplantation.
  • [MeSH-major] Cytokine-Induced Killer Cells / immunology. Cytotoxicity, Immunologic. Rhabdomyosarcoma / immunology. Rhabdomyosarcoma / therapy

  • Genetic Alliance. consumer health - Transplantation.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Bone Marrow Transplant. 1999 May;23(10):1071-9 [10373075.001]
  • [Cites] Eur J Immunol. 1999 May;29(5):1656-66 [10359120.001]
  • [Cites] J Clin Oncol. 2005 Jan 1;23(1):242-4 [15625381.001]
  • [Cites] Biol Blood Marrow Transplant. 2005 Mar;11(3):181-7 [15744236.001]
  • [Cites] Clin Immunol. 2005 Jun;115(3):240-9 [15893691.001]
  • [Cites] World J Gastroenterol. 2005 Jun 14;11(22):3339-45 [15948236.001]
  • [Cites] J Orthop Res. 2005 Nov;23(6):1460-6 [15908161.001]
  • [Cites] Bone Marrow Transplant. 2006 Feb;37(3):297-305 [16327814.001]
  • [Cites] Clin Exp Immunol. 2006 Jun;144(3):528-33 [16734623.001]
  • [Cites] Eur J Cancer. 2006 Sep;42(13):2136-49 [16919777.001]
  • [Cites] Int J Cancer. 2006 Sep 15;119(6):1377-82 [16642465.001]
  • [Cites] J Leukoc Biol. 2006 Dec;80(6):1345-53 [16997856.001]
  • [Cites] Blood. 2007 Jan 1;109(1):365-73 [16931626.001]
  • [Cites] Cancer Res. 2007 Apr 15;67(8):3540-4 [17440061.001]
  • [Cites] Haematologica. 2007 Jul;92(7):952-9 [17606446.001]
  • [Cites] Int Immunopharmacol. 2007 Dec 15;7(13):1793-801 [17996690.001]
  • [Cites] Exp Hematol. 2009 May;37(5):616-628.e2 [19375652.001]
  • [Cites] J Clin Oncol. 2004 Dec 1;22(23):4787-94 [15570080.001]
  • [Cites] Exp Hematol. 2005 Jun;33(6):671-81 [15911091.001]
  • [Cites] J Clin Oncol. 1999 Nov;17(11):3487-93 [10550146.001]
  • [Cites] J Clin Oncol. 1999 Dec;17(12):3706-19 [10577842.001]
  • [Cites] FASEB J. 2000 Jun;14(9):1147-58 [10834937.001]
  • [Cites] Br J Haematol. 2000 Jun;109(3):644-51 [10886218.001]
  • [Cites] Blood. 2001 May 15;97(10):2923-31 [11342413.001]
  • [Cites] Biol Blood Marrow Transplant. 2001;7(4):216-22 [11349808.001]
  • [Cites] Nat Immunol. 2001 Aug;2(8):661 [11477395.001]
  • [Cites] Biol Blood Marrow Transplant. 2001;7(10):532-42 [11760085.001]
  • [Cites] J Pediatr Hematol Oncol. 2001 May;23(4):225-33 [11846301.001]
  • [Cites] Nat Rev Immunol. 2002 Oct;2(10):735-47 [12360212.001]
  • [Cites] Int J Hematol. 2003 Feb;77(2):175-9 [12627854.001]
  • [Cites] Curr Opin Immunol. 2003 Jun;15(3):308-14 [12787756.001]
  • [Cites] Leuk Lymphoma. 2003 Sep;44(9):1457-62 [14565644.001]
  • [Cites] Blood. 2004 Apr 15;103(8):3065-72 [15070686.001]
  • [Cites] J Exp Med. 1991 Jul 1;174(1):139-49 [1711560.001]
  • [Cites] Exp Hematol. 1993 Dec;21(13):1673-9 [7694868.001]
  • [Cites] Br J Haematol. 1994 Jul;87(3):453-8 [7527643.001]
  • [Cites] Blood. 1995 Nov 1;86(9):3493-9 [7579455.001]
  • [Cites] Blood. 1996 Aug 15;88(4):1501-8 [8695872.001]
  • [Cites] Res Immunol. 1997 Mar-Apr;148(3):155-9 [9255866.001]
  • [Cites] Med Pediatr Oncol. 1998 May;30(5):269-75 [9544222.001]
  • [Cites] J Exp Med. 1998 Jun 15;187(12):2065-72 [9625766.001]
  • [CommentIn] Haematologica. 2011 Mar;96(3):e21-2 [21357712.001]
  • (PMID = 20378565.001).
  • [ISSN] 1592-8721
  • [Journal-full-title] Haematologica
  • [ISO-abbreviation] Haematologica
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Italy
  • [Other-IDs] NLM/ PMC2930961
  •  go-up   go-down


88. Rao PK, Missiaglia E, Shields L, Hyde G, Yuan B, Shepherd CJ, Shipley J, Lodish HF: Distinct roles for miR-1 and miR-133a in the proliferation and differentiation of rhabdomyosarcoma cells. FASEB J; 2010 Sep;24(9):3427-37
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Distinct roles for miR-1 and miR-133a in the proliferation and differentiation of rhabdomyosarcoma cells.
  • Rhabdomyosarcoma is the most common soft tissue sarcoma in the pediatric population.
  • Levels of miR-1 and miR-133a are drastically reduced in representative cell lines from each major rhabdomyosarcoma subtype (embryonal and alveolar).
  • Introduction of miR-1 and miR-133a into an embryonal rhabdomyosarcoma-derived cell line is cytostatic, thereby suggesting a tumor suppressor-like role for these myogenic miRNAs.
  • More important, these results point to the promise of enhancing rhabdomyosarcoma therapy using miRNAs as agents that mediate cytostasis and promote muscle differentiation.

  • Genetic Alliance. consumer health - Rhabdomyosarcoma 1.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Genome Biol. 2004;5(3):R13 [15003116.001]
  • [Cites] Genes Chromosomes Cancer. 2009 Jun;48(6):455-67 [19235922.001]
  • [Cites] J Clin Invest. 2009 Aug;119(8):2366-78 [19620785.001]
  • [Cites] J Biol Chem. 2009 Oct 23;284(43):29596-604 [19710019.001]
  • [Cites] Genes Chromosomes Cancer. 1999 Dec;26(4):275-85 [10534762.001]
  • [Cites] J Biol Chem. 2000 Jan 7;275(1):41-6 [10617583.001]
  • [Cites] Mol Cell. 2000 Aug;6(2):233-44 [10983972.001]
  • [Cites] Nat Genet. 2001 Feb;27(2):187-90 [11175787.001]
  • [Cites] J Biol Chem. 2001 Nov 2;276(44):41486-91 [11522799.001]
  • [Cites] Development. 2001 Nov;128(22):4623-33 [11714687.001]
  • [Cites] Exp Cell Res. 1993 Sep;208(1):209-17 [8395398.001]
  • [Cites] Mol Cell Biol. 1995 Mar;15(3):1522-35 [7862145.001]
  • [Cites] Oncogene. 1999 Sep 20;18(38):5340-8 [10498887.001]
  • [Cites] Cancer. 1958 Jan-Feb;11(1):181-99 [13500314.001]
  • [Cites] Cell. 2005 Jan 14;120(1):15-20 [15652477.001]
  • [Cites] RNA. 2005 Mar;11(3):241-7 [15701730.001]
  • [Cites] Genes Dev. 2005 Mar 1;19(5):553-69 [15706034.001]
  • [Cites] Science. 2005 Jul 8;309(5732):310-1 [15919954.001]
  • [Cites] Nature. 2005 Jul 14;436(7048):214-20 [15951802.001]
  • [Cites] Cell. 2005 Dec 16;123(6):1133-46 [16337999.001]
  • [Cites] Nat Genet. 2006 Feb;38(2):228-33 [16380711.001]
  • [Cites] Pathol Int. 2006 May;56(5):246-55 [16669873.001]
  • [Cites] Proc Natl Acad Sci U S A. 2006 Jun 6;103(23):8721-6 [16731620.001]
  • [Cites] Cancer Res. 2006 Jul 15;66(14):6936-46 [16849537.001]
  • [Cites] Am J Surg Pathol. 2006 Aug;30(8):962-8 [16861966.001]
  • [Cites] Dev Biol. 2007 Nov 15;311(2):359-68 [17936265.001]
  • [Cites] Proc Natl Acad Sci U S A. 2007 Dec 26;104(52):20844-9 [18093911.001]
  • [Cites] Blood. 2008 Mar 1;111(5):2505-15 [18299451.001]
  • [Cites] Oncogene. 2008 Mar 27;27(14):2015-26 [17922033.001]
  • [Cites] Oncogene. 2008 Nov 20;27(51):6550-60 [18679424.001]
  • [Cites] Cancer Cell. 2008 Nov 4;14(5):369-81 [18977326.001]
  • [Cites] Nat Protoc. 2009;4(1):44-57 [19131956.001]
  • [Cites] Cell. 2009 Jan 23;136(2):215-33 [19167326.001]
  • [Cites] Mol Biol Cell. 2009 Feb;20(4):1120-31 [19109424.001]
  • [Cites] Genes Dev. 2009 Mar 1;23(5):619-32 [19240126.001]
  • [Cites] Curr Biol. 2002 Apr 30;12(9):735-9 [12007417.001]
  • [Cites] Genome Biol. 2003;4(5):P3 [12734009.001]
  • [Cites] Cell. 2003 Dec 26;115(7):787-98 [14697198.001]
  • [Cites] Cell. 2004 Jan 23;116(2):281-97 [14744438.001]
  • (PMID = 20466878.001).
  • [ISSN] 1530-6860
  • [Journal-full-title] FASEB journal : official publication of the Federation of American Societies for Experimental Biology
  • [ISO-abbreviation] FASEB J.
  • [Language] ENG
  • [Grant] United States / NIDDK NIH HHS / DK / R01 DK068348; United Kingdom / Cancer Research UK / / C5066/A9541
  • [Publication-type] Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / MicroRNAs
  • [Other-IDs] NLM/ PMC3231107
  •  go-up   go-down


89. Miron I, Miron L, Dumitraş S, Aprodu G, Ciobanu A, Tansanu I: [Statistical study of the evolution over ten years of the clinical and therapeutic approach in childhood soft tissue sarcoma]. Rev Med Chir Soc Med Nat Iasi; 2007 Apr-Jun;111(2):358-62
MedlinePlus Health Information. consumer health - Soft Tissue Sarcoma.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Statistical study of the evolution over ten years of the clinical and therapeutic approach in childhood soft tissue sarcoma].
  • Soft tissue sarcoma has a primitive mesenchymal origin and represents a heterogeneous group of malignant entities with a continuous rising frequency in the age range below 18.
  • Rhabdomyosarcoma (RMS) constitutes 5.8% from the whole amount of pediatric solid tumors, taking the fourth place after CNS tumors, neuroblastoma, and Wilms tumors.
  • The other category of non-rhabdomyosarcoma tumors in children and teenagers represents 3% of the solid malignancies under 18 years old.
  • We included in the study a well-known category of soft tissue tumors called of uncertain malignancy.
  • Based on histological examination 19 cases (32.75%) were of rhabdomyosarcoma type with following subtypes: alveolar--7 patients, embryonic-- 9 cases, fusiform - 2 cases, bothrioid--1 case), 8 cases were undifferentiated soft tissue sarcomas and one patient had a tumor of pleiomorphic type; 13 children (22.41%) had non-rhabdomyosarcoma soft tissue sarcomas: 6 fibrosarcomas, 2 synovial sarcomas, 1 leiomyosarcoma, 1 Kaposi sarcoma, 1 case of malignant peripheral nerve sheath tumor, 1 case of angioma tumor, one liposarcoma; 16 cases were included in soft tissue tumors of uncertain origin (fibromatosis--6 cases, fibrous histiocytoma--4 cases, hamartoma--cases, myoblastoma--1 case, fibro-xanthoma--1 case, hemangioendothelioma--1 case); 1 PPNET (Askin tumor).
  • CONCLUSIONS: The continuously augmented incidence of soft tissue sarcoma in young ages and the advanced stages initial presentations of tumors require a much more serious and rhythmic survey at general practitioner level.
  • [MeSH-major] Sarcoma / pathology. Sarcoma / therapy. Soft Tissue Neoplasms / pathology. Soft Tissue Neoplasms / therapy

  • Genetic Alliance. consumer health - Soft tissue sarcoma.
  • Genetic Alliance. consumer health - TEN.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17983168.001).
  • [ISSN] 0048-7848
  • [Journal-full-title] Revista medico-chirurgicală̆ a Societă̆ţ̜ii de Medici ş̧i Naturaliş̧ti din Iaş̧i
  • [ISO-abbreviation] Rev Med Chir Soc Med Nat Iasi
  • [Language] rum
  • [Publication-type] English Abstract; Journal Article
  • [Publication-country] Romania
  •  go-up   go-down


90. Schaaf GJ, Ruijter JM, van Ruissen F, Zwijnenburg DA, Waaijer R, Valentijn LJ, Benit-Deekman J, van Kampen AH, Baas F, Kool M: Full transcriptome analysis of rhabdomyosarcoma, normal, and fetal skeletal muscle: statistical comparison of multiple SAGE libraries. FASEB J; 2005 Mar;19(3):404-6
Hazardous Substances Data Bank. GLUCOSE .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Full transcriptome analysis of rhabdomyosarcoma, normal, and fetal skeletal muscle: statistical comparison of multiple SAGE libraries.
  • Rhabdomyosarcoma (RMS) is the most frequent soft tissue sarcoma in children.
  • With a G-test for the simultaneous comparison of subsets of SAGE libraries of normal skeletal muscle, embryonal (ERMS) and alveolar (ARMS) RMS, we identified 251 differentially expressed genes.
  • [MeSH-major] Gene Expression Profiling. Gene Library. Muscle, Skeletal / chemistry. Muscle, Skeletal / embryology. Rhabdomyosarcoma / genetics

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15629888.001).
  • [ISSN] 1530-6860
  • [Journal-full-title] FASEB journal : official publication of the Federation of American Societies for Experimental Biology
  • [ISO-abbreviation] FASEB J.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 63231-63-0 / RNA; IY9XDZ35W2 / Glucose
  •  go-up   go-down


91. Wolf SJ, Wakelin LP, He Z, Stewart BW, Catchpoole DR: In vitro assessment of novel transcription inhibitors and topoisomerase poisons in rhabdomyosarcoma cell lines. Cancer Chemother Pharmacol; 2009 Nov;64(6):1059-69
NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] In vitro assessment of novel transcription inhibitors and topoisomerase poisons in rhabdomyosarcoma cell lines.
  • PURPOSE: Rhabdomyosarcoma (RMS) is the most common soft tissue sarcoma in children.
  • [MeSH-major] Drug Evaluation, Preclinical. Nucleic Acid Synthesis Inhibitors / pharmacology. Rhabdomyosarcoma / drug therapy. Rhabdomyosarcoma, Alveolar / drug therapy. Rhabdomyosarcoma, Embryonal / drug therapy. Topoisomerase Inhibitors

  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19277661.001).
  • [ISSN] 1432-0843
  • [Journal-full-title] Cancer chemotherapy and pharmacology
  • [ISO-abbreviation] Cancer Chemother. Pharmacol.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] Germany
  • [Chemical-registry-number] 0 / Acridines; 0 / Aminoacridines; 0 / Antigens, Neoplasm; 0 / Antineoplastic Agents; 0 / DNA-Binding Proteins; 0 / Enzyme Inhibitors; 0 / Nucleic Acid Synthesis Inhibitors; 0 / Phenazines; 0 / Topoisomerase Inhibitors; EC 5.99.1.2 / DNA Topoisomerases, Type I; EC 5.99.1.3 / DNA Topoisomerases, Type II; EC 5.99.1.3 / DNA topoisomerase II alpha; EC 5.99.1.3 / DNA topoisomerase II beta
  •  go-up   go-down


92. Antillon F, Castellanos M, Valverde P, Luna-Fineman S, Garrido C, Serrato T, Rodriguez-Galindo C, Casanova M, Ferrari A: Treating Pediatric soft tissue sarcomas in a country with limited resources: the experience of the Unidad Nacional de Oncologia Pediatrica in Guatemala. Pediatr Blood Cancer; 2008 Dec;51(6):760-4
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Treating Pediatric soft tissue sarcomas in a country with limited resources: the experience of the Unidad Nacional de Oncologia Pediatrica in Guatemala.
  • BACKGROUND: About 250-300 children with newly diagnosed cancer are treated each year at the Unidad Nacional de Oncologia Pediatrica in Guatemala City; less than 5% of them have soft tissue sarcomas (STS).
  • PATIENTS AND METHODS: We reviewed the clinical data, treatment and outcome of 80 patients, 47 cases of rhabdomyosarcoma (RMS) and 33 of non-rhabdomyosarcoma soft tissue sarcoma (NRSTS), treated between January 2000 and October 2007.
  • RESULTS: Most of the RMS patients had advanced disease at diagnosis (87% groups III-IV).
  • Late diagnosis and the consequently high proportion of cases of advanced disease at diagnosis, the large number of patients failing to complete the treatment, and the poor quality of local control (in RMS) adversely influence outcome.
  • [MeSH-major] Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Developing Countries. Rhabdomyosarcoma, Alveolar / drug therapy. Rhabdomyosarcoma, Embryonal / drug therapy. Soft Tissue Neoplasms / drug therapy

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18680154.001).
  • [ISSN] 1545-5017
  • [Journal-full-title] Pediatric blood & cancer
  • [ISO-abbreviation] Pediatr Blood Cancer
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


93. Makawita S, Ho M, Durbin AD, Thorner PS, Malkin D, Somers GR: Expression of insulin-like growth factor pathway proteins in rhabdomyosarcoma: IGF-2 expression is associated with translocation-negative tumors. Pediatr Dev Pathol; 2009 Mar-Apr;12(2):127-35
The Lens. Cited by Patents in .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Expression of insulin-like growth factor pathway proteins in rhabdomyosarcoma: IGF-2 expression is associated with translocation-negative tumors.
  • Recent studies have shown a significant involvement of insulin-like growth factor (IGF) signaling components in the pathogenesis of rhabdomyosarcoma (RMS).
  • The present study utilized immunohistochemistry to determine the expression patterns of IGF1, IGF2, IGF binding protein 2 (IGFBP2), IGF receptor 1 (IGF1R), and IGF receptor 2 (IGF2R) in 24 embryonal RMS (ERMS) and 8 alveolar RMS (ARMS).
  • [MeSH-major] Insulin-Like Growth Factor II / metabolism. Rhabdomyosarcoma / metabolism. Soft Tissue Neoplasms / metabolism. Translocation, Genetic / genetics
  • [MeSH-minor] Biomarkers, Tumor / metabolism. Cell Line, Tumor. Fluorescent Antibody Technique, Direct. Forkhead Transcription Factors / genetics. Forkhead Transcription Factors / metabolism. Gene Expression Profiling. Gene Expression Regulation, Neoplastic / genetics. Humans. Paired Box Transcription Factors / genetics. Paired Box Transcription Factors / metabolism. RNA, Messenger / metabolism. RNA, Neoplasm / analysis. Tissue Array Analysis

  • COS Scholar Universe. author profiles.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18788888.001).
  • [ISSN] 1093-5266
  • [Journal-full-title] Pediatric and developmental pathology : the official journal of the Society for Pediatric Pathology and the Paediatric Pathology Society
  • [ISO-abbreviation] Pediatr. Dev. Pathol.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Biomarkers, Tumor; 0 / Forkhead Transcription Factors; 0 / PAX3 protein, human; 0 / Paired Box Transcription Factors; 0 / RNA, Messenger; 0 / RNA, Neoplasm; 67763-97-7 / Insulin-Like Growth Factor II
  •  go-up   go-down


94. Singh S, Vinson C, Gurley CM, Nolen GT, Beggs ML, Nagarajan R, Wagner EF, Parham DM, Peterson CA: Impaired Wnt signaling in embryonal rhabdomyosarcoma cells from p53/c-fos double mutant mice. Am J Pathol; 2010 Oct;177(4):2055-66
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Impaired Wnt signaling in embryonal rhabdomyosarcoma cells from p53/c-fos double mutant mice.
  • Rhabdomyosarcoma is a primitive neoplasm with a poorly understood etiology that exhibits features of fetal skeletal muscle.
  • It represents the most frequent malignant soft tissue sarcoma affecting the pediatric population and is often treated very aggressively.
  • Embryonal rhabdomyosarcoma (ERMS) and alveolar rhabdomyosarcoma constitute the two major subtypes and exhibit different molecular features.
  • Identification of the Wnt2 gene and its overexpression in ERMS cells was confirmed in human rhabdomyosarcoma cell lines and prompted further analysis of the Wnt signaling pathway.

  • Genetic Alliance. consumer health - Rhabdomyosarcoma embryonal.
  • COS Scholar Universe. author profiles.
  • KOMP Repository. gene/protein/disease-specific - KOMP Repository (subscription/membership/fee required).
  • Mouse Genome Informatics (MGI). Mouse Genome Informatics (MGI) .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] FEBS Lett. 2004 Aug 27;573(1-3):83-92 [15327980.001]
  • [Cites] Cancer Res. 2004 Aug 1;64(15):5385-9 [15289346.001]
  • [Cites] Cell. 1989 Aug 25;58(4):659-67 [2548731.001]
  • [Cites] Proc Natl Acad Sci U S A. 1990 Aug;87(15):5863-7 [2143022.001]
  • [Cites] J Cell Biol. 1990 Sep;111(3):1149-59 [2167895.001]
  • [Cites] Cancer Res. 1991 Oct 1;51(19):5100-6 [1717137.001]
  • [Cites] Genomics. 1992 Aug;13(4):1322-4 [1505965.001]
  • [Cites] Proc Natl Acad Sci U S A. 1993 Apr 1;90(7):2910-4 [7681991.001]
  • [Cites] J Med Genet. 2006 Feb;43(2):119-28 [15908567.001]
  • [Cites] Cancer Res. 2006 Aug 1;66(15):7578-88 [16885357.001]
  • [Cites] Breast Cancer Res Treat. 2006 Nov;100(1):49-58 [16791480.001]
  • [Cites] Arch Pathol Lab Med. 2006 Oct;130(10):1454-65 [17090187.001]
  • [Cites] J Cell Sci. 2006 Dec 1;119(Pt 23):4850-6 [17090604.001]
  • [Cites] Oncogene. 2007 May 24;26(24):3492-502 [17146436.001]
  • [Cites] Cancer Res. 2007 Jul 15;67(14):6691-9 [17638879.001]
  • [Cites] Cytotherapy. 2007;9(7):667-81 [17917885.001]
  • [Cites] Clin Cancer Res. 2008 Jan 1;14(1):55-61 [18172252.001]
  • [Cites] Mol Cell Biol. 2008 May;28(9):2941-51 [18316399.001]
  • [Cites] J Gerontol A Biol Sci Med Sci. 2008 Jun;63(6):566-79 [18559630.001]
  • [Cites] Am J Pathol. 2009 Feb;174(2):550-64 [19147825.001]
  • [Cites] Pediatr Dev Pathol. 2009 Sep-Oct;12(5):371-3 [19222307.001]
  • [Cites] Biochem Cell Biol. 1993 Mar-Apr;71(3-4):197-204 [8398078.001]
  • [Cites] Nat Genet. 1993 Nov;5(3):225-9 [8275085.001]
  • [Cites] Clin Exp Metastasis. 1994 Jul;12(4):329-34 [7913670.001]
  • [Cites] J Clin Invest. 1994 Jul;94(1):445-8 [8040287.001]
  • [Cites] Cell. 1995 Sep 8;82(5):721-32 [7545543.001]
  • [Cites] Development. 1996 Feb;122(2):429-37 [8625794.001]
  • [Cites] Curr Biol. 1996 Dec 1;6(12):1664-8 [8994831.001]
  • [Cites] Proc Natl Acad Sci U S A. 1997 Jan 21;94(2):701-6 [9012848.001]
  • [Cites] Trends Genet. 1997 Apr;13(4):157-62 [9097727.001]
  • [Cites] J Biol Chem. 1997 Oct 3;272(40):24735-8 [9312064.001]
  • [Cites] Mol Cell Biol. 1997 Nov;17(11):6563-73 [9343420.001]
  • [Cites] Nat Med. 1998 May;4(5):619-22 [9585239.001]
  • [Cites] Oncologist. 1999;4(1):34-44 [10337369.001]
  • [Cites] Genes Dev. 2004 Nov 1;18(21):2614-26 [15489287.001]
  • [Cites] J Cell Sci. 2004 Dec 1;117(Pt 25):5965-73 [15564374.001]
  • [Cites] Mod Pathol. 2005 Jan;18(1):68-74 [15375433.001]
  • [Cites] Pediatr Dev Pathol. 2004 Nov-Dec;7(6):583-94 [15630526.001]
  • [Cites] Cell Res. 2005 Jan;15(1):28-32 [15686623.001]
  • [Cites] Mol Biol Cell. 2005 Apr;16(4):2039-48 [15673614.001]
  • [Cites] Cancer Res. 2005 Jun 1;65(11):4490-5 [15930263.001]
  • [Cites] Int J Oncol. 2005 Sep;27(3):791-8 [16077930.001]
  • [Cites] Oncogene. 2000 Aug 31;19(37):4210-20 [10980594.001]
  • [Cites] Oncogene. 2001 Apr 30;20(19):2334-5 [11402330.001]
  • [Cites] Oncogene. 2001 Apr 30;20(19):2390-400 [11402335.001]
  • [Cites] Oncogene. 2001 Apr 30;20(19):2453-64 [11402340.001]
  • [Cites] Genes Chromosomes Cancer. 2002 Mar;33(3):310-21 [11807989.001]
  • [Cites] Cancer Res. 2002 Jan 15;62(2):409-16 [11809689.001]
  • [Cites] Cancer Biol Ther. 2002 Mar-Apr;1(2):97-104 [12170781.001]
  • [Cites] Bioessays. 2002 Oct;24(10):881-4 [12325120.001]
  • [Cites] J Cell Sci. 2003 Jul 1;116(Pt 13):2627-34 [12775774.001]
  • [Cites] Cancer Res. 2003 Jun 1;63(11):2728-32 [12782574.001]
  • [Cites] Development. 2003 Aug;130(15):3503-14 [12810597.001]
  • [Cites] Cell. 2003 Jun 27;113(7):841-52 [12837243.001]
  • [Cites] Br J Cancer. 2003 Jul 21;89(2):327-32 [12865925.001]
  • [Cites] Int J Mol Med. 2003 Nov;12(5):811-6 [14533014.001]
  • [Cites] Cancer Cell. 2003 Nov;4(5):349-60 [14667502.001]
  • [Cites] Nat Rev Cancer. 2003 Nov;3(11):859-68 [14668816.001]
  • [Cites] Cancer Cell. 2003 Dec;4(6):477-82 [14706339.001]
  • [Cites] Cancer Treat Rev. 2004 May;30(3):269-80 [15059650.001]
  • [Cites] N Engl J Med. 2004 Apr 1;350(14):1464-6; author reply 1464-6 [15074001.001]
  • [Cites] Mod Pathol. 2004 Jun;17(6):660-9 [15098008.001]
  • [Cites] Cell. 2004 Jun 25;117(7):927-39 [15210113.001]
  • [Cites] Exp Cell Res. 1987 May;170(1):80-92 [3569436.001]
  • (PMID = 20829439.001).
  • [ISSN] 1525-2191
  • [Journal-full-title] The American journal of pathology
  • [ISO-abbreviation] Am. J. Pathol.
  • [Language] ENG
  • [Grant] United States / NIA NIH HHS / AG / R01 AG020941; United States / NIA NIH HHS / AG / AG20941
  • [Publication-type] Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / RNA, Messenger; 0 / Transcription Factor AP-1; 0 / Tumor Suppressor Protein p53; 0 / Wnt Proteins; 0 / beta Catenin; EC 1.13.12.- / Luciferases
  • [Other-IDs] NLM/ PMC2947299
  •  go-up   go-down


95. Stejskalová E, Jarosová M, Malis J, Sumerauer D, Urbánková H, Krsková L, Pýcha K, Schovanec J, Balcárková J, Smelhaus V, Kodetová D, Starý J: [Clinical relevance of chromosomal aberrations in bone and soft tissue tumors in children and young adults]. Klin Onkol; 2009;22(2):58-66
MedlinePlus Health Information. consumer health - Bone Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Clinical relevance of chromosomal aberrations in bone and soft tissue tumors in children and young adults].
  • BACKGROUND: We present the results of a cytogenetic and molecular cytogenetic analysis of a series of patients with bone and soft tissue tumors.
  • PATIENTS ANDMETHODS: We analyzed a cohort of 26 patients with Ewing sarcoma/PNET, 15 patients with rhabdomyosarcoma, 5 with synovial sarcoma and one patient with an undifferentiated sarcoma using the cytogenetic and molecular cytogenetic techniques M-FISH and arrayCGH.
  • In the RMS patients we detected the t(1;13)(p36;q14) once and the t(2;13)(q35;q14) four times, both of them characteristic for the alveolar subtype with poor prognosis and numerical aberrations, characteristic for the embryonal subtype, in five patients.
  • CONCLUSION: Cytogenetic and molecular cytogenetic analysis is a valuable diagnostic tool in bone and soft tissue tumors, especially in less differentiated subtypes, and as such it should be an integral part of curative care.
  • [MeSH-major] Bone Neoplasms / genetics. Chromosome Aberrations. Soft Tissue Neoplasms / genetics

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19522375.001).
  • [ISSN] 0862-495X
  • [Journal-full-title] Klinická onkologie : casopis Ceské a Slovenské onkologické spolecnosti
  • [ISO-abbreviation] Klin Onkol
  • [Language] cze
  • [Publication-type] English Abstract; Journal Article
  • [Publication-country] Czech Republic
  •  go-up   go-down


96. Davicioni E, Anderson MJ, Finckenstein FG, Lynch JC, Qualman SJ, Shimada H, Schofield DE, Buckley JD, Meyer WH, Sorensen PH, Triche TJ: Molecular classification of rhabdomyosarcoma--genotypic and phenotypic determinants of diagnosis: a report from the Children's Oncology Group. Am J Pathol; 2009 Feb;174(2):550-64
NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Molecular classification of rhabdomyosarcoma--genotypic and phenotypic determinants of diagnosis: a report from the Children's Oncology Group.
  • Rhabdomyosarcoma (RMS) in children occurs as two major histological subtypes, embryonal (ERMS) and alveolar (ARMS).
  • ERMS is associated with an 11p15.5 loss of heterozygosity (LOH) and may be confused with nonmyogenic, non-RMS soft tissue sarcomas.
  • Here, we describe a genomic-based classification scheme that is derived from the combined gene expression profiling and LOH analysis of 160 cases of RMS and non-RMS soft tissue sarcomas that is at variance with conventional histopathological schemes.
  • These objectively derived molecular classes are based solely on genomic analysis at the time of diagnosis and are highly reproducible.

  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] J Mol Diagn. 2006 May;8(2):202-8 [16645206.001]
  • [Cites] Hum Genomics. 2004 May;1(4):287-99 [15588488.001]
  • [Cites] Nat Rev Cancer. 2006 Jan;6(1):52-62 [16397527.001]
  • [Cites] N Engl J Med. 2006 Jun 8;354(23):2463-72 [16760446.001]
  • [Cites] Cancer Res. 2006 Jul 15;66(14):6936-46 [16849537.001]
  • [Cites] Am J Surg Pathol. 2006 Aug;30(8):962-8 [16861966.001]
  • [Cites] J Pathol. 2007 Jun;212(2):143-51 [17471488.001]
  • [Cites] Am J Surg Pathol. 2007 Jun;31(6):895-901 [17527077.001]
  • [Cites] Genes Chromosomes Cancer. 2008 Jun;47(6):510-20 [18335505.001]
  • [Cites] Genes Chromosomes Cancer. 1999 Dec;26(4):275-85 [10534762.001]
  • [Cites] Genes Chromosomes Cancer. 2000 Apr;27(4):337-44 [10719362.001]
  • [Cites] Neoplasia. 1999 Oct;1(4):340-8 [10935489.001]
  • [Cites] Genome Res. 2000 Aug;10(8):1126-37 [10958631.001]
  • [Cites] Proc Natl Acad Sci U S A. 2001 Apr 24;98(9):5116-21 [11309499.001]
  • [Cites] Nat Med. 2001 Jun;7(6):673-9 [11385503.001]
  • [Cites] J Clin Oncol. 2001 Jun 15;19(12):3091-102 [11408506.001]
  • [Cites] Med Pediatr Oncol. 2001 Feb;36(2):259-67 [11452933.001]
  • [Cites] Am J Pathol. 2001 Sep;159(3):1089-96 [11549601.001]
  • [Cites] Oncogene. 2001 Sep 10;20(40):5736-46 [11607823.001]
  • [Cites] Am J Surg Pathol. 2001 Sep;25(9):1150-7 [11688574.001]
  • [Cites] Trends Genet. 2002 Jan;18(1):41-7 [11750700.001]
  • [Cites] Genes Chromosomes Cancer. 2002 Mar;33(3):310-21 [11807989.001]
  • [Cites] J Pediatr Hematol Oncol. 2001 May;23(4):215-20 [11846299.001]
  • [Cites] Nat Rev Cancer. 2001 Nov;1(2):151-7 [11905806.001]
  • [Cites] Lancet. 2002 Apr 13;359(9314):1301-7 [11965276.001]
  • [Cites] Proc Natl Acad Sci U S A. 2002 May 14;99(10):6567-72 [12011421.001]
  • [Cites] J Clin Oncol. 2002 Jun 1;20(11):2672-9 [12039929.001]
  • [Cites] Cancer Res. 2002 Aug 15;62(16):4704-10 [12183429.001]
  • [Cites] J Clin Oncol. 2003 Jan 1;21(1):78-84 [12506174.001]
  • [Cites] J Natl Cancer Inst. 2003 Jan 1;95(1):14-8 [12509396.001]
  • [Cites] Cancer Res. 2003 May 1;63(9):2216-22 [12727842.001]
  • [Cites] Mol Biol Cell. 2003 Jun;14(6):2201-5 [12808022.001]
  • [Cites] Am J Pathol. 2003 Aug;163(2):691-700 [12875988.001]
  • [Cites] Genome Biol. 2003;4(10):R70 [14519205.001]
  • [Cites] Cancer Treat Rev. 2004 May;30(3):269-80 [15059650.001]
  • [Cites] Bioinformatics. 2004 May 1;20(7):1060-5 [14764574.001]
  • [Cites] Ann N Y Acad Sci. 2004 May;1020:49-66 [15208183.001]
  • [Cites] Blood. 2004 Aug 15;104(4):923-32 [15155462.001]
  • [Cites] Cancer Res. 2004 Aug 15;64(16):5539-45 [15313887.001]
  • [Cites] Virchows Arch A Pathol Anat Histopathol. 1986;409(2):183-94 [3012860.001]
  • [Cites] Arch Pathol Lab Med. 1986 Sep;110(9):776-8 [3530185.001]
  • [Cites] J Clin Oncol. 1988 Jan;6(1):67-75 [3275751.001]
  • [Cites] J Clin Oncol. 1990 Mar;8(3):443-52 [2407808.001]
  • [Cites] Histopathology. 1990 Oct;17(4):301-9 [2258169.001]
  • [Cites] Cancer Res. 1991 Oct 1;51(19):5100-6 [1717137.001]
  • [Cites] Am J Surg Pathol. 1992 Mar;16(3):229-35 [1599014.001]
  • [Cites] Arch Pathol Lab Med. 1992 Aug;116(8):847-55 [1497467.001]
  • [Cites] Am J Surg Pathol. 1993 Mar;17(3):221-30 [8434703.001]
  • [Cites] Cancer. 1994 Nov 1;74(9):2579-88 [7923014.001]
  • [Cites] Hum Genet. 1996 Feb;97(2):163-70 [8566947.001]
  • [Cites] Cancer. 1995 Sep 15;76(6):1073-85 [8625211.001]
  • [Cites] Exp Mol Pathol. 1995 Aug;63(1):1-15 [8759049.001]
  • [Cites] Curr Top Microbiol Immunol. 1997;220:113-29 [9103678.001]
  • [Cites] Oncogene. 1997 Sep;15(11):1309-14 [9315099.001]
  • [Cites] Pediatr Dev Pathol. 1998 Nov-Dec;1(6):550-61 [9724344.001]
  • [Cites] Ann Anat Pathol (Paris). 1956 Jan-Mar;1(1):88-111 [13340265.001]
  • [Cites] Am J Clin Pathol. 1958 Apr;29(4):356-66 [13533329.001]
  • [Cites] Eur J Surg Oncol. 2004 Dec;30(10):1131-6 [15522563.001]
  • [Cites] J Clin Oncol. 2006 Feb 10;24(5):816-22 [16391296.001]
  • (PMID = 19147825.001).
  • [ISSN] 1525-2191
  • [Journal-full-title] The American journal of pathology
  • [ISO-abbreviation] Am. J. Pathol.
  • [Language] ENG
  • [Grant] United States / NCI NIH HHS / CA / U01 CA088199; United States / NCI NIH HHS / CA / U01 CA114757; United States / NCI NIH HHS / CA / CA-88199; United States / NCI NIH HHS / CA / U01CA-114757
  • [Publication-type] Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Biomarkers, Tumor; 0 / HMGA2 Protein; 0 / TFAP2B protein, human; 0 / Transcription Factor AP-2
  • [Other-IDs] NLM/ PMC2630563
  •  go-up   go-down


97. Raney RB, Chintagumpala M, Anderson J, Pappo A, Qualman S, Wharam M, Wiener E, Meyer W, Soft-Tissue Sarcoma Committee of the Children's Oncology Group, Arcadia, California: Results of treatment of patients with superficial facial rhabdomyosarcomas on protocols of the Intergroup Rhabdomyosarcoma Study Group (IRSG), 1984-1997. Pediatr Blood Cancer; 2008 May;50(5):958-64

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Results of treatment of patients with superficial facial rhabdomyosarcomas on protocols of the Intergroup Rhabdomyosarcoma Study Group (IRSG), 1984-1997.
  • PURPOSE: We analyzed the outcome of 47 patients with superficial facial rhabdomyosarcoma (RMS) treated on Intergroup Rhabdomyosarcoma Study Group (IRSG) Protocols-III, -IV-Pilot, and -IV.
  • RESULTS: Thirty-two patients were males; 35 patients were 1-9 years old at diagnosis.
  • Eight-year EFS rates were 72% for 22 patients with embryonal RMS and 53% for 23 patients with alveolar RMS (P = 0.28).

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] (c) 2008 Wiley-Liss, Inc.
  • [Cites] Cancer. 1984 Feb 15;53(4):1016-9 [6692285.001]
  • [Cites] Med Pediatr Oncol. 1987;15(2):51-7 [3587117.001]
  • [Cites] J Clin Oncol. 1995 Mar;13(3):610-30 [7884423.001]
  • [Cites] J Pediatr Hematol Oncol. 1997 Mar-Apr;19(2):124-9 [9149741.001]
  • [Cites] Cancer. 1996 Jan 1;77(1):193-200 [8630930.001]
  • [Cites] J Pediatr Hematol Oncol. 1995 Nov;17(4):331-7 [7583389.001]
  • [Cites] Br J Cancer. 1977 Jan;35(1):1-39 [831755.001]
  • [Cites] J Clin Oncol. 2003 Feb 15;21(4):638-45 [12586800.001]
  • [Cites] Head Neck. 2002 May;24(5):468-73 [12001077.001]
  • [Cites] Arch Otolaryngol Head Neck Surg. 1987 Nov;113(11):1225-7 [3663351.001]
  • [Cites] Ophthalmology. 1987 Mar;94(3):251-4 [3587902.001]
  • [Cites] J Clin Oncol. 2001 Jun 15;19(12):3091-102 [11408506.001]
  • [Cites] Cancer. 2001 Dec 15;92(12):3135-46 [11753993.001]
  • [Cites] Med Pediatr Oncol. 2002 Jan;38(1):22-32 [11835233.001]
  • [Cites] Cancer. 1988 Jan 15;61(2):209-20 [3275486.001]
  • [Cites] Am J Surg. 1989 Oct;158(4):373-7 [2802044.001]
  • [Cites] Arch Otolaryngol Head Neck Surg. 1990 Apr;116(4):428-31 [2317324.001]
  • [Cites] Cancer. 1993 Mar 1;71(5):1904-22 [8448756.001]
  • (PMID = 18240175.001).
  • [ISSN] 1545-5017
  • [Journal-full-title] Pediatric blood & cancer
  • [ISO-abbreviation] Pediatr Blood Cancer
  • [Language] ENG
  • [Grant] United States / NCI NIH HHS / CA / U10 CA072989; United States / NCI NIH HHS / CA / U10 CA029511; United States / NCI NIH HHS / CA / U10 CA072989-04; United States / NCI NIH HHS / CA / CA-24507; United States / NCI NIH HHS / CA / CA-72989; None / None / / U10 CA072989-04; United States / NCI NIH HHS / CA / U10 CA024507-26; None / None / / U10 CA024507-26; United States / NCI NIH HHS / CA / U10 CA029511-28; United States / NCI NIH HHS / CA / CA-29511; United States / NCI NIH HHS / CA / U10 CA024507
  • [Publication-type] Clinical Trial; Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Other-IDs] NLM/ NIHMS319313; NLM/ PMC3357210
  •  go-up   go-down


98. Gee MF, Tsuchida R, Eichler-Jonsson C, Das B, Baruchel S, Malkin D: Vascular endothelial growth factor acts in an autocrine manner in rhabdomyosarcoma cell lines and can be inhibited with all-trans-retinoic acid. Oncogene; 2005 Dec 1;24(54):8025-37
The Lens. Cited by Patents in .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Vascular endothelial growth factor acts in an autocrine manner in rhabdomyosarcoma cell lines and can be inhibited with all-trans-retinoic acid.
  • Rhabdomyosarcoma (RMS) is the most common paediatric soft-tissue sarcoma, and is dependent on autocrine signalling for its growth.
  • The alveolar subtype of RMS is often characterized by the presence of a PAX3-FKHR translocation, and when introduced into non-RMS cells, the resultant fusion protein induces expression of VEGFR1.
  • [MeSH-major] Autocrine Communication / drug effects. Rhabdomyosarcoma, Alveolar / metabolism. Rhabdomyosarcoma, Embryonal / metabolism. Tretinoin / pharmacology. Vascular Endothelial Growth Factor A / pharmacology

  • COS Scholar Universe. author profiles.
  • Hazardous Substances Data Bank. ALL-TRANS-RETINOIC ACID .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16116481.001).
  • [ISSN] 0950-9232
  • [Journal-full-title] Oncogene
  • [ISO-abbreviation] Oncogene
  • [Language] eng
  • [Publication-type] Comparative Study; Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] England
  • [Chemical-registry-number] 0 / RNA, Messenger; 0 / Recombinant Proteins; 0 / Vascular Endothelial Growth Factor A; 5688UTC01R / Tretinoin; EC 2.7.10.1 / Vascular Endothelial Growth Factor Receptor-1; EC 2.7.10.1 / Vascular Endothelial Growth Factor Receptor-2; EC 2.7.11.24 / Mitogen-Activated Protein Kinase 1; EC 2.7.11.24 / Mitogen-Activated Protein Kinase 3
  •  go-up   go-down


99. Goldstein M, Meller I, Orr-Urtreger A: FGFR1 over-expression in primary rhabdomyosarcoma tumors is associated with hypomethylation of a 5' CpG island and abnormal expression of the AKT1, NOG, and BMP4 genes. Genes Chromosomes Cancer; 2007 Nov;46(11):1028-38
The Lens. Cited by Patents in .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] FGFR1 over-expression in primary rhabdomyosarcoma tumors is associated with hypomethylation of a 5' CpG island and abnormal expression of the AKT1, NOG, and BMP4 genes.
  • Rhabdomyosarcoma (RMS), the most common pediatric soft tissue sarcoma likely results from abnormal proliferation and differentiation during skeletal myogenesis.
  • Multiple genetic alterations are associated with the three RMS histopathological subtypes, embryonal, alveolar, and pleomorphic adult variant.
  • [MeSH-major] Bone Morphogenetic Proteins / genetics. Carrier Proteins / genetics. CpG Islands. DNA Methylation. Proto-Oncogene Proteins c-akt / genetics. Receptor, Fibroblast Growth Factor, Type 1 / genetics. Rhabdomyosarcoma / genetics

  • COS Scholar Universe. author profiles.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] Copyright (c) 2007 Wiley-Liss, Inc.
  • (PMID = 17696196.001).
  • [ISSN] 1045-2257
  • [Journal-full-title] Genes, chromosomes & cancer
  • [ISO-abbreviation] Genes Chromosomes Cancer
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / BMP4 protein, human; 0 / Bone Morphogenetic Protein 4; 0 / Bone Morphogenetic Proteins; 0 / Carrier Proteins; 0 / DNA Primers; 148294-77-3 / noggin protein; EC 2.7.10.1 / FGFR1 protein, human; EC 2.7.10.1 / Receptor, Fibroblast Growth Factor, Type 1; EC 2.7.11.1 / AKT1 protein, human; EC 2.7.11.1 / Proto-Oncogene Proteins c-akt
  •  go-up   go-down


100. Lott S, Lopez-Beltran A, Montironi R, MacLennan GT, Cheng L: Soft tissue tumors of the urinary bladder Part II: malignant neoplasms. Hum Pathol; 2007 Jul;38(7):963-77
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Soft tissue tumors of the urinary bladder Part II: malignant neoplasms.
  • The second half of this two-part review will describe rare nonurothelial malignant tumors of the urinary bladder including leiomyosarcoma, rhabdomyosarcoma, angiosarcoma, malignant fibrous histiocytoma (undifferentiated sarcoma), primitive neuroectodermal tumor, malignant peripheral nerve sheath tumor, hemangiopericytoma, and alveolar soft-parts sarcoma.
  • [MeSH-major] Soft Tissue Neoplasms / pathology. Urinary Bladder Neoplasms / pathology
  • [MeSH-minor] Diagnosis, Differential. Hemangiopericytoma / pathology. Histiocytoma, Malignant Fibrous / pathology. Humans. Immunohistochemistry. Nerve Sheath Neoplasms / pathology. Neuroectodermal Tumors, Primitive / pathology. Sarcoma / pathology

  • MedlinePlus Health Information. consumer health - Bladder Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17574946.001).
  • [ISSN] 0046-8177
  • [Journal-full-title] Human pathology
  • [ISO-abbreviation] Hum. Pathol.
  • [Language] eng
  • [Publication-type] Journal Article; Review
  • [Publication-country] United States
  • [Number-of-references] 60
  •  go-up   go-down






Advertisement